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Inherited predisposition to breast cancer is estimated to account for about 5-
10% of all cases and is characterized by an autosomal dominant pattern of 
inheritance, young age at presentation, and association with bilateral breast cancer 
and ovarian cancer. Germline pathogenic mutations in the BRCA1 and BRCA2 genes 
are responsible for the Hereditary Breast and Ovarian Cancer (HBOC) syndrome. 
Mutations in the BRCA1/BRCA2 genes have also been associated with inherited 
predisposition to other cancers in HBOC families, like those of the prostate, pancreas, 
male breast, peritoneum, and fallopian tube. Molecular analyses of the BRCA1 and 
BRCA2 genes have shown that most populations exhibit a wide spectrum of mutations 
throughout both genes and several founder mutations have been identified in 
individuals of different ancestries. In the Portuguese population, the BRCA2 
c.156_157insAlu and the BRCA1 c.3331_3334del account for about 43% of the total 
deleterious mutations in these genes. Multiple other genes, besides BRCA1 and 
BRCA2, have been described as conferring an increased risk for the development of 
breast or ovarian cancer when mutated and many of these genes are involved in 
homologous DNA recombination. 
The aims of this thesis were to characterize the phenotypic heterogeneity 
associated with BRCA1 and BRCA2 mutations and the genetic heterogeneity of 
hereditary breast and ovarian cancer. Specifically, the objectives of this thesis were: 
a) To develop a method to detect the founder mutations BRCA2 c.156_157insAlu and 
BRCA1 c.3331_3334del in formalin-fixed paraffin-embedded archival tissue; b) To 
quantify the contribution of the founder mutations BRCA2 c.156_157insAlu and 
BRCA1 c.3331_3334del for cancer etiology in unselected hospital-based cohorts of 
patients diagnosed with rarer cancers associated with HBOC, namely, cancer of the 
pancreas, male breast, peritoneum, and fallopian tube; c) To compare the sensitivity 
and specificity of next-generation sequencing (NGS) and those of Sanger sequencing 
for the detection of point mutations in the BRCA1 and BRCA2 genes; d) To evaluate 
the genetic heterogeneity of hereditary breast and ovarian cancer by analyzing a panel 
of 17 genes associated with predisposition to these diseases in a consecutive series 
of high-risk breast/ovarian cancer families.  
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The BRCA2 c.156_157insAlu mutation was observed with a frequency of 7.8% 
in male breast cancers, 3.0% in peritoneal/fallopian tube cancers, and 1.6% in 
pancreatic cancers, with estimated total contributions of germline BRCA2 mutations 
of 14.3%, 5.5%, and 2.8%, respectively. No carriers of the BRCA1 c.3331_3334del 
mutation were identified. During our study, a patient with an ampulla of Vater 
carcinoma was incidentally found to carry the BRCA2 c.156_157insAlu mutation, so 
we decided to test a consecutive series of additional 15 ampullary carcinomas for 
BRCA1/BRCA2 mutations using a combination of direct founder mutation testing and 
full gene analysis with NGS. BRCA2 mutations were observed with a frequency of 
14.3% in ampulla of Vater carcinomas. In suspected HBOC families, the frequency of 
deleterious mutations identified was 22.3% for BRCA2, 10.6% for BRCA1, 5% for 
PALB2, 2.5% for ATM, and 1.3% for both CHEK2 and TP53. In addition, the efficiency 
of NGS for the detection of BRCA1/BRCA2 point mutations was validated with a 100% 
sensitivity and specificity obtained when compared to the gold standard Sanger 
sequencing. 
The main conclusions of this thesis are: a) The detection of germline founder 
mutations and full BRCA1/BRCA2 gene analysis are possible in archival tissue, 
making it an alternative for the molecular diagnosis of inherited predisposition; b) 
BRCA2 germline mutations are estimated to occur in 14.3% of male breast cancers, 
5.5% of peritoneal/fallopian tube cancers, and 2.8% of pancreatic cancers; c) BRCA2 
germline mutations were observed recurrently for the first time in patients with ampulla 
of Vater carcinomas, with a frequency of 14.3%; d) The sensitivity and specificity of 
NGS are as high as those of the gold-standard Sanger sequencing for the detection 
of BRCA1/BRCA2 germline point mutations, when a validated bioinformatic pipeline 
is used; e) Hereditary breast and ovarian cancer is genetically heterogeneous, with 
20.5% of the germline deleterious mutations being found in genes other than 
BRCA1/BRCA2. 
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A predisposição hereditária para cancro da mama é responsável por cerca de 
5-10% de todos os casos e é caracterizada por um padrão de transmissão 
autossómico dominante, idade precoce de diagnóstico e associação com cancro da 
mama bilateral e cancro do ovário. Mutações germinativas patogénicas nos genes 
BRCA1 e BRCA2 predispõem para a síndrome de cancro da mama/ovário hereditário 
(Hereditary Breast and Ovarian Cancer – HBOC). Mutações nestes genes estão 
também associadas com predisposição para outros tumores em famílias HBOC, 
nomeadamente, tumores da próstata, pâncreas, peritoneu, trompa do Falópio e 
tumores da mama em homens. A análise molecular dos genes BRCA1 e BRCA2 
mostra que a maioria das populações apresenta um padrão de mutações 
heterogéneo, havendo várias mutações fundadoras identificadas em diferentes 
populações. Na população portuguesa, as mutações BRCA2 c.156_157insAlu e 
BRCA1 c.3331_3334del representam cerca de 43% de todas as mutações 
patogénicas nestes genes. Múltiplos outros genes, para além dos genes BRCA1 e 
BRCA2, estão descritos como conferindo um risco aumentado para o 
desenvolvimento de cancro da mama ou do ovário quando mutados, estando estes 
normalmente envolvidos na recombinação homóloga do DNA.  
O presente trabalho teve como objetivos a caracterização da heterogeneidade 
fenotípica associada a mutações nos genes BRCA1 e BRCA2 e da heterogeneidade 
genética do cancro hereditário da mama e do ovário. Mais especificamente, os 
objetivos foram: a) Desenvolver um método para a deteção das mutações fundadoras 
BRCA2 c.156_157insAlu e BRCA1 c.3331_3334del em tecido fixado em formalina e 
incluído em parafina; b) Quantificar a contribuição das mutações fundadoras BRCA2 
c.156_157insAlu e BRCA1 c.3331_3334del para a etiologia de cancro em pacientes 
diagnosticados com tumores mais raros associados a HBOC, nomeadamente, 
carcinomas do pâncreas, peritoneu, trompa do Falópio e da mama masculino; c) 
Comparar a sensibilidade e especificidade da sequenciação de nova-geração (Next-
generation sequencing – NGS) e da sequenciação de Sanger para a deteção de 
mutações pontuais nos genes BRCA1 e BRCA2; d) Avaliar a heterogeneidade 
genética do cancro hereditário da mama e do ovário, analisando um painel de 17 
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genes associados a predisposição para estes tumores numa série consecutiva de 
famílias com alto risco para cancro da mama/ovário.  
A mutação BRCA2 c.156_157insAlu foi observada com uma frequência de 
7.8% em homens com cancro da mama, 3.0% em carcinomas peritoneais/trompa do 
Falópio, e 1.6% em carcinomas do pâncreas, com estimativas de mutações 
germinativas no gene BRCA2 de 14.3%, 5.5% e 2.8%, respetivamente. Não foram 
identificados portadores da mutação BRCA1 c.3331_3334del. Durante o estudo, um 
paciente com carcinoma da ampola de Vater foi identificado como sendo portador da 
mutação BRCA2 c.156_157insAlu, pelo que analisamos uma série adicional 
consecutiva de 15 tumores da ampola de Vater para a presença de mutações nos 
genes BRCA1/BRCA2 usando uma combinação de pesquisa de mutações 
fundadoras com análise completa destes genes por NGS. Mutações no gene BRCA2 
foram observadas com uma frequência de 14.3% em carcinomas da ampola de Vater. 
Em famílias suspeitas de HBOC, a frequência de mutações patogénicas identificada 
foi de 22.3% no gene BRCA2, 10.6% no BRCA1, 5% no PALB2, 2.5% no ATM, e 
1.3% nos genes CHEK2 e TP53. Adicionalmente, a eficiência de NGS para a deteção 
de mutações pontuais nos genes BRCA1/BRCA2 foi validada, tendo sido obtida uma 
sensibilidade e especificidade de 100% comparada com a sequenciação de Sanger. 
As principais conclusões desta tese são: a) A deteção de mutações fundadoras 
germinativas e a análise completa dos genes BRCA1/BRCA2 é possível em tecido 
de arquivo, sendo uma alternativa para o diagnóstico molecular de predisposição 
hereditária; b) Mutações germinativas no gene BRCA2 estimaram-se ocorrer em 
14.3% dos homens com cancro da mama, 5.5% dos carcinomas peritoneais/trompa 
do Falópio e 2.8% em carcinomas do pâncreas; c) Mutações germinativas no gene 
BRCA2 foram observadas recorrentemente pela primeira vez em pacientes com 
carcinoma ampular, com uma frequência de 14.3%; d) A sensibilidade e 
especificidade da NGS são tão elevadas como as da sequenciação de Sanger para 
a deteção de mutações pontuais nos genes BRCA1/BRCA2, quando uma “pipeline” 
bioinformática validada é utilizada; e) O cancro hereditário da mama e do ovário é 
geneticamente heterogéneo, sendo que 20.5% de todas as mutações patogénicas 
identificadas são em outros genes que não os genes BRCA1/BRCA2.
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1. Cancer epidemiology 
Cancer is a major concern in public health and despite the efforts to improve 
prevention, diagnosis and treatment, the incidence is expected to grow, mostly due to 
the growth and aging of the world population and the increasing prevalence of 
established risk factors worldwide [Torre et al, 2015]. In 2012, 14.1 million new cases 
and 8.2 million cancer-related deaths were estimated by GLOBOCAN, through the 
International Agency for Research on Cancer (IARC) [Ferlay et al, 2015]. Cancer 
epidemiology is different between developed and developing countries, with the most 
incident and leading cancer death being lung cancer among males and breast cancer 
among females in less developed countries. In developed countries, although lung 
cancer leads mortality rates, prostate and breast cancer are the most incident, 
respectively, among males and females. In Europe, breast, colorectal, prostate and 
lung cancers are the most frequently diagnosed cancers, together representing half 
of the overall cancer burden [Ferlay et al, 2013]. 
 
1.1. Breast cancer epidemiology and risk factors 
 Breast cancer is the most frequent cancer and the leading cause of cancer 
death among females worldwide, with estimates of 1.7 million cases and 522,000 
deaths in 2012, representing 25% and 15% of all cancer cases and deaths, 
respectively [Torre et al, 2015]. In males, breast cancer is a rare disease. Incidence 
rates are higher in more developed countries when compared with less developed 
countries. In most of the developed countries incidence rates have been stable 
recently, with mortality rates decreasing. In contrast, in less developed countries both 
the incidence and mortality rates are increasing [DeSantis et al, 2015]. In the United 
States of America (USA), the 5-year survival rate has increased from 60% in the 1950s 
to about 90% in the 2000s [Ban and Godellas, 2014]. In Portugal, breast cancer is the 
most frequent cancer among women, representing about 30% of the cancers 
diagnosed, with an estimated age-standardized rate (ASR) incidence of 85.6 per 
100,000. Breast cancer is the main cause of death by cancer in Portuguese women, 
with an estimated ASR of 18.4 in 2012 [Ferlay et al, 2013].  
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 Similar to most cancers, age is an established risk factor for breast cancer. The 
incidence of breast cancer increases rapidly with age during the reproductive years, 
increasing at a slower rate after 50 years old, the average age at menopause [Key et 
al, 2001]. Gender is probably the most important risk factor of breast cancer, being at 
least 100 times more common in women than in men. A higher exposure of the breast 
tissue to endogenous and exogenous hormones (progesterone and, especially, 
estrogen) also increases the risk of breast cancer. Reproductive hormones stimulate 
cell division, thereby increasing the likelihood of DNA damage and the risk of cancer. 
Hence, factors such as an early menarche, late menopause, use of oral 
contraceptives, hormone replacement therapy and higher serum concentration of 
endogenous hormones all contribute to an increase in breast cancer risk [Hsieh et al, 
1990, Collaborative Group on Hormonal Factors in Breast Cancer, 1997, Key and 
Verkasalo, 1999, Hunter et al, 2010]. Childbearing has a dual effect on breast cancer 
risk; immediately after pregnancy the risk is higher, but it diminishes gradually and in 
the long term there is a protective effect [Lambe et al, 1994]. Women with a personal 
and/or family history of breast cancer have an increased risk for developing breast 
cancer, being about double of the general population if the affected member is a first 
degree relative [Pharoah et al, 1997]. Familial aggregation is present in about 20% of 
the cases and can be attributed to genetic, environmental, and lifestyle factors. 
Pathogenic mutations in the BRCA1 and BRCA2 genes account for about 5-10% of 
all breast cancers and are responsible for the Hereditary Breast and Ovarian Cancer 
(HBOC) syndrome. The cumulative risk for developing breast cancer at 70 years old 
is 60% for BRCA1 mutation carriers and 55% for BRCA2 carriers [Mavaddat et al, 
2013]. Other breast cancer risk factors include race, ethnicity, breast density, breast 
benign lesions, breastfeeding, alcohol use, diet, physical activity and exposure to 
radiation [Ban and Godellas, 2014]. 
 
1.2. Ovarian cancer epidemiology and risk factors 
Ovarian cancer is the seventh most common cancer worldwide among women, 
with 238,700 new cancer cases diagnosed in 2012 and the eight most lethal cancer 
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with 151,900 deaths estimated [Torre et al, 2015]. In Portugal, it accounts for about 
3% of the cancers diagnosed in women, with an estimated ASR incidence of 8.2 and 
is the sixth cause of cancer death in Portuguese females with an estimated ASR of 
4.4 [Ferlay et al, 2013]. 
 The risk of ovarian cancer increases with age, whereas the use of oral 
contraceptives confers long-term protection [Tsilidis et al, 2011, Doufekas and Olaitan, 
2014]. Factors that interrupt ovulation, such as pregnancy and breastfeeding, are also 
associated with a reduced risk of developing ovarian cancer [Whittemore et al, 1992, 
Adami et al, 1994]. Women with endometriosis have an increased risk of ovarian 
cancer and the use of hormone replacement therapy is also associated with a small 
increase in risk [Modugno et al, 2004, Beral et al, 2007]. Women with a personal 
history of breast cancer have a two-fold increase in ovarian cancer risk, increasing to 
four-fold if it was diagnosed before 40 years old and even more if they also have a 
family history of breast and/or ovarian cancer [Bergfeldt et al, 2002]. Pathogenic 
mutations in BRCA1 or BRCA2 confer a cumulative risk for developing ovarian cancer 
at age 70 of 59% and 17%, respectively [Mavaddat et al, 2013]. Other risk factors 
such as age at menarche and menopause or infertility have been studied, but without 
a clear association demonstrated [Whittemore et al, 1992, Venn et al, 1995].  
 
2. Inherited predisposition to breast and ovarian cancer 
 Descriptions of families with multiple cases of breast cancer date back to 
ancient Greek physicians. In 1866, Paul Broca was the first to report in detail a family 
with multiple generations affected with breast cancer. At the time, he hypothesized 
that breast cancer in this family was hereditary, present in a “latent state” until later in 
life, when it presented and progressed to a malignant disease. In the 1920s, Janet 
Elizabeth Lane-Claypon demonstrated that women whose mothers had died of breast 
cancer had an increased mortality due to breast cancer when compared with women 
whose mothers had died of other causes. By the 1970s, multiple families with two or 
more first-degree relatives affected with breast cancer in association with ovarian 
cancer and other cancers were described together with epidemiological studies 
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showing that the risk of breast cancer was increased in first-degree relatives of 
affected women [Anderson, 1972, Lynch et al, 1972]. In 1988, Newman and 
colleagues evaluated a total of 1579 families and demonstrated that familial clustering 
of breast cancer was fully explained by an autosomal dominant, highly penetrant 
susceptibility gene. Using a mathematical model, they predicted that in 4% of the 
families breast cancer could be explained by the presence of a susceptibility gene and 
that in these, the risk of breast cancer by age 70 was 82% [Newman et al, 1988]. By 
that time, “the race” to find a high susceptibility gene to breast cancer was ongoing 
and in 1990, Hall and coworkers [1990] mapped a hypothetical gene to chromosome 
17q21, which was immediately confirmed by Narod and colleagues [1991], who 
mapped predisposition to breast and ovarian cancer on the same location in different 
families. It was only four years later that the BRCA1 gene was positionally cloned by 
Miki et al [1994] and subsequently confirmed in an independent study [Friedman et al, 
1994]. These two studies together presented 15 families with truncating mutations 
cosegregating with breast and ovarian cancer. One year later, a second breast cancer 
gene, BRCA2, located on chromosome 13q12-13, was identified with germline 
mutations present in six different families [Wooster et al, 1995].   
Inherited predisposition to breast cancer is estimated to account for about 5-
10% of all cases. Breast cancer susceptibility genes can be divided in three classes: 
rare high penetrance genes, rare moderate penetrance genes and common low 
penetrance alleles. High penetrance genes are those who confer a risk of breast 
cancer, defined in terms of disease incidence, more than four times as high as that in 
the general population and they were mostly identified through linkage analysis. 
Moderate penetrance genes are those who confer a risk between two to four times 
higher than the general population and most have been identified by mutational 
screening of candidate genes. Genome-wide association studies (GWAS) have been 
used to identify low penetrance variants and they all confer risks that are less than 1.5 
times as high as those in general population [Turnbull and Rahman, 2008, Easton et 
al, 2015]. Ovarian cancer susceptibility genes include BRCA1, BRCA2, MLH1, MSH2, 
MSH6, PMS2, BRIP1, RAD51C and RAD51D [ten Broeke et al, 2015, Norquist et al, 
2016]. 
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Pathogenic mutations in the BRCA1 and BRCA2 genes account for about 15% 
of familial breast cancers and 30% of high-risk breast cancer families, with mutations 
in other high or moderate penetrance genes accounting for about 7% of familial breast 
cancer (Figure 1) [Couch et al, 2014]. These families are often characterized by an 
autosomal dominant pattern of inheritance, young age at presentation, and 
association with bilateral breast cancer and ovarian cancer. 
 
Figure 1 – Estimated percentage contribution of genetic variants that predispose to familial breast cancer, namely, 
BRCA1 and BRCA2 genes, other high penetrance genes (TP53, PTEN, STK11 and CDH1), moderate penetrance 
genes (ATM, CHEK2 and PALB2), and common low penetrance alleles (Single Nucleotide Polymorphisms, SNPs) 
[adapted from Couch et al, 2014]. 
 
2.1. Hereditary breast and ovarian cancer syndrome 
 
2.1.1. BRCA1 
BRCA1 is a large gene with 23 exons (22 of them coding) encoding a protein 
with 1863 aminoacids and a predicted molecular mass of 207kDa. Exon 11 is 
unusually large and encodes almost 60% of the full length BRCA1 protein. The BRCA1 
gene is ubiquitously expressed and plays a role in multiple DNA repair pathways, 
namely, homologous recombination (HR), nonhomologous end joining (NHEJ) and 
INTRODUCTION 
24 
 
single-strand annealing (SSA) and in checkpoint regulation [Roy et al, 2012]. This 
gene contains two highly conserved domains in the N- and C-terminal regions of the 
protein (Figure 2). The N-terminal region of BRCA1 has the RING (Really Interesting 
New Gene) domain (aminoacids 1-109) with a conserved pattern of cysteine and 
histidine residues that is found in a large number of proteins and functions as an E3 
ligase enzyme involved in ubiquitination [Clark et al, 2012]. It also encompasses 
sequences responsible for the interaction and formation of a heterodimer with BARD1, 
which enhances BRCA1 ubiquitin ligase activity [Wu et al, 1996]. At the C-terminal 
end lie two tandem repeat globular domains (aminoacids 1650-1863), termed BRCA1 
C-terminal (BRCT), a common feature of proteins involved in the DNA damage repair 
and cell cycle control [Clark et al, 2012]. This domain is responsible for interactions 
with other proteins involved in DNA damage repair (Abraxas, BRIP1 and CtIP) that 
are phosphorylated by DNA damage-activated kinases, such as ATM [Huen et al, 
2010]. 
Figure 2 – BRCA1 functional domains. At the N-terminus lies a RING domain (encoded by exons 2-7, aminoacids 
1-109) and two NLS within the large central exon 11 (aminoacids 503-508 and 607-614). The C-terminus of BRCA1 
contains a coiled-coil domain spanning exons 11-13 (aminoacids 1364-1437) that associates with PALB2, and a 
BRCT domain (exons 16-24, aminoacids 1650-1863) that binds to Abraxas, CtIP and BRIP1 [Narod and Foulkes, 
2004, Clark et al, 2012, Roy et al, 2012]. 
 
Other BRCA1 functional domains include two central nuclear localization 
signals (NLS) within exon 11 (aminoacids 503-508 and 607-614) and a coiled-coil 
domain spanning exons 11-13 (aminoacids 1364-1437). NLS domains are highly 
important for BRCA1 localization mediating BRCA1 transport from the cytosol to the 
nucleus, whereas the coiled-coil domain mediates protein-protein interactions and 
contains the binding site for PALB2 protein [Clark et al, 2012]. Mutations in this domain 
inhibit the interaction between BRCA1 and PALB2 [Sy et al, 2009].  
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The prevalence of BRCA1 mutations in the general population is estimated to 
be about 0.1%, 3.7% in women diagnosed with breast cancer and 9.5% in women 
diagnosed with ovarian cancer [Lalloo and Evans, 2012, Norquist et al, 2016, Tung et 
al, 2016]. More than 1800 rare variants have been reported, most of them only once. 
Mutations are found throughout the coding sequence of the gene, with the majority of 
pathogenic mutations being either frameshift or nonsense mutations that result in 
truncated proteins. Missense mutations account for approximately 2% of pathogenic 
mutations in BRCA1, usually in either the RING or BRCT domains [Lalloo and Evans, 
2012]. Large gene rearrangements (LGRs), including deletions and duplications of 
one or more exons represent 10-15% of all deleterious germline mutations in BRCA1 
[Mazoyer, 2005, Sluiter and van Rensburg, 2011]. Mutations in either the 5’ or 3’ end 
of the gene are more associated with breast cancer, whereas mutations in the central 
part of BRCA1 (approximately exon 11) are associated with the development of 
ovarian cancer [Rebbeck et al, 2015].  
 
2.1.2. BRCA2 
 BRCA2 is a large gene with 27 exons, 26 of them coding, encoding a 3418 
aminoacid protein with a predicted molecular mass of 384kDa. Like in BRCA1, exon 
11 is the largest. BRCA2 primary function is to facilitate HR but it is also involved in 
protection of the DNA replication fork [Schlacher et al, 2011]. It can be divided into 
three regions: the N-terminal region, the BRC repeat region, and the C-terminal region 
containing a DNA Binding Domain (DBD) and an NLS domain (Figure 3). The N-
terminal region contains a conserved sequence (aminoacids 21-39) that provides a 
binding site for PALB2 protein [Oliver et al, 2009]. In the central region of the BRCA2 
protein there are eight copies of the BRC repeat motifs of ~40 residues each 
(aminoacids 900-2000), which play a central role in mediating binding to RAD51 [Bork 
et al, 1996, Chen et al, 1998]. The C-terminal region (aminoacids 2459-3190) contains 
a DBD, which comprises a 190 aminoacid helical domain, three oligonucleotide 
binding (OB) folds that are single-strand DNA-binding modules, and a tower domain 
that mediates BRCA2 binding to single-strand DNA (ssDNA) and double-strand DNA 
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(dsDNA). The helical domain, OB1 and OB2 also associate with DSS1, a small acidic 
protein that has been linked to BRCA2 protein stabilization [Yang et al, 2002]. In the 
C-terminus region there is another RAD51 binding site (aminoacids 3265-3330) and 
two NLS (aminoacids 3263-3269 and 3381-3385) that are important for the 
translocation of BRCA2 to the nucleus [Spain et al, 1999]. 
 
Figure 3 – Functional domains of the BRCA2 gene. The N-terminus binds to PALB2 at aminoacids 21-39. The 
central region (within exon 11) contains eight copies of the BRC repeat motifs (aminoacids 900-2000), which 
mediates binding to the RAD51 recombinase. The C-terminal region (aminoacids 2459-3190) contains a DBD, 
which includes a helical domain (H), three OB folds, and a tower domain (T). This domain also associates with 
DSS1. The C-terminus of BRCA2 contains another RAD51 binding site (aminoacids 3265-3330) and two NLS 
(aminoacids 3263-3269 and 3381-3385) [Venkitaraman, 2009, Roy et al, 2012, Guidugli et al, 2014]. 
 
 BRCA2 mutations are present in about 0.1% of the general population, in 2.5% 
of women with breast cancer and in 5.1% of women diagnosed with ovarian cancer 
[Lalloo and Evans, 2012, Norquist et al, 2016, Tung et al, 2016]. More than 2000 
individual variants have been described and, similar to BRCA1, there are no hotspots 
for mutations and most of the pathogenic mutations are either frameshift or nonsense. 
Pathogenic missense mutations are usually found within the DBD domain [Guidugli et 
al, 2013]. The frequency of LGRs is lower, accounting for 1-7% of all deleterious 
mutations [Mazoyer, 2005, Sluiter and van Rensburg, 2011]. Biallelic mutations in 
BRCA2 have been shown to cause Fanconi anemia, a condition characterized by 
multiple congenital abnormalities including short stature and microcephaly, and 
predisposition to childhood solid tumors and hematological malignancies [Reid et al, 
2005]. As in BRCA1, breast cancer cluster regions are found in the 5’ and 3’ end of 
the gene with ovarian cancer cluster regions located in the central region of BRCA2 
[Rebbeck et al, 2015]. 
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2.1.3. Cancers associated with BRCA1 and BRCA2 mutations 
HBOC syndrome is an autosomal dominant disease with incomplete 
penetrance. The most common cancers associated with this syndrome are breast and 
ovarian cancer. Women carrying germline BRCA1 mutations have a cumulative risk 
at 70 years of 60% for breast cancer and 59% for ovarian cancer, whereas BRCA2 
mutations appear to confer a similar risk of breast cancer in females (55%), but a lower 
risk (17%) for ovarian cancer [Mavaddat et al, 2013]. 
Most BRCA1 breast tumors are high grade, invasive breast carcinomas of no 
special type (NST), with a high incidence of triple negative tumors: negative staining 
for estrogen receptor, progesterone receptor, and human epidermal growth factor 
receptor 2 (HER2) [Mavaddat et al, 2012]. There is also an increased frequency of 
medullary features like pushing margins, high degree of nuclear pleomorphism and 
mitotic frequency. They have a similar immunohistological profile to sporadic basal 
carcinomas, expressing basal markers such as cytokeratins 5/6 and cytokeratin 14 
[Lakhani et al, 2005]. Ovarian tumors associated with BRCA1 mutations are usually 
high-grade serous epithelial carcinomas with endometrioid, clear cell and mucinous 
carcinomas occurring less frequently [Mavaddat et al, 2012]. 
In contrast to tumors in BRCA1 carriers, BRCA2 associated breast tumors 
appear to be more heterogeneous. The most common histological type in BRCA2 
tumors is invasive breast carcinoma NST with a higher frequency of lobular and 
tubular carcinomas described [Mavaddat et al, 2012]. Ductal carcinoma in situ (DCIS) 
is also more common in BRCA2 carriers. Overall, these tumors are similar to sporadic 
tumors regarding expression of estrogen and progesterone receptors and rarely 
overexpress HER2 [Lakhani et al, 2002, Mavaddat et al, 2012]. Ovarian tumors 
associated with BRCA2 have similar features to those associated with BRCA1 
mutations [Lakhani et al, 2004]. 
Mutations in the BRCA1/BRCA2 genes have also been associated with 
inherited predisposition to other cancers in HBOC families, like those of the prostate, 
pancreas, male breast, peritoneum, fallopian tube and melanoma. The lifetime risk of 
male breast cancer has been estimated to be 5-10% for BRCA2, and 1-5% for BRCA1 
mutation carriers, compared with a risk of 0.1% in the general population [Thompson 
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et al, 2002, van Asperen et al, 2005, Tai et al, 2007]. The frequency of BRCA2 
mutations in male breast cancer has been reported as ranging between 7-16% 
[Chodick et al, 2008, Ottini et al, 2009, Ding et al, 2011]. BRCA-associated male breast 
tumors have distinct pathologic characteristics compared with BRCA-associated 
female breast tumors, being usually of a higher stage and more likely to be estrogen 
and progesterone receptor positive [Silvestri et al, 2016]. Similar to male breast 
cancer, pancreatic and prostate cancers are also more commonly associated with 
BRCA2 mutations. Estimates of the cumulative prostate cancer risk are around 9% for 
BRCA1 and 15% for BRCA2 mutation carriers at age 65, with BRCA1/BRCA2 
mutations accounting for about 2% of prostate cancer cases [Kote-Jarai et al, 2011, 
Leongamornlert et al, 2012]. Prostate tumors of BRCA1/BRCA2 mutation carriers are 
also associated with a more aggressive phenotype [Castro et al, 2013]. A large study 
with BRCA2 mutation carriers described that the occurrence of pancreatic cancer in 
males and females was 22 times greater than expected in the study population 
[Mersch et al, 2015]. The prevalence of BRCA1/BRCA2 mutations in pancreatic 
cancer varies according to the selection criteria used. In unselected series was 
reported to be about 5%, ranging from 13% to 19% in patients with a strong family 
history of the disease or in individuals with Ashkenazi Jewish ancestry [Lal et al, 2000, 
Murphy et al, 2002, Hahn et al, 2003, Stadler et al, 2012, Holter et al, 2015]. 
Peritoneal and fallopian tube cancer are more associated with mutations in the 
BRCA1 gene, although there is limited data available. Only a few studies have 
analyzed the frequency of BRCA1/BRCA2 mutations in fallopian tube and peritoneal 
cancer independently of ovarian cancer, with frequencies observed ranging from 16% 
to 30% [Vicus et al, 2010, Walsh et al, 2011, Alsop et al, 2012]. An increased incidence 
of melanoma has been reported in both BRCA1 and BRCA2 mutation carriers [Moran 
et al, 2012, Mersch et al, 2015].  
 
2.1.4. BRCA1 and BRCA2 mutation pattern in Portuguese HBOC families 
A large characterization of the mutational spectrum of germline BRCA1/BRCA2 
mutations in 1050 Portuguese breast/ovarian cancer families has recently been 
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performed [Peixoto et al, 2015]. In 524 families, screening of the entire coding regions 
of BRCA1/BRCA2 was performed, with the remaining 526 families screened for the 
two most prevalent founder mutations in Portuguese HBOC families, the BRCA2 
c.156_157insAlu and the BRCA1 c.3331_3334del mutation. Inherited cancer 
predisposition could be linked to BRCA1 or BRCA2 mutations in 21.4% of the 524 fully 
screened probands, a proportion that reaches 28.9% of the families with an a priori 
BRCAPRO mutation probability >10%. Seven additional pathogenic mutations were 
detected in the 526 families with BRCAPRO mutation probability <10% that were 
screened only for the two most frequent mutations. A total of 119 pathogenic mutations 
were detected, 41.2% in BRCA1 and 58.8% in BRCA2. The BRCA2 c.156_157insAlu 
mutation was present in 32% of all Portuguese HBOC families and represented 55% 
of the BRCA2 mutations, whereas the BRCA1 c.3331_3334del mutation was present 
in 11% of all families and 26% of the families with a BRCA1 mutation, together 
representing a large proportion of the mutations identified in Portuguese HBOC 
families. The BRCA2 c.156_157insAlu mutation has only been reported in families of 
Portuguese ancestry [Teugels et al, 2005, Machado et al, 2007, Peixoto et al, 2009, 
Peixoto et al, 2011, Moreira et al, 2012, Peixoto et al, 2015], whereas the BRCA1 
c.3331_3334del mutation has been reported in several populations, including 
Spanish, Canadian and Colombian [Durocher et al, 1996, Blesa et al, 2000, Torres et 
al, 2007]. 
 
2.2. Other breast cancer predisposition genes 
 
2.2.1. Genes associated with other hereditary cancer syndromes  
 
2.2.1.1. TP53 
TP53 is a tumor suppressor gene, located on chromosome 17, consisting of 11 
exons with the core DNA binding domain encoded by exons 4-8. It has been called 
the “guardian of the genome” and plays an essential role in cell-cycle control and 
apoptosis [Lane, 1992, Levine, 1997]. Somatic mutations in the TP53 gene are 
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common in solid tumors. Germline mutations are rare and responsible for the Li-
Fraumeni syndrome (LFS), a cancer predisposition syndrome affecting children and 
adults [Li et al, 1988]. It is associated with soft tissue sarcomas, osteosarcomas, early 
onset breast cancer, acute leukemia, colon cancer, adrenocortical carcinoma, and 
brain tumors [Li et al, 1988, Malkin et al, 1990, Varley et al, 1997, Krutilkova et al, 
2005, Gonzalez et al, 2009]. Sarcoma, breast cancer, adrenocortical tumors, and 
certain brain tumors are considered the “core” cancers of LFS, since they account for 
the majority of cancers observed in individuals with germline mutations in the TP53 
gene [Gonzalez et al, 2009]. Carriers of TP53 mutations have a risk of developing 
cancer estimated to be approximately 60% and 95% by 45 and 70 years, respectively 
[Lustbader et al, 1992]. Patients with germline TP53 mutations have an abnormal 
response to low-dose radiation, hence radiotherapy is not recommended in these 
patients because of the increased risk of developing a second primary tumor [Evans 
et al, 2006].  
Although LFS only accounts for about 0.1% of breast cancer cases and 1% of 
hereditary breast cancer cases, mutations in TP53 confer a 105 estimated relative risk 
(RR) (90% confidence interval (CI), 62 to 165) of developing early onset breast cancer 
[Sidransky et al, 1992, Lalloo and Evans, 2012, Easton et al, 2015]. In patients with 
early onset breast cancer (<30 years) the frequency of TP53 mutations ranges from 3 
to 8% [Lalloo et al, 2006, Gonzalez et al, 2009, Mouchawar et al, 2010, McCuaig et 
al, 2012, Bougeard et al, 2015]. More recently, a very high frequency of HER2-positive 
breast tumors (67-83%) was observed in patients with germline TP53 mutations, 
which can be helpful for directing TP53 mutation testing and for targeted treatment 
[Wilson et al, 2010, Melhem-Bertrandt et al, 2012]. 
 
2.2.1.2. PTEN 
Germline mutations in the tumor suppressor gene PTEN are responsible for 
the Cowden syndrome, a multiple hamartoma syndrome that includes increased risk 
of benign and malignant tumors of the breast, thyroid and endometrium [Pilarski, 
2009]. Other features associated with this syndrome are mucocutaneous lesions, 
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macrocephaly and hamartomatous intestinal polyps. The PTEN gene is located on 
chromosome 10q, contains 9 exons, and encodes a lipid phosphatase that functions 
as a tumor suppressor through negative regulation of a cell-survival signaling pathway 
[Cully et al, 2006]. Over 90% of individuals with Cowden syndrome will express some 
clinical manifestation in their lifetime [Hobert and Eng, 2009].  
Several studies have projected lifetime estimates of cancer risk and determined 
cumulative risks of 77-85% for female breast cancer, 21-38% for thyroid cancer and 
19-28% for endometrial cancer [Riegert-Johnson et al, 2010, Tan et al, 2012, Bubien 
et al, 2013]. Other studies have estimated that women diagnosed with Cowden 
syndrome have a lifetime risk of breast cancer between 25-50%, with the average age 
of diagnosis ranging from 38 to 50 years old [Brownstein et al, 1978, Starink et al, 
1986, Pilarski et al, 2013]. Although PTEN is usually considered a high penetrance 
breast cancer gene, the selection of patients for studies evaluating PTEN penetrance 
was based on the presence of features associated with the syndrome, suffering from 
ascertainment bias, therefore not making possible to estimate reliable RR for the 
development of breast cancer in mutation carriers [Easton et al, 2015].    
 
2.2.1.3. STK11 
Peutz-Jeghers syndrome is an autosomal dominant disorder, characterized by 
hamartomatous intestinal polyps, mucocutaneous pigmentation, and elevated risk for 
gastrointestinal cancers as well as breast, ovarian, small bowel or pancreatic cancers 
[Hearle et al, 2006]. Mutations in the tumor suppressor gene STK11, located on 
chromosome 19p, were identified by studying patterns of loss of heterozygosity in 
polyps of affected individuals from 17 Peutz-Jeghers families [Hemminki et al, 1998, 
Jenne et al, 1998]. STK11 is a serine/threonine kinase that inhibits cellular 
proliferation, controls cell polarity and interacts with the TOR pathway. Carriers of 
STK11 mutations have a cumulative risk of 85% to develop any cancer by 70 years, 
with breast cancer risk estimated to be 45% at the same age [Hearle et al, 2006].  
 
INTRODUCTION 
32 
 
2.2.1.4. CDH1 
Germline mutations in CDH1 are associated with the development of hereditary 
diffuse gastric carcinoma (HDGC), often with signet ring cells histology. The 
cumulative risk for developing HDGC in male and female carriers is 67% and 83%, 
respectively [Pharoah et al, 2001]. This gene consists of 16 exons, is located on 
chromosome 16q, and encodes the E-cadherin protein, a calcium-dependent cell-cell 
adhesion molecule important for the maintenance of cell polarity [Graziano et al, 
2003]. A high frequency of lobular breast cancer is also observed in carriers of CDH1 
pathogenic mutations [Pharoah et al, 2001], with the occasional observation of 
families with lobular breast cancer without gastric cancer [Masciari et al, 2007]. The 
cumulative risk for developing breast cancer is estimated to be 53% with a reported 
RR of 6.6 (90% CI, 2.2 to 19.9) but, similar to PTEN and STK11, studies performed 
on CDH1 carriers are subject to ascertainment bias and reliable RR for the 
development of breast cancer are not possible to determine [Pharoah et al, 2001, 
Easton et al, 2015]. 
 
2.2.2. Moderate penetrance breast cancer predisposition genes 
 
2.2.2.1. PALB2 
 PALB2 was originally identified as interacting with the BRCA2 protein by 
precipitation of BRCA2-containing complexes, showing that this protein was important 
for the localization and stability of BRCA2, facilitating BRCA2-mediated DNA repair 
[Xia et al, 2006]. Biallelic truncating mutations were afterwards detected in Fanconi 
anemia families with phenotypes very similar to those of Fanconi anemia caused by 
mutations in BRCA2 [Reid et al, 2007, Xia et al, 2007]. These findings provided 
sufficient evidence to consider PALB2 as an attractive candidate for breast cancer 
predisposition. Mutation analysis in 923 breast cancer families negative for 
BRCA1/BRCA2 mutations identified 10 carriers of truncating mutations (1%) [Rahman 
et al, 2007]. Two different founder mutations, one in Canada and another in Finland, 
were identified in 0.5% and 1%, respectively, of women with breast cancer not 
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selected on the basis of a positive family history [Foulkes et al, 2007, Erkko et al, 
2008]. In families with a family history of breast cancer, pathogenic mutations are 
found in 0.6% to 3.9% of patients, depending on the population [Antoniou et al, 2014].  
 The cumulative risk by 70 years of age for developing breast cancer in a large 
cohort of PALB2 mutation carriers has been reported to range from 33% without family 
history taken into account to 58% in those with a strong family history (being 44% and 
67%, respectively, at age 80), which is similar to the risks described for BRCA2 
[Antoniou et al, 2014]. A meta-analysis of published case-control and family studies 
estimated the RR for developing breast cancer to be 5.3 (90% CI, 3.0 to 9.4) [Easton 
et al, 2015]. Although the estimated RR points towards PALB2 being a high 
penetrance gene, the lower CI is below four, with larger studies required for a 
reclassification of the penetrance of this gene. Similar to BRCA2, an increased risk to 
male breast cancer and pancreatic cancer has also been associated with carriers of 
PALB2 loss-of-function mutations [Jones et al, 2009, Slater et al, 2010, Ding et al, 
2011, Blanco et al, 2012].  
 
2.2.2.2. ATM 
 Ataxia-telangiectasia is an autosomal recessive disease caused by 
homozygous or compound heterozygote mutations in the ATM gene. This condition is 
characterized by progressive cerebellar ataxia, oculomotor apraxia, 
immunodeficiency, and cancer predisposition. Individuals with ataxia-telangiectasia 
are estimated to have a 100-fold increased risk of cancer compared with the general 
population. Lymphoid cancers predominate in childhood, and epithelial cancers, 
including breast cancer, are seen in adults [Ahmed and Rahman, 2006]. The ATM 
gene is located at 11q and consists of 66 exons, 62 of which encode a protein of 3056 
aminoacids. The first observation of ATM as a possible breast cancer predisposition 
gene came in 1976, when an excess of breast cancer in female relatives of patients 
with ataxia-telangiectasia was observed in an epidemiological study [Swift et al, 1976]. 
When the function of this protein started to be uncovered, the initial suspicions 
increased; ATM belongs to a family of proteins known as the PI3K-related protein 
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kinases (PIKK) and plays a central role in the response to double-stranded DNA 
breaks (DSBs) by initiating a pathway that includes other proteins, such as p53, 
BRCA1 and CHK2 [Ahmed and Rahman, 2006]. 
 After some inconclusive studies regarding its involvement in breast cancer 
susceptibility, in 2006 one study found heterozygous mutations in 12/443 familial 
cases negative for mutations in BRCA1 and BRCA2 and only 2 in 521 controls 
[Renwick et al, 2006]. Many breast cancer predisposing ATM variants have been 
identified, including not only truncating variants but also a variety of missense ones. 
In fact, some missense ATM variants have been described as conferring a higher risk 
for breast cancer than truncating variants [Goldgar et al, 2011]. The prevalence of 
these variants varies greatly among populations from different geographical areas or 
ethnicity. The cumulative risk for developing breast cancer at age 80 is estimated to 
be 27% and two different meta-analyses have identified similar RR, 2.8 (90% CI, 2.2 
to 3.7) and 3.2 (95% CI, 2.04 to 5.04) [Aloraifi et al, 2015, Easton et al, 2015]. Loss-
of-function variants in ATM were also recently associated with an increased risk for 
the development of gastric, pancreatic, prostate and colorectal cancer [Helgason et 
al, 2015]. 
 
2.2.2.3. CHEK2 
 The checkpoint kinase gene CHEK2, a tumor suppressor gene, encodes 
CHK2, a serine/threonine kinase that is activated in response to DNA damage and 
phosphorylates both p53 and BRCA1 to regulate repair of DSBs [Stracker et al, 2009]. 
Most of the data about the involvement of CHEK2 mutations in predisposition to breast 
cancer comes from the c.1100delC mutation that is found fairly frequently in Northern 
European populations. This mutation was identified with a frequency of 4.2% (30/718) 
in breast cancer families and with a frequency of 1.9% (201/10860) in population-
based breast cancer cases compared to 0.7% (64/9065) in controls [Meijers-Heijboer 
et al, 2002, Chek Breast Cancer Case-Control Consortium, 2004]. In other 
populations, this mutation is much less frequent [Cybulski et al, 2009]. The RR for the 
development of breast cancer in carriers of this mutation is estimated to be 3.0 (90% 
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CI, 2.6 to 3.5) with an absolute risk of 29% at age 80 [Easton et al, 2015]. CHEK2 
c.1100delC carriers have an increased risk of bilateral breast cancer and, more 
recently, homozygous carriers were identified with a 6-fold higher risk of breast cancer 
when compared to heterozygotes [Mellemkjaer et al, 2008, Adank et al, 2011].  
 A summary of the genes conferring an increased risk for the development of 
breast cancer can be found on Table 1. 
 
Table 1 – Genes associated with predisposition to breast cancer 
Gene Population frequency (%) 
Proportion of 
familial breast 
cancer risk (%) 
Estimated relative 
risk (90% CI) 
Cumulative risk 
by age 80 (%) 
BRCA1 0.1 5-10 11.4 75 
BRCA2 0.1 5-10 11.7 76 
TP53 <0.1 0.1 105 (62-165) 80-90 
CDH1 <0.1 0.1 6.6 (2.2-19.9) 53 
PTEN <0.1 0.02 No reliable estimate 25-50 
STK11 <0.1 0.04 No reliable estimate 45 
ATM 0.5 2 2.8 (2.2-3.7) 27 
CHEK2 0.5 2 3.0 (2.6-3.5) 29 
PALB2 0.1 2.4 5.3 (3.0-9.4) 44 
   
2.2.3. Low penetrance breast cancer predisposition alleles 
 Until now, common genetic variants in 94 loci associated with breast cancer 
risk have been identified [Couch et al, 2014, Michailidou et al, 2015]. The majority of 
these variants have been identified through GWAS of large numbers of breast cancer 
patients from the general population along with healthy controls and large-scale 
replication studies. Some are associated with a slightly increased risk, whereas others 
confer a small decrease in breast cancer risk. They can follow a polygenic risk model, 
or can act synergistically with environmental factors or lifestyle, to account for a 
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fraction of familial breast cancer cases. The 94 loci identified so far explain 16% of the 
two-fold risk of breast cancer in the first-degree relatives of women with the disease, 
with another 12% estimated to be explained by currently unknown loci (Figure 1). 
Some of these variants are associated with overall breast cancer risk, while others are 
associated with a specific molecular subtype of breast cancer: estrogen receptor 
positive, estrogen receptor negative or triple-negative breast cancer. The clinical utility 
of these low-penetrant common variants, either alone or in combination, remains 
debatable, although there are reports that, for instance, a combination of five common 
variants in BRCA2 carriers can vary the lifetime risk of breast cancer from 45% to 95% 
[Antoniou et al, 2010]. A recent study showed that combining 77 common genetic 
variants into a polygenic risk score can be useful to stratify breast cancer risk in 
women without family history and to refine genetic risk in women with a family history 
of breast cancer [Mavaddat et al, 2015]. 
 
2.3. Other ovarian cancer predisposition genes 
 
2.3.1. BRIP1 
BRIP1, also known as BACH1, encodes a protein that was identified as a 
binding partner of BRCA1 and has BRCA1-dependent roles in DNA repair and 
checkpoint control [Cantor et al, 2001]. Biallelic mutations in BRIP1 result in Fanconi 
anemia complementation group J (FANC-J), which is phenotypically different from that 
associated with BRCA2.  In 2006, truncating mutations in this gene were identified in 
families negative for BRCA1 and BRCA2 mutations with estimated RR of 2.0 for breast 
cancer [Seal et al, 2006]. However, a recent study in a large cohort of 48,144 cases 
and 43,607 controls found no association of truncating variants with breast cancer risk 
[Easton et al, 2016].  
The association of BRIP1 mutations and ovarian cancer risk is more consistent. 
Three independent large studies conducted in women diagnosed with ovarian 
carcinoma found 0.9-1.4% frequencies of deleterious mutations in this gene with RR 
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estimated to be 8.1-11.2 for the development of this disease [Rafnar et al, 2011, 
Ramus et al, 2015, Norquist et al, 2016].  
 
2.3.2. RAD51C and RAD51D 
Genes of the RAD51 protein family are involved in HR and DNA repair. The 
initial report of RAD51C involvement in cancer predisposition was done in families 
with breast and ovarian cancer [Meindl et al, 2010], but subsequent analyses only 
revealed an association of RAD51C or RAD51D mutations to the development of 
ovarian cancer [Loveday et al, 2011, Pelttari et al, 2011, Loveday et al, 2012, Pelttari 
et al, 2012, Song et al, 2015, Norquist et al, 2016]. Overall, mutations in these two 
genes together seem to account to about 1% of ovarian cancer cases, with estimates 
of RR varying from 5.2 to 6.3 for RAD51C and 6.3 to 12.0 for RAD51D. 
 
2.3.3. MLH1, MSH2, MSH6 and PMS2 
 Lynch syndrome is a hereditary disease caused by germline mutations in one 
of the DNA mismatch repair genes (MMR), MLH1, MSH2, MSH6 or PMS2. Colorectal 
cancer is the most common cancer associated with this syndrome, with mutations in 
these genes accounting for 2-4% of all cases [Hampel et al, 2005, Hampel et al, 2008]. 
The lifetime risk for developing colorectal cancer in carriers of MMR mutations is 
estimated to be up to 80% and microsatellite instability is a common feature of these 
tumors, occurring in up to 90% of them [Aaltonen et al, 1994, Vasen et al, 1996]. Other 
tumors associated with this syndrome, in women, include endometrial and ovarian 
cancer, with risks estimated to be up to 54% and 24%, respectively [Bonadona et al, 
2011]. Ovarian cancers in Lynch syndrome are usually diagnosed at a younger age 
(average 42-48) compared to the general population with a predominance of 
endometrioid/clear cells histology [Lu and Daniels, 2013, Helder-Woolderink et al, 
2016]. A summary of the contribution of genetic variants to ovarian cancer can be 
found on Figure 4. 
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Figure 4 – Estimated percentage contribution of genetic variants in consecutive series of ovarian cancer, namely, 
BRCA1 and BRCA2 genes, RAD51C, RAD51D, BRIP1, MMR genes (MLH1, MSH2, MSH6 and PMS2) and SNPs 
[Walsh et al, 2011, Kuchenbaecker et al, 2015, Song et al, 2015, Norquist et al, 2016]. 
 
2.3.4. Low penetrance ovarian cancer predisposition alleles 
Similar to breast cancer, several common genetic variants associated with an 
increased risk for the development of ovarian cancer have been described. In total, 
18 different loci have been identified, explaining approximately 3.9% of the excess 
familial relative risk of ovarian cancer in the general population [Kuchenbaecker et al, 
2015]. The majority of the identified loci displayed associations in BRCA1 and BRCA2 
mutation carriers similar with the associations observed in cases from the general 
population, suggesting a general model of susceptibility whereby BRCA1 and BRCA2 
mutations and common alleles interact multiplicatively on the relative risk for ovarian 
cancer [Wacholder et al, 2011]. Hence, the incorporation of ovarian cancer 
susceptibility variants for risk assessment might be particularly useful for 
BRCA1/BRCA2 mutation carriers. 
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2.4. Homologous recombination and predisposition to breast 
and ovarian cancer 
During chromosome replication, errors can occur that ultimately result in a stall 
of DNA replication forks. Stalled forks can be cleaved to generate DSBs and these 
can be repaired by HR, an error-free DNA repair mechanism that uses an undamaged 
sister chromatid as a template. In the absence of HR, DSBs can be repaired by error-
prone mechanisms, such as NHEJ, that generate chromosome deletions and 
translocations causing genomic instability [Schlacher et al, 2011]. BRCA1 and BRCA2 
are individually essential for efficient HR in mammalian cells, but there are other 
proteins involved in this pathway [Moynahan et al, 1999, Moynahan et al, 2001]. 
The DNA damage response (DDR) to DSBs involves sensors for the detection 
of broken ends, effectors that execute repair and mediators that facilitate interactions 
between sensors and effectors. It also includes the activation of checkpoints that allow 
time for DNA repair to be executed, by delaying the cell cycle before or during 
replication or before cell division (Figure 5) [Roy et al, 2012]. BRCA1 binds to DSBs 
through its association with the abraxas-RAP80 complex that is activated by 
ubiquitylated histones at DSBs [Wang et al, 2007]. BRCA1 is also involved in 
processing DSBs, forming a complex with CtIP that associates with the MRN complex 
(MRE11-RAD50-NBS1), a DNA damage sensor, and promotes resection of 5´ends of 
the broken DSB ends. After resection of DSBs, long stretches of 3’ ssDNA are 
produced on either side of the DSB. Replication protein A (RPA) binds to the ssDNA 
preventing the formation of secondary DNA structures. Another BRCA1 complex 
(BRCA1/PALB2/BRCA2) promotes the exchange of RPA for RAD51. Phosphorylation 
of BRCA1 by CHK2 seems to be required for the formation of this 
BRCA1/PALB2/BRCA2 effector complex [Roy et al, 2012]. BRCA2 is an important 
mediator in the recruitment of RAD51 and on its function as an effector of HR. RAD51 
must form a helical nucleoprotein filament on ssDNA but, under normal conditions, 
RAD51 preferentially forms stable complexes on dsDNA. BRCA2 binds directly to 
RAD51, through its BRC repeats, stabilizing RAD51 filament formation on ssDNA 
while inhibiting RAD51-dsDNA binding. The RAD51-ssDNA filament subsequently 
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mediates sister chromatid strand invasion, promoting DNA pairing between 
homologous sequences resulting in an error-free repair [Venkitaraman, 2014]. 
 
 
Figure 5 – Homologous recombination. In response to DNA DSBs, sensors (light blue) detect the damage, and 
signaling mediators recruit or activate effectors that repair the damage and activate cell cycle checkpoints. 
BRCA1-containing macro-complexes (dark blue) are crucial mediators of the DNA damage response. The BRCA1–
abraxas–RAP80 complex associates with ubiquitylated histones near the sites of DNA damage, that is dependent 
on phosphorylation of histone H2AX. The BRCA1-CtIP complex associates with the MRN complex (MRE11-
RAD50-NBS1), which senses DSBs and is responsible for DSB resection. The BRCA1-PALB2-BRCA2 complex is 
important in mediating RAD51-dependent HR. CHK2-dependent phosphorylation of S988 in BRCA1 appears to 
be required for the BRCA1–PALB2–BRCA2 effector complex, which is important in RAD51-mediated HR. DNA 
damage is also recognized by ATM and ATR kinases, which phosphorylate BRCA1, BRCA1-associated proteins 
and p53 and mediate signaling to form macro-complexes and activate cell cycle checkpoints [adapted from Roy et 
al, 2012]. 
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Germline mutations in many of the genes involving this common HR pathway 
are associated with predisposition to breast and/or ovarian cancer, which suggests 
that this pathway is crucial in the suppression of tumorigenesis.  
 
3. Hereditary breast and ovarian cancer diagnosis and 
management 
 
3.1. Risk assessment 
 Assessment of the a priori probability of finding a BRCA1 or BRCA2 mutation 
is essential to select patients who are eligible for genetic testing. In general, this risk 
increases with increasing number of personal and family history of associated cancers 
and decreasing age at which those cancers were diagnosed. The National 
Comprehensive Cancer Network (NCCN) panel has recommendations on the criteria 
for referral of patients to genetic counseling for a personalized risk assessment 
[NCCN, 2016]. Briefly, they include any breast cancer diagnosed before 45 years old, 
a breast cancer diagnosed before 50 years old plus another primary breast cancer or 
family history of breast, pancreatic or prostate, or a breast cancer diagnosed at any 
age plus one of the following: one close blood relative with breast cancer before 50 
years, two relatives with breast cancer, one family member affected with ovarian 
cancer, one case of male breast cancer in the family or two cases of prostate and/or 
pancreatic cancer. Individuals with ovarian cancer or male breast cancer diagnosed 
at any age should also be referred to genetic counseling. An individual diagnosed with 
prostate or pancreatic cancer also fulfills criteria for genetic counseling if they have a 
family history of other tumors (breast, ovarian, pancreatic or prostate).  
 
3.2. Genetic testing 
The criteria for genetic testing might vary between countries based on mutation 
prevalence and the existence of founder mutations. Several methods to determine the 
likelihood of detecting a BRCA1 or BRCA2 mutation exist, including computer models 
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such as BRCAPRO or BOADICEA [Parmigiani et al, 1998, Antoniou et al, 2008]. A 
common threshold to perform genetic testing in several countries is 10% [NICE 
guidelines [CG164], 2015]. Genetic testing should be performed in adults after they 
have received genetic counseling and given informed consent and, whenever 
possible, in the affected family member with the highest likelihood of carrying a BRCA1 
or BRCA2 mutation. 
Until recently, genetic testing of hereditary breast and ovarian cancer had been 
based on the identification of mutations in BRCA1/BRCA2 by Sanger sequencing or 
alternative screening methods that are labor-intensive, have low throughput, and high 
turnaround time. With the advent of next-generation sequencing (NGS), a multi-gene 
testing approach is now possible, including other genes of high or moderate 
penetrance to breast and ovarian cancer, which can explain a fraction of 
BRCA1/BRCA2 negative families. The detection of a deleterious germline mutation in 
an established breast or ovarian cancer predisposition gene has the potential to alter 
clinical management [Desmond et al, 2015]. However, knowledge on the penetrance 
and the clinical utility of germline mutations in many of the genes included in 
commercial panels is still incomplete and, for some, the information from testing does 
not change risk management compared to that based of family history alone [Easton 
et al, 2015]. Furthermore, the probability of finding variants of uncertain significance 
(VUS) increases when genetic testing is performed for multiple genes.  
 
3.3. Surveillance and prevention 
 Breast cancer surveillance in carriers of a BRCA1 or BRCA2 mutation includes 
breast self-examination, clinical breast examination, mammography and magnetic 
resonance imaging (MRI). Mammography has been the standard screening method 
for detection of breast cancer in the last decades, but recently has been under great 
scrutiny because decreasing breast cancer mortality rates have been more attributed 
to improvements in treatment than mammography. Furthermore, a lower sensitivity for 
detection of breast cancers in high-risk women was observed due to a variety of 
factors, including an increased density of breast tissue and the presence of more 
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aggressive and rapidly growing tumors, both of which are common in younger women 
[Tilanus-Linthorst et al, 2002]. MRI has greater sensitivity, although with a lower 
specificity, and studies have demonstrated that a combination of MRI and 
mammography detects 70-100% of tumors in high-risk women [Kriege et al, 2004, 
Warner et al, 2004, Leach et al, 2005].  
Current guidelines for female carriers recommend monthly breast self-
examination, starting at age 18, and semiannual clinical breast examination beginning 
at age 25 years [NCCN, 2016]. MRI screening should be performed between the ages 
of 25 and 29 years with both annual mammography and MRI recommended between 
30-75 years. After age 75, management should be considered on an individual basis. 
Current surveillance methods available for ovarian cancer (transvaginal ultrasounds 
and CA-125 serum levels) should only be considered for women who have not opted 
to perform ovarian cancer risk-reducing surgery, as they have not been shown to be 
effective [Evans et al, 2009]. 
Male carriers of a BRCA1/BRCA2 mutation are recommended to perform 
monthly breast self-examination and annual clinical breast examination starting at age 
35 years. Screening for prostate cancer after age 40 is recommended for BRCA2 
carriers and should be considered for BRCA1 carriers. For both male and female 
carriers, a full body skin and eye exam for melanoma screening and investigational 
screening protocols for pancreatic cancer should be considered [NCCN, 2016]. 
 Risk-reduction surgeries are one of the options for women at high risk of breast 
and ovarian cancer. These include risk-reducing mastectomy (RRM) and risk-reducing 
bilateral salpingo-oophorectomy (RRBSO). RRM decreases the risk of developing 
breast cancer by at least 90% [Hartmann et al, 2001]. Complete removal of breast 
tissue is not obtained and, therefore, there is a small residual risk of breast cancer 
[Rebbeck et al, 2004]. RRBSO has been shown to reduce the risk of ovarian cancer 
by about 80% and breast cancer risk by approximately 50%, if performed before 40-
45 years old, although a recent study suggests that estimates of breast cancer risk 
after RRBSO may be overestimated due to several types of bias [Rebbeck et al, 2009, 
Heemskerk-Gerritsen et al, 2015]. Current guidelines from the NCCN panel support 
discussing the option to perform RRM for women on a case-by-case basis, taking into 
INTRODUCTION 
44 
 
account the potential psychosocial effects of RRM, and recommend the performance 
of RRBSO due to the absence of reliable screening methods for ovarian cancer and 
its poor prognosis. As ovarian cancer is more common and has a younger age of 
onset in BRCA1 carriers, the recommendation to perform RRBSO in these is between 
ages 35 and 40 years and between 40-45 years for BRCA2 carriers, in both cases 
after completion of childbearing [NCCN, 2016]. 
 The most recent NCCN guidelines already recommend breast MRI screening 
for carriers of ATM, CHEK2 and PALB2 mutations (in addition to previously known 
breast cancer genes BRCA1, BRCA2, TP53, CDH1, STK11 and PTEN), and that the 
possibility of RRM should be discussed with PALB2 carriers. Carriers of mutations in 
ovarian cancer susceptibility genes (BRIP1, RAD51C and RAD51D), on the other 
hand, should consider the option of performing RRBSO in line with what is 
recommended for BRCA1/BRCA2 and Lynch syndrome carriers [NCCN, 2016]. 
 Tamoxifen, a selective estrogen receptor modulator, works by binding to the 
estrogen receptor, blocking the proliferative effect of estrogen on breast tissue. This 
agent has been shown to be effective in reducing the risk of breast cancer by about 
50% in high-risk women [Fisher et al, 1998]. It has also been associated with a 
reduction in risk for contralateral breast cancer in BRCA1/BRCA2 carriers [Gronwald 
et al, 2006]. In unaffected individuals, the association with risk reduction was seen 
only in BRCA2 mutation carriers, but the available data are too limited for statistical 
significance [King et al, 2001]. The use of oral contraceptives has been shown to 
reduce risk for ovarian cancer by about 50% in both BRCA1 and BRCA2 mutation 
carriers [Iodice et al, 2010]. There are conflicting reports regarding its effect on breast 
cancer risk, but no association seems to exist between the use of oral contraceptives 
and risk for breast cancer in BRCA1/BRCA2 mutation carriers [Moorman et al, 2013]. 
 
3.4. Targeted therapy 
 BRCA1 and BRCA2 mutation carriers can also benefit from targeted therapy. 
BRCA1 and BRCA2 are critical proteins in the process of HR repair of DSBs. The 
absence of HR, which is a characteristic of BRCA1/BRCA2 deficient cancer cells, 
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activates error-prone DSB mechanisms like NHEJ and results in genomic instability 
[Bryant et al, 2005]. BRCA1/BRCA2-deficient cancers are now recognized as the 
target for a class of drugs known as PARP (poly (ADP-ribose) polymerase) inhibitors. 
PARP inhibition, by blocking Base Excision Repair (BER), prevents single-strand 
break repair and leads to the formation of DSBs, which cannot be accurately repaired 
in HR-deficient cells and may result in cell death [Ashworth, 2008]. This synthetic 
lethality in BRCA-deficient tumors is the basis for the improved response in patients 
treated with PARP inhibitors. So far, PARP inhibitors have been approved in Europe 
and in the USA for the treatment of ovarian cancer in BRCA1/BRCA2 mutation carriers 
[Ledermann et al, 2014]. They are also currently being evaluated for the treatment of 
other BRCA-associated tumors and for the treatment of patients with mutations in 
other genes that could impair HR [Kaufman et al, 2015, Mateo et al, 2015]. 
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The aims of this thesis were to characterize the phenotypic heterogeneity 
associated with BRCA1 and BRCA2 mutations and the genetic heterogeneity of 
hereditary breast and ovarian cancer. Specifically, the objectives of this thesis were: 
 
1. To develop a method to detect the founder mutations BRCA2 
c.156_157insAlu and BRCA1 c.3331_3334del in formalin-fixed paraffin-
embedded archival tissue. 
 
2. To quantify the contribution of the founder mutations BRCA2 
c.156_157insAlu and BRCA1 c.3331_3334del for cancer etiology in 
unselected hospital-based cohorts of patients diagnosed with rarer 
cancers associated with hereditary breast and ovarian cancer 
syndrome, namely, cancer of the pancreas, male breast, peritoneum, 
and fallopian tube. 
 
3. To compare the sensitivity and specificity of next-generation sequencing 
and Sanger sequencing for the detection of point mutations in the 
BRCA1 and BRCA2 genes. 
 
4. To evaluate the genetic heterogeneity of hereditary breast and ovarian 
cancer by analyzing a panel of 17 genes associated with predisposition 
to these diseases in a consecutive series of high-risk breast/ovarian 
cancer families. 
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Abstract 
BRCA1 and BRCA2 mutations are responsible for hereditary breast and 
ovarian cancer, but they also confer an increased risk for the development of rarer 
cancers associated with this syndrome, namely, cancer of the pancreas, male breast, 
peritoneum, and fallopian tube. The objective of this work was to quantify the 
contribution of the founder mutations BRCA2 c.156_157insAlu and BRCA1 
c.3331_3334del for cancer etiology in unselected hospital-based cohorts of 
Portuguese patients diagnosed with these rarer cancers, by using a strategy that 
included testing of archival tumor tissue. A total of 102 male breast, 68 pancreatic and 
33 peritoneal/fallopian tube carcinoma cases were included in the study. The BRCA2 
c.156_157insAlu mutation was observed with a frequency of 7.8% in male breast 
cancers, 3.0% in peritoneal/fallopian tube cancers, and 1.6% in pancreatic cancers, 
with estimated total contributions of germline BRCA2 mutations of 14.3%, 5.5%, and 
2.8%, respectively. No carriers of the BRCA1 c.3331_3334del mutation were 
identified. During our study, a patient with an ampulla of Vater carcinoma was 
incidentally found to carry the BRCA2 c.156_157insAlu mutation, so we decided to 
test a consecutive series of additional 15 ampullary carcinomas for BRCA1/BRCA2 
mutations using a combination of direct founder mutation testing and full gene analysis 
with next generation sequencing. BRCA2 mutations were observed with a frequency 
of 14.3% in ampulla of Vater carcinomas. In conclusion, taking into account the 
implications for both the individuals and their family members, we recommend that 
patients with these neoplasias should be offered BRCA1/BRCA2 genetic testing and 
we here show that it is feasible to test for founder mutations in archival tumor tissue. 
Furthermore, we identified for the first time a high frequency of germline BRCA2 
mutations in ampullary cancers. 
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Introduction 
Inherited predisposition to breast cancer is estimated to account for about 5-
10% of all cases and is characterized by an autosomal dominant pattern of 
inheritance, young age at presentation, and association with bilateral breast cancer 
and ovarian cancer [1, 2]. It has been estimated that up to 1 in 300 and 1 in 800 
individuals of the general population carry a BRCA1 or BRCA2 mutation, 
respectively, two genes that are responsible for hereditary breast and ovarian cancer 
(HBOC). Women carrying germline BRCA1 mutations have a cumulative risk at 70 
years of 60% for breast cancer and 59% for ovarian cancer, whereas BRCA2 
mutations appear to confer a similar risk of breast cancer in females (55%), but a 
lower risk (17%) for ovarian cancer [3]. Mutation analysis is required to confirm the 
clinical suspicion of HBOC and to allow appropriate screening and prophylactic 
measures to carriers in the family [2].  
Molecular analyses of the BRCA1 and BRCA2 genes have shown that most 
populations exhibit a wide spectrum of mutations throughout both genes and several 
founder mutations have been identified in individuals of different ancestries [4]. We 
have recently characterized the mutational spectrum of the BRCA1 and BRCA2 
genes in Portuguese HBOC families [5], showing that it is indeed heterogeneous, 
including two prevalent founder mutations, the BRCA2 c.156_157insAlu mutation 
and the BRCA1 c.3331_3334del mutation. The BRCA2 c.156_157insAlu mutation 
was present in 32% of all Portuguese HBOC families and represented 55% of the 
BRCA2 mutations, whereas the BRCA1 c.3331_3334del mutation was present in 
11% of all families and 26% of the families with a BRCA1 mutation, together 
representing a large proportion of the mutations identified in Portuguese HBOC 
families. The BRCA2 c.156_157insAlu mutation has only been reported in families 
of Portuguese ancestry [5-10], whereas the BRCA1 c.3331_3334del mutation has 
been reported in several populations, including Spanish, Canadian and Colombian 
[11-13].  
Mutations in the BRCA1/BRCA2 genes have also been associated with 
inherited predisposition to other cancers in HBOC families, like those of the prostate, 
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pancreas, male breast, peritoneum, and fallopian tube [14, 15]. We have recently 
evaluated the contribution of the germline BRCA1/BRCA2 founder mutations for early-
onset and/or familial prostate cancer in Portugal [16]. Mutations in BRCA2 confer a 
higher risk for developing cancers of the pancreas and male breast, and BRCA1 
mutations seem to be predominantly associated with a higher risk for developing 
peritoneal and fallopian tube cancer. The objective of this work was to quantify the 
contribution of the founder mutations BRCA2 c.156_157insAlu and BRCA1 
c.3331_3334del for cancer etiology in unselected hospital-based cohorts of patients 
diagnosed with these rarer cancers in Portugal. 
 
Materials and Methods 
Ethics Statement 
This study was approved by the Institutional Ethics Committee of the 
Portuguese Oncology Institute of Porto (IPO-Porto) (approval number CES 019/08 
regarding the use of archival samples for research) and written informed consent was 
obtained for all patients referred for genetic counselling. 
 
Subjects 
A consecutive series of patients diagnosed at IPO-Porto with any of the cancers 
strongly associated with HBOC besides female breast, ovarian, and prostate cancer 
(pancreatic, male breast, peritoneal and fallopian tube) from 1997 to 2013, and from 
which formalin-fixed, paraffin-embedded (FFPE) tissue was available, was identified. 
A total of 68 patients with pancreatic tumors (65 ductal adenocarcinomas, 1 mixed 
ductal-neuroendocrine carcinoma, 1 intraductal papillary mucinous neoplasm with an 
associated invasive carcinoma and 1 mucinous cystic neoplasm with low grade 
dysplasia), 27 with male breast invasive ductal carcinomas of no special type and 33 
with peritoneal/fallopian tube high-grade serous carcinomas were included in the 
study with FFPE tissue. Given the large retrospective period of time covered, 
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peritoneal/fallopian tube carcinomas included in the study were limited to those that 
involved the peritoneum and/or fallopian tube without or only with superficial (<5mm) 
involvement of the ovary. Furthermore, a consecutive series of 16 patients diagnosed 
at IPO-Porto with carcinomas of the ampullary region (7 pancreato-biliary type and 9 
intestinal type adenocarcinomas), from 1997 to 2013, and from which FFPE tissue 
was available, were subsequently included. Hematoxylin and eosin-stained slides 
were carefully reviewed by a pathologist, who delimited tumor and surrounding non-
tumoral areas. Family history was not available from any of the patients from whom 
FFPE tissue was collected. Patients where a mutation was identified during this study 
were subsequently contacted to provide genetic counselling and to offer their family 
history. 
Additionally, 75 male breast cancer (MBC) patients (39 previously reported by 
Peixoto et al. [5]) that were referred to the Genetics Department of IPO-Porto for 
genetic testing of BRCA1/BRCA2 mutations, not selected for family history of cancer, 
were also included and peripheral blood samples were collected, giving a total of 102 
MBC patients.  
 
Founder Mutation Screening 
In FFPE samples, DNA extraction was performed from both tumor and 
surrounding non-tumoral tissue, whenever available, with the QIAamp DNA FFPE 
Tissue Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s protocol and 
DNA quality was evaluated with the NanoDrop ND-1000 (Thermo Fisher Scientific, 
Waltham, MA). The BRCA2 c.156_157insAlu mutation was detected by amplification 
of exon 3 followed by a nested PCR specific for the Alu rearrangement. BRCA2 exon 
3 amplification was performed with the following primers: forward 5`-
CTGAACCTGCAGAAGAATCTGAA-3`; reverse 5`-
GAAGCCAGCTGATTATAAGATGGTT-3`. The cycling conditions were 94ºC for 1 
min, 35 cycles of 94ºC for 1 min, 52ºC for 1 min, and 72ºC for 4 min, and a final 
extension of 72ºC for 10 min. In the nested PCR, specific primers for the 
c.156_157insAlu mutation were used (forward 5`-GACACCATCCCGGCTGAAA-3`; 
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reverse 5`-GAAGCCAGCTGATTATAAGATGGTT-3`) and the cycling conditions were 
95ºC for 10 min, 25 cycles of 95ºC for 45 sec, 62ºC for 45 sec, and 72ºC for 45 sec, 
and a final extension of 72ºC for 7 min. In the first PCR, due to preferential 
amplification of the shorter allele, only one amplicon of 111 bp corresponding to the 
wild-type allele is visible. In the nested PCR, a second amplicon (in positive samples) 
of about 343 bp corresponding to the allele with the c.156_157insAlu mutation is 
expected (Fig 1A). Sequence analysis of genomic fragments with the insertion was 
carried out on an ABI PRISM 310 Genetic Analyser (Applied Biosystems, Carlsbad, 
CA), using the dye terminator method. 
 
Figure 1 – Detection of the BRCA2 c.156_157insAlu mutation and the BRCA1 c.3331_3334del mutation in 
FFPE tissue. (A) Gel electrophoresis pattern of amplification of BRCA2 exon 3 (left panel) and nested PCR specific 
for the BRCA2 c.156_157insAlu mutation (right panel). In non-carriers of the mutation (N) only one amplicon is 
expected, whereas in carriers (P) a second amplicon is visible in the nested PCR. Non template control (NTC) and 
100 bp DNA standard (M) also shown. (B) Capillary electrophoresis pattern from a negative sample (left panel) 
and a positive control of the BRCA1 c.3331_3334del mutation (right panel) showing one peak (wild-type alleles) 
and two peaks (wild-type and mutant allele with 4 bp deletion), respectively. 
 
The c.3331_3334del mutation located in BRCA1 exon 11 was screened using 
the labelled primers forward 5`-TTAAAGAAGCCAGCTCAAGC-3` and reverse 
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5`HEX-CTGAAATCAGATATGGAGAG-3`, with the following cycling conditions: 95ºC 
for 10 min, 35 cycles of 95ºC for 45 sec, 58ºC for 45 sec, and 72ºC for 45 sec, and a 
final extension of 72ºC for 10 min. Each sample was run on an ABI PRISM 310 Genetic 
Analyser together with a fluorescence labeled DNA fragment size standard. The 
c.3331_3334del mutation status was determined by the presence of one or two peaks 
corresponding to the wild type and mutated samples, respectively (Fig 1B). All 
mutations were confirmed by Sanger DNA sequencing. 
In patients from whom DNA was extracted from peripheral blood samples, both 
the BRCA2 c.156_157insAlu and BRCA1 c.3331_3334del mutations were screened 
as previously described [5]. 
 
Next-Generation Sequencing 
Next-generation sequencing (NGS) was performed in 12 ampullary tumors in 
which no founder mutations had been found (in two tumors DNA did not have enough 
quality). Library preparation was performed using the BRCA Tumor MASTR™ Plus 
Dx (Multiplicom, Niel, Belgium), which targets the full coding sequence and adjacent 
intronic regions of the BRCA1/BRCA2 genes and is optimized for FFPE tissue, 
following the manufacturer’s protocol. Sequencing was carried out using a standard 
flow cell in the MiSeq platform (Illumina, Inc., San Diego, CA, USA) in a 2x250 bp 
paired end run. Sequencing alignment and variant analysis was performed using the 
software Sophia DDM® version 3.5 (Sophia Genetics, Saint-Sulpice, Switzerland). All 
variants with an alternative variant frequency ≤5%, minor allele frequency (MAF) >1% 
and/or intronic variants at more than 12bp away from exon-intron boundaries were 
excluded. For MAF filtering, data was obtained from the 1000 Genomes Project 
(1000G; Based on Project Phase III Data), Exome Variant Server (from NHLBI Exome 
Sequencing Project) and Exome Aggregation Consortium (ExAC) databases. 
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Results 
A total of 102 MBC patients were analyzed for both the BRCA2 
c.156_157insAlu and BRCA1 c.3331_3334del mutations. Of the total samples 
analyzed, eight (7.8%) were positive for the BRCA2 c.156_157insAlu mutation (three 
detected in FFPE and five in peripheral blood samples, of which two had previously 
been reported by us [5]) and the BRCA1 c.3331_3334del mutation was not identified 
in any case (Table 1). Of the three patients where the mutation was identified in FFPE 
tissue, in one the mutation was confirmed to be germline in peripheral blood, another 
was deceased but belonged to a family that had already been identified in our 
institution, and in the third it was not possible to test the germline. The age of diagnosis 
of breast cancer in the BRCA2 carriers ranged from 47 to 78 years old with a median 
age of 65 years. It was possible to obtain family history information for seven patients 
and all of them had a family history of cancers associated with HBOC. One of the 
patients, besides breast cancer at the age of 47, was also diagnosed with prostate 
cancer at the age of 55 and four women in his family were diagnosed with breast 
cancer. Four patients had only family history of female breast cancer, two with one 
family member (Fig 2A), one with three family members, and the other with five women 
affected with breast cancer. One patient had three family members affected with 
female breast cancer and one with ovary cancer. The last patient belongs to a large 
family with 12 cases of female breast cancer, five cases of prostate cancer and one 
case with pancreatic cancer. 
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Table 1 – Samples analyzed and mutation frequencies observed in tumors associated 
with HBOC. 
Cancer Samples BRCA2 c.156_157insAlu 
BRCA1 
c.3331_3334del 
% 
Positive 
Estimated 
BRCA2 (%)a 
BRCA1 / 
BRCA2 (%) 
Male Breast 102 8 0 7.8 14.3 NA 
Peritoneal / 
Fallopian Tube 33 1 0 3.0 5.5 NA 
Pancreatic 64 1 0 1.6 2.8 NA 
Ampullary 16 2 0 12.5 NA 14.3b 
NA – Not available/not applicable 
a BRCA2 c.156_157insAlu represents 55% of the total BRCA2 mutations identified in Portuguese HBOC 
families that performed screening of the entire BRCA1/BRCA2 coding regions [5]. 
b Frequency of BRCA1/BRCA2 mutations observed in the 14 samples in which screening of the entire 
BRCA1/BRCA2 coding regions was performed. 
PAPER I 
63 
 
 
Figure 2 – Pedigrees of individuals with the BRCA2 c.156_157insAlu mutation detected in FFPE tissue. 
Family of an individual with male breast cancer (A), an individual with peritoneal/fallopian tube cancer (B), and one 
individual with an ampulla of Vater carcinoma (C). The index case is indicated by an arrow. 
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In the 33 patients with peritoneal/fallopian tube cancer analyzed, none was 
carrier of the BRCA1 c.3331_3334del mutation and one patient (3.0%) was a carrier 
of the BRCA2 c.156_157insAlu mutation (Table 1). This patient was diagnosed at 74 
years old with a high-grade serous carcinoma of the fallopian tube with extensive 
involvement of the peritoneum. The mutation was confirmed to be germline in 
peripheral blood and the patient belonged to a family that had already been identified 
in our institution. She was also diagnosed with breast cancer at 56 years of age and 
had two sisters with breast cancer (Fig 2B). 
An initial series of 69 consecutive cases of putative pancreatic carcinoma was 
analyzed for the Portuguese founder mutations. Of these, four samples did not have 
good quality DNA and it was not possible to obtain a result. The BRCA2 
c.156_157insAlu mutation was identified in two samples and no carriers of the BRCA1 
c.3331_3334del mutation were found. When the histopathology material was 
reviewed it was shown that one of the patients carrying the BRCA2 c.156_157insAlu 
mutation had a pancreato-biliary type adenocarcinoma that originated in the ampulla 
of Vater and not in the pancreas. Hence, a consecutive series of 15 carcinomas of the 
ampulla of Vater were collected in order to evaluate the contribution of the founder 
mutations for the pathogenesis of these tumors. One more patient carrying the BRCA2 
c.156_157insAlu mutation was identified in this series, giving a total of two (12.5%) 
positive samples in the 16 cases of ampullary cancer analyzed for founder mutations 
(Table 1). The first carrier identified was diagnosed with an adenocarcinoma of the 
ampulla of Vater at the age of 73 and had been previously diagnosed with prostate 
cancer at 65 years old. The mutation was confirmed to be germline in peripheral blood 
and his family history included his mother and one sister diagnosed with breast cancer 
at the ages of 45 and 60, respectively (Fig 2C). The other patient was diagnosed at 
68 years also with a pancreato-biliary type adenocarcinoma of the ampullary region 
and had no family history of tumors associated with HBOC, only one sister diagnosed 
with colorectal cancer.  
Given the high frequency of the BRCA2 c.156_157insAlu mutation observed in 
the ampullary tumors analyzed, we decided to perform screening of the entire 
BRCA1/BRCA2 coding regions by NGS. In two of the fourteen negative samples for 
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founder mutations it was not possible to obtain DNA of sufficient quality to perform the 
analysis. A median coverage of 5100 was obtained for BRCA1 and of 3770 for BRCA2 
with a minimum coverage of 150 obtained in all samples and only 4.3% of the exons 
analyzed with a minimum coverage below 500 (data not shown). No additional 
BRCA1/BRCA2 deleterious mutations were identified in the 12 samples analyzed by 
NGS (Table 1). 
Of the 64 pancreatic cancer samples where it was possible to obtain a result, 
one (1.6%) individual carrying the BRCA2 c.156_157insAlu mutation was identified 
and none was a carrier of the BRCA1 c.3331_3334del mutation (Table 1). This patient 
was diagnosed with an intraductal papillary mucinous neoplasm with an associated 
invasive carcinoma (ductal adenocarcinoma) of the pancreas at the age of 72 and he 
had one cousin diagnosed with ovary cancer and another with breast cancer.  
 
Discussion 
The aim of this study was to quantify the contribution of the founder mutations 
prevalent in Portugal (BRCA2 c.156_157insAlu and BRCA1 c.3331_3334del) for 
cancers associated with HBOC other than the common female breast, ovarian, and 
prostate cancer, more specifically, the rarer pancreatic, male breast, peritoneal, and 
fallopian tube cancers. In the 102 MBC patients screened for these mutations, we 
identified eight (7.8%) carriers of the BRCA2 c.156_157insAlu mutation. Although 
these patients were not selected for family history of cancer, all the seven carriers 
from whom it was possible to obtain information about family history had at least one 
more family member affected with breast cancer. BRCA2 mutations are considered 
the major genetic risk factor for male breast cancer, conferring a lifetime cumulative 
risk to develop the disease of about 9% [17], but the frequency of these mutations 
varies considerably between different populations. A study in Southern California 
detected BRCA2 mutations in 4% of MBC patients [18], whereas another study in 
Iceland found mutations in the BRCA2 gene in 40% of the cases [19]. More recent 
and larger studies in Israel, Italy and USA described prevalences of 8%, 7%, and 16%, 
respectively, of BRCA2 mutations in male breast cancer patients [20-22]. These 
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differences in the frequency of BRCA2 mutations across different studies can be 
caused by small sample sizes, mutation screening methods with different sensitivities, 
mutation screening strategy (entire gene vs founder mutations only), 
presence/absence of family history of tumors associated with HBOC or different 
classifications of missense mutations. In our study, only the c.156_157insAlu mutation 
was tested, which accounts for about 55% of all families with pathogenic BRCA2 
mutations in the Portuguese population [5]. Hence, we could expect an overall 
frequency of about 14.3% of BRCA2 germline mutations in Portuguese male breast 
cancer patients in an unselected hospital-based cohort. On the other hand, our data 
shows that germline BRCA1 mutations have a limited contribution to the pathogenesis 
of male breast cancer, which is in accordance with the literature [22, 23]. 
 In the series of 33 peritoneal/fallopian tube cancers analyzed, we identified only 
one patient (3.0%) carrying the BRCA2 c.156_157insAlu mutation (estimated total 
contribution of BRCA2 mutations of 5.5%) and no carriers of the BRCA1 
c.3331_3334del mutation. There are only a few studies that have analyzed the 
frequency of BRCA1/BRCA2 mutations in fallopian tube and peritoneal cancer 
independently of ovarian cancer. Alsop and colleagues [24] analyzed a series of 152 
patients with peritoneal cancer and 40 with fallopian tube cancer and identified a total 
of 15.8% and 20% patients carrying a BRCA1/BRCA2 mutation, respectively. Another 
study performed on 108 patients with fallopian tube cancer identified 21% of patients 
with a mutation in BRCA1 and 9% in BRCA2, whereas one study performed on 79 
patients with peritoneal/fallopian tube cancer identified mutations in BRCA1/BRCA2 
in 23% of the patients [25, 26]. Our low frequency of mutations (3.0%) identified 
compared to these studies can be explained by the fact that only founder mutations 
were analyzed and the BRCA1 founder mutation, which is the gene more commonly 
associated with these tumors, only represents 11% of all families and 26% of the 
families identified with a BRCA1 mutation in Portuguese HBOC families. Whereas our 
estimation of the contribution of BRCA2 germline mutations for peritoneal/fallopian 
tube cancers in hospital-based cohorts is likely to be reliable, the evaluation of the 
contribution of BRCA1 mutations may require additional larger studies that include full 
gene analysis.   
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We have also evaluated the contribution of BRCA1/BRCA2 founder mutations 
in a consecutive series of pancreatic cancers diagnosed at a tertiary cancer center. 
One of the 64 tumors analyzed (1.6%) had the BRCA2 c.156_157insAlu mutation. 
Since this mutation represents 55% of all BRCA2 germline mutations in our 
population, it can be estimated that the total contribution of mutations in this gene for 
pancreatic cancer is about 2.8%. Most of the previous studies conducted for the 
detection of BRCA1/BRCA2 mutations in pancreatic cancer were performed in 
patients with a strong family history of the disease or in individuals with Ashkenazi 
Jewish ancestry and the reported prevalence of BRCA mutations is variable, ranging 
from 13% to 19% [27-30]. A recent study was carried out on an unselected, 
consecutive series of 306 patients from Canada with pancreatic ductal 
adenocarcinoma and mutations in BRCA2 were identified in 3.6% of the patients, with 
a total of 4.6% BRCA1/BRCA2 carriers identified [31], which does not differ 
significantly from our estimate for unselected Portuguese patients.  
Perhaps the most interesting aspect of our study was the recurrent finding of 
germline BRCA2 mutations in carcinomas of the ampullary region. Two of 16 cases 
of this rare tumor (12.5%) were shown to have the BRCA2 Portuguese founder 
mutation, with a 14.3% (2/14) frequency observed when considering only the samples 
with mutations and those in which all BRCA1/BRCA2 coding regions were analyzed. 
Ampullary carcinomas are very rare, accounting for about 0.5% of all gastrointestinal 
cancers, being often included in the group of pancreato-biliary tumors, but usually 
have a good prognosis when compared to pancreatic carcinomas [32]. Familial 
adenomatous polyposis (FAP) patients often develop ampullary adenomas that may 
progress to ampullary cancer, with a cumulative risk of 10% at the age 60 [33]. Until 
now, only one study has identified a BRCA2 mutation in one patient with a carcinoma 
of the ampulla of Vater, but it was identified in an individual with a family history of 
breast cancer where this mutation had previously been identified in other family 
members [34]. To our knowledge, this is the first study that has performed full analysis 
of the BRCA1/BRCA2 genes in a consecutive series of ampullary carcinomas. 
Although the mutation frequency observed is high, our sample size is relatively small 
PAPER I 
68 
 
and further studies are warranted to confirm the association of BRCA1/BRCA2 
mutations with this rare neoplasia.  
The identification of BRCA mutation carriers has implications for both the 
individuals and their family members, allowing reliable genetic counseling and 
predictive genetic testing. Female carriers of BRCA mutations can decide whether 
they want to participate in surveillance protocols and/or perform risk-reducing surgical 
interventions such as prophylactic bilateral mastectomy and bilateral salpingo-
oophorectomy, whereas mutation positive males can engage in breast and/or prostate 
cancer screening [15]. Moreover, BRCA mutation carriers can also benefit from 
targeted therapy. BRCA1 and BRCA2 are critical proteins in the process of 
homologous recombination (HR) repair of double-strand DNA breaks (DSBs). The 
absence of HR, which is a characteristic of BRCA1/BRCA2 deficient cancer cells, 
activates error-prone DSB mechanisms like non-homologous end joining (NHEJ) and 
results in genomic instability [35]. BRCA1/BRCA2-deficient cancers are now 
recognized as the target for a class of drugs known as PARP (poly (ADP-ribose) 
polymerase) inhibitors. PARP inhibition, by blocking Base Excision Repair (BER), 
prevents single-strand break repair and leads to the formation of DSBs, which cannot 
be accurately repaired in HR-deficient cells and may result in cell death [36]. This 
synthetic lethality in BRCA-deficient tumors is the basis for the improved response in 
patients treated with PARP inhibitors [37, 38]. We here show that rarer cancers 
besides female breast, ovarian, and prostate cancer may be sentinel features that 
allow the diagnosis of HBOC families and these patients may be included in clinical 
trials with PARP inhibitors. 
In conclusion, we report the contribution of founder mutations to rarer cancers 
associated with HBOC in Portugal and an optimized method for the detection of these 
mutations in FFPE tissue (applicable both in neoplastic cells or in the surrounding 
normal tissue). This optimized method for FFPE tissue is especially important for the 
detection of the BRCA2 c.156_157insAlu mutation in patients with Portuguese 
ancestry, as this prevalent mutation is not readily detectable by standard sequencing 
technologies [5, 10], therefore allowing its detection even in deceased patients 
diagnosed with poor prognosis cancers like that of the pancreas. The BRCA2 
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c.156_157insAlu mutation was observed with a frequency of 7.8% in male breast 
cancers, 3.0% in peritoneal/fallopian tube cancers, and 1.6% in pancreatic cancers, 
with estimated total contributions of germline BRCA2 mutations of 14.3%, 5.5%, and 
2.8%, respectively. In ampullary cancers, we here show for the first time a frequency 
of 14.3% BRCA1/BRCA2 mutations after a combination of direct founder mutation 
testing and full gene analysis in archival tissue with NGS. Taking into account the 
implications for both the individuals and their family members, we recommend that 
patients with these neoplasias may be offered BRCA1/BRCA2 genetic testing and we 
here show that it is feasible to reliably perform this analysis in FFPE tissue.   
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Abstract 
Molecular diagnosis of hereditary breast and ovarian cancer (HBOC) by 
standard methodologies has been limited to the BRCA1 and BRCA2 genes. With the 
recent development of new sequencing methodologies, the speed and efficiency of 
DNA testing has dramatically improved. The aim of this work was to validate the use 
of next-generation sequencing (NGS) for the detection of BRCA1/BRCA2 point 
mutations in a diagnostic setting and to study the role of other genes associated with 
HBOC in Portuguese families. A cohort of 94 high-risk families was included in the 
study and they were initially screened for the two common founder mutations with 
variant-specific methods. Fourteen index patients were shown to carry the Portuguese 
founder mutation BRCA2 c.156_157insAlu and the remaining 80 were analyzed in 
parallel by Sanger sequencing for the BRCA1/BRCA2 genes and by NGS for a panel 
of 17 genes that have been described as involved in predisposition to breast and/or 
ovarian cancer. A total of 506 variants in the BRCA1/BRCA2 genes were detected by 
both methodologies, with a 100% concordance between them.  This strategy allowed 
the detection of a total of 39 deleterious mutations in the 94 index patients, namely, 
10 in BRCA1 (25.6%), 21 in BRCA2 (53.8%), four in PALB2 (10.3%), two in ATM 
(5.1%), one in CHEK2 (2.6%), and one in TP53 (2.6%), with 20.5% of the deleterious 
mutations being found in genes other than BRCA1/BRCA2. These results 
demonstrate the efficiency of NGS for the detection of BRCA1/BRCA2 point mutations 
and highlight the genetic heterogeneity of HBOC. 
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Introduction 
More than 20 years have passed since the identification of the two major breast 
cancer susceptibility genes, BRCA1 and BRCA2 [1,2]. The identification of pathogenic 
mutations in these two genes in families with multiple cases of early onset breast 
cancer was at the time a major breakthrough in hereditary cancer genetics. In BRCA1 
and BRCA2 mutation carriers, the cumulative risk at 70 years of developing breast 
cancer is estimated to be 60% and 55%, respectively, whereas for ovarian cancer is 
estimated to be 59% and 17%, respectively [3]. Genetic testing of BRCA1/BRCA2 has 
several clinical implications, especially for female carriers, who should be offered the 
option to undergo annual MRI screening and mammography, prophylactic 
mastectomy and/or salpingo-oophorectomy [4]. In addition, BRCA1/BRCA2 mutation 
carriers can now benefit from the use of targeted therapy with the recent approval of 
PARP inhibitors for the treatment of ovarian cancer [5]. However, the contribution of 
BRCA1/BRCA2 pathogenic mutations to high-risk breast cancer families is only 
around 30%, and can vary according to the population and the criteria for selection of 
patients with predisposition to breast and/or ovarian cancer [6]. In a recent study from 
our group, 28.9% of the families with an a priori BRCAPRO mutation probability >10% 
harbored deleterious mutations in these genes [7].  
Until now, molecular diagnosis of hereditary breast and/or ovarian cancer 
(HBOC) has been based on the identification of mutations in BRCA1/BRCA2 and is 
usually performed by Sanger sequencing or alternative screening methods that are 
labor-intensive, have low throughput, and high turnaround time. With the recent 
development of next-generation sequencing (NGS), the speed and efficiency of DNA 
testing has dramatically improved. At the same time, NGS allows the possibility to 
analyze not only BRCA1/BRCA2 but multiple other genes that have been described 
as conferring an increased risk for the development of breast or ovarian cancer and 
that can explain a fraction of BRCA1/BRCA2 negative families. Germline mutations in 
TP53 (Li-Fraumeni syndrome) [8], CDH1 (Hereditary diffuse gastric cancer) [9], 
STK11 (Peutz-Jeghers syndrome) [10], and PTEN (Cowden syndrome) [11] 
predispose to a variety of different cancers, but have in common the fact that they 
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confer a high risk of breast cancer. Additionally, PALB2, ATM, CHEK2 and NBN are 
considered moderate risk breast cancer genes [12-15]. On the other hand, mutations 
in Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2), together with those in 
BRIP1, RAD51C and RAD51D, are associated with an increased risk for the 
development of ovarian cancer [16-19]. However, knowledge on the penetrance and 
the clinical utility of germline mutations in many of these genes is still incomplete [20]. 
The aim of this work was to validate the use of NGS for the detection of mutations in 
the BRCA1 and BRCA2 genes in a diagnostic setting by performing parallel analysis 
by Sanger sequencing and NGS in a consecutive series of high-risk breast/ovarian 
cancer families, as well as to evaluate the genetic heterogeneity in this setting by 
analyzing a panel of 17 genes associated with predisposition to those diseases.  
 
Methods 
Patients 
The study included a consecutive series of 94 patients referred to the Genetics 
Department of the Portuguese Oncology Institute of Porto (IPO Porto) with a family 
history of breast and/or ovarian cancer and with either an a priori >20% probability of 
finding a BRCA1/BRCA2 mutation using the BRCAPRO software or a high-risk familial 
history for which BRCAPRO could underestimate the mutation probability. Samples 
for genetic testing were obtained after genetic counseling according to institutional 
review board approved guidelines and standard clinical practice. DNA was extracted 
from peripheral blood leucocytes and its quality was evaluated using Qubit® 
Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). 
 
BRCA1/BRCA2 analysis 
Screening of the Portuguese founder mutations (BRCA1 c.3331_3334del and 
BRCA2 c.156_157insAlu) was initially performed in all cases using a methodology we 
previously described [7]. In the 80 samples in which no founder mutations were 
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identified, Sanger sequencing of the entire coding regions and adjacent intronic 
regions of BRCA1 and BRCA2 was performed using the BigDye® Terminator v3.1 
Cycle Sequencing Kit in a 3500 Genetic Analyzer (Thermo Fisher Scientific), 
according to the manufacturer’s instructions. Sanger sequencing was also performed 
for confirmation of all the deleterious variants identified by NGS. Multiplex Ligation-
dependent Probe Amplification (MLPA) (MRC-Holland, Amsterdam, Netherlands) was 
used to detect BRCA1/BRCA2 large genomic rearrangements (LGRs) in the 80 
samples negative for founder mutations, according to the manufacturer’s instructions. 
 
Next-generation sequencing 
Panel gene testing with NGS was used in the 80 samples in which no founder 
mutations were found after the initial screening. Library preparation was performed 
using the TruSight Cancer kit (Illumina, Inc., San Diego, CA, USA), which targets the 
full coding sequence of 94 genes involved in hereditary predisposition to cancer, 
following the manufacturer’s protocol. Sequencing was carried out using a standard 
flow cell in the MiSeq platform (Illumina, Inc.) in 2x150 bp paired end runs of 24 
samples. Sequencing alignment and variant analysis was performed using a 
bioinformatics pipeline previously validated by us for 23 different genes (Paulo et al., 
submitted). In brief, alignment and variant calling was done using three different 
software programs, namely, Isaac Enrichment (v2.1, Illumina, Inc.), BWA Enrichment 
(v2.1, Illumina, Inc.) and NextGENe (v2.3.4.4, Softgenetics, State College, PA, USA), 
with .vcf files being imported into GeneticistAssistantTM (Softgenetics) for variant 
annotation. For the purpose of this study, a virtual panel of 17 genes associated with 
predisposition to breast and/or ovarian cancer was created for variant analysis (Table 
1). Variants were retained according to the following criteria: ≤10% frequency in our 
in-house database, coverage ≥15x, alternative variant frequency ≥15% and minor 
allele frequency (MAF) <1%, excluding intronic variants more than 12bp away from 
exon-intron boundaries. For MAF filtering, data was obtained from the 1000 Genomes 
Project (1000G; Phase III Data), Exome Variant Server (ESP6500) and Exome 
Aggregation Consortium (ExAC) databases. 
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Table 1 – Genes included in the NGS panel associated with predisposition to breast/ovarian 
cancer. 
Gene Reference sequence Cancer risk Median coverage 
ATM NM_000051.3 Breast 420 
BRCA1 NM_007294.3 Breast/Ovarian 285 
BRCA2 NM_000059.3 Breast/Ovarian 367 
BRIP1 NM_032043.2 Ovarian 363 
CDH1 NM_004360.3 Breast 315 
CHEK2 NM_007194.3 Breast 303 
MLH1 NM_000249.3 Ovarian 320 
MSH2 NM_000251.2 Ovarian 380 
MSH6 NM_000179.2 Ovarian 327 
NBN NM_002485.4 Breast 383 
PALB2 NM_024675.3 Breast 324 
PMS2 NM_000535.5 Ovarian 383 
PTEN NM_000314.4 Breast 370 
RAD51C NM_058216.2 Ovarian 339 
RAD51D NM_002878.3 Ovarian 255 
STK11 NM_000455.4 Breast 161 
TP53 NM_000546.5 Breast 242 
 
Variant classification 
Variants were classified as deleterious if they were predicted to originate a 
premature codon stop, if they were located in canonical splice sites or if there was 
literature and/or own evidence to support their classification as pathogenic/likely 
pathogenic. The potential pathogenicity of the remaining variants, after variant filtering 
settings were applied, was evaluated depending on the type of mutation. Missense 
variants were evaluated using MetaSVM and MetaLR scores, which combine 10 
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different in silico prediction tools (SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, 
GERP++, MutationTaster, Mutation Assessor, FATHMM, LRT, SiPhy and PhyloP) and 
the maximum frequency observed in 1000G, having a higher predictive power than 
any of the prediction tools alone [21]. They were also evaluated using the Combined 
Annotation–Dependent Depletion (CADD) method, which integrates many diverse 
annotations into a single measure (C-Score) [22]. Missense variants were retained as 
variants of uncertain significance (VUS) only if they were predicted to be damaging by 
MetaSVM (rankscore>0.834), MetaLR (rankscore>0.823) and CADD (C-Score>15).  
Synonymous and intronic variants were retained only if they were predicted to have 
an impact on splicing by having at least a 15% decrease in MaxEntScan and a 5% 
decrease of the SpliceSiteFinder score, which was shown to have a 96% sensitivity 
and 83% specificity for the prediction of BRCA1/BRCA2 VUS that result in a splicing 
defect when compared with transcript analysis [23]. Ada and RF scores (dbscSNV), 
two ensemble learning methods integrating several in silico prediction tools, were also 
evaluated with a cutoff value of 0.6 used [24]. In-frame deletions and insertions were 
also retained.  
 
Results 
Deleterious mutations in BRCA1 and BRCA2 
The two most common BRCA1/BRCA2 mutations in the Portuguese population 
were screened in the 94 index patients under study and 14 (14.9%) were shown to be 
carriers of the BRCA2 c.156_157insAlu (no BRCA1 c.3331_334del carriers were 
identified). In the 80 samples negative for founder mutations, BRCA1/BRCA2 
screening of the entire coding regions was performed by Sanger sequencing. A total 
of 10 pathogenic mutations in BRCA1 and seven in BRCA2 were additionally 
detected, corresponding to a total of 31 (33%) BRCA1/BRCA2 pathogenic mutations 
identified in the 94 index cases analyzed. Personal and family cancer history of all 
BRCA1/BRCA2 carriers is detailed on Table 2.  
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Table 2 – Deleterious mutations identified in the 80 index patients by NGS 
Sample Gene HGVSc Predicted Protein Personal History 
Family 
Historya 
S25 BRCA1 c.211A>G r.(spl?) BC (34) 4x PrCa 
S76 BRCA1 c.470_471del p.(Ser157Ter) OC (46) 2x BC 
S75 BRCA1 c.2037delinsCC p.(Lys679AsnfsTer4) BC (47) 1x BBC, 1x PrCa 
S63 BRCA1 c.2309C>A p.(Ser770Ter) BBC (34,34) 1x BC 
S41 BRCA1 c.2418del p.(Ala807HisfsTer8) OC (46) 4x BC 
S32 BRCA1 c.3477_3480del p.(Ile1159MetfsTer50) OC (41), BC (52) - 
S21 BRCA1 c.3817C>T p.(Gln1273Ter) BC (38) 1xBC 
S44 BRCA1 c.3817C>T p.(Gln1273Ter) BC (40) 2x BC 
S58 BRCA1 c.4165_4166del p.(Ser1389Ter) BBC (32,47) 
3x BC, 1x 
PrCa 
S49 BRCA1 c.5266dup p.(Gln1756ProfsTer74) BC (37) 3x BC 
S54 BRCA2 c.2T>G p.Met1? BC (41) 4x BC 
S61 BRCA2 c.793+1G>A r.spl? BC (49) 3x BC, 1x OC 
S34 BRCA2 c.5934dup p.(Ser1979Ter) BC (52) 1x MBC 
S52 BRCA2 c.6656C>G p.(Ser2219Ter) BC (60) 3x BC, 1x MBC 
S55 BRCA2 c.7738C>T p.(Gln2580Ter) BC (50) 2x BC, 1x OC 
S61 BRCA2 c.9097dup p.(Thr3033AsnfsTer11) BC (43) 1x BBC, 3x BC, 1x OC 
S57 BRCA2 c.9453del p.(Glu3152ArgfsTer11) BC (50) 3x BC, 1x PrCa 
S66 PALB2 c.1192del p.(Val398CysfsTer26) BC (52) 5x BC 
S49 PALB2 c.1240C>T p.(Arg414Ter) BC (37) 3x BC 
S67 PALB2 c.1633G>T p.(Glu545Ter) BC (47) 5x BC 
S56 PALB2 c.2257C>T p.(Arg753Ter) BC (49) 1x BBC, 2x BC 
S5 ATM c.652C>T p.(Gln218Ter) BBC (36,48) 3x BC 
S28 ATM c.8264_8268del p.(Tyr2755CysfsTer12) CRC (57), BC (79) 1x BBC, 4x BC 
S1 CHEK2 c.349A>G p.(Arg117Gly) BC (79) 1x BBC, 1x BC, 1x OC 
S13 TP53 c.388C>T p.(Leu130Phe) CRC (17) 8x BC 
a Only tumors associated with HBOC included: Breast, Ovarian, Prostate and Pancreatic cancer. 
Legend: BC – breast cancer; BBC – bilateral breast cancer; OC – ovarian cancer; PrCa – prostate cancer; MBC – 
male breast cancer; CRC – colorectal cancer 
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In order to compare the efficiency of NGS for the detection of BRCA1/BRCA2 
point mutations, we analyzed the same 80 samples that were fully screened by Sanger 
sequencing using the TruSight Cancer panel. The comparison between NGS and 
Sanger sequencing was extended to all single nucleotide variants (SNVs) and indels 
identified. Analysis was restricted to all the variants detected in the coding regions and 
12 bp flanking the exons. All the variants detected by NGS with coverage ≤15x and 
alternative variant frequency ≤15% were filtered out. A total of 506 variants (495 SNVs, 
11 indels) were detected by NGS, giving a 100% concordance with Sanger 
sequencing for detecting BRCA1/BRCA2 point mutations (data not shown). A median 
coverage of 285 was obtained for BRCA1 and of 367 for BRCA2 (Table 1). Overall, 
3840 regions were analyzed in both genes considering all samples, with only 33 
(0.86%) having at least one nucleotide with a coverage below 30 and 10 (0.26%) with 
a coverage below 20 (data not shown).  
 
Deleterious mutations in other genes 
 In the 80 samples where NGS was performed, we evaluated 15 other genes 
besides BRCA1/BRCA2 that have been associated with increased risk of developing 
either breast or ovarian cancer. The median coverage ranged from 161 in STK11 to 
420 in ATM (Table 1). Deleterious mutations were detected in eight different families 
(10%), four in PALB2 (three nonsense and one frame-shift mutation) (Fig. 1), two in 
ATM (one nonsense and one frame-shift) (Fig. 2), one missense mutation in CHEK2 
(Fig. 3a) and one missense mutation in TP53 (Fig. 3b). The CHEK2 missense 
mutation c.349A>G (p.Arg117Gly) has been reported in ClinVar as likely pathogenic, 
with functional studies showing that this variant results in a CHEK2 protein with 
impaired function due to reduced kinase activity, reduced protein stability, and 
incomplete phosphorylation [25-27]. The c.388C>T (p.Leu130Phe) missense mutation 
in TP53 has been previously described as deleterious [28,29]. Personal and family 
cancer history of all carriers is detailed on Table 2. 
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Figure 1 – Pedigrees of individuals with PALB2 deleterious mutations detected. Family of the individual with 
both the BRCA1 c.5266dup and the PALB2 c.1240C>T mutation (A), the individual with the PALB2 c.1633G>T 
mutation (B), the individual with the PALB2 c.1192del mutation (C) and the individual with the PALB2 c.2257C>T 
mutation (D). The index case is indicated by an arrow. 
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Figure 2 – Pedigrees of individuals with ATM deleterious mutations detected. Family of the individual with 
the ATM c.652C>T mutation (A) and the individual with the ATM c.8264_8268del mutation (B). The index case is 
indicated by an arrow. 
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Figure 3 – Pedigrees of individuals with CHEK2 and TP53 deleterious mutations detected. Family of the 
individual with the CHEK2 c.349A>G mutation (A) and the individual with the TP53 c.388C>T mutation (B). The 
index case is indicated by an arrow. 
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Incidental findings 
We detected an in-frame deletion of 15 bp in the MSH6 gene (c.3848_3862del, 
p.Ile1283_Tyr1287del) in a patient diagnosed with breast cancer at the age of 32 
years. This variant had been previously identified in two Lynch syndrome families in 
our laboratory with loss of MSH6 expression in the tumor (unpublished data) and it is 
also described as a causal mutation in the UMD database (www.umd.be) in a patient 
with colorectal cancer and loss of MSH6 expression in the tumor, hence we consider 
it to be likely pathogenic. However, we did not observe loss of MSH6 expression in 
the breast tumor of our index patient (data not shown). Her family history includes an 
uncle diagnosed with male breast cancer at 60 years and both the maternal and 
paternal grandmother diagnosed with colorectal cancer at 72 years (Online Resources 
1).  
 
Variants of uncertain significance 
Applying the thresholds for missense and potential splicing mutations 
described earlier (see variant classification) after variant filtering, 10 missense variants 
were predicted to be deleterious, one variant was predicted to induce a splicing defect 
and one in-frame deletion was retained (Table 3). Of these, eight variants (66.7%) 
were observed in families where no clearly deleterious mutations were identified. 
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Table 3 – Variants of uncertain significance identified in the 80 index patients by NGS 
Sample  Gene HGVSc  Predicted Protein  dbSNP ID  1000G_AF ExAC_AF ESP6500_AF MetaSVMa MetaLRa
CADD 
(C‐Score)a
MaxEntScan 
(% decrease)b 
SpliceSiteFinder 
(% decrease)b 
Ada 
Scoreb 
RF 
Scoreb 
S67  ATM  c.1049C>T  p.Ala350Val  rs375049090 N/A  N/A  0.008  0.853  0.845  27.8  N/A  N/A  N/A  N/A 
S80  BRCA1 c.80+5G>C  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  ‐48.8%  ‐13.9%  0.998  0.876 
S36  BRCA1 c.190T>A  p.Cys64Ser  N/A  N/A  N/A  N/A  0.968  0.998  25.1  N/A  N/A  N/A  N/A 
S21  BRCA2 c.4933_4935del  p.Lys1645del N/A  N/A  0.001  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
S77  BRCA2 c.7975A>G  p.Arg2659Gly rs80359026  N/A  N/A  N/A  0.960  0.958  27.7  N/A  N/A  N/A  N/A 
S79  BRCA2 c.9004G>A  p.Glu3002Lys rs80359152  N/A  N/A  N/A  0.910  0.903  22.4  N/A  N/A  N/A  N/A 
S9, S49  BRIP1 c.139C>G  p.Pro47Ala  rs28903098  N/A  0.024  0.023  0.836  0.829  24.1  N/A  N/A  N/A  N/A 
S39  CHEK2 c.757A>G  p.Lys253Glu  N/A  N/A  N/A  N/A  0.912  0.899  17.1  N/A  N/A  N/A  N/A 
S60  CHEK2 c.1169A>C  p.Tyr390Ser  rs200928781 N/A  0.004  N/A  0.944  0.915  28.7  N/A  N/A  N/A  N/A 
S3  MLH1 c.649C>T  p.Arg217Cys rs4986984  0.060  0.032  N/A  0.952  0.943  22.4  N/A  N/A  N/A  N/A 
S43  MLH1 c.2066A>G  p.Gln689Arg rs63750702  N/A  0.028  0.023  0.840  0.877  22.2  N/A  N/A  N/A  N/A 
S63  MSH6 c.3478G>A  p.Val1160Ile  rs376799914 N/A  0.005  0.008  0.864  0.866  22.1  N/A  N/A  N/A  N/A 
N/A – Not available/Not applicable 
a Missense variants were retained as VUS if they were predicted to be damaging by MetaSVM (rankscore>0.834), MetaLR (rankscore>0.823) and CADD (C‐
Score>15) [21,22]. 
b Synonymous and intronic variants were retained if they had at least a 15% decrease in MaxEntScan, a 5% decrease of the SpliceSiteFinder score and an 
Ada and RF score higher than 0.6 [23,24]. 
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Discussion 
NGS is increasingly being adopted in diagnostic laboratories because it offers 
higher throughput, faster turnaround time and the possibility to expand the molecular 
diagnosis to rarer causative mutations, all without an increase in the cost of the 
analysis when compared to conventional methodologies. Nevertheless, before 
integration of NGS in a clinical setting, the efficiency of the methodology needs to be 
validated by individual laboratories, considering the different library preparation 
methods, the different sequencing chemistries and especially the different 
bioinformatics algorithms for alignment, variant calling and variant filtering available. 
We have recently established a bioinformatics NGS pipeline validated on a series of 
32 samples with various types of mutations in 23 different genes involved in hereditary 
predisposition to cancer (Paulo et al., submitted). Here, we wanted to validate this 
previously established pipeline for the detection of BRCA1/BRCA2 point mutations in 
a large series of high-risk HBOC patients and to take advantage of the higher 
throughput offered by NGS to characterize the involvement of other genes associated 
with an increased risk for developing breast and/or ovarian cancer.  
We obtained 100% sensitivity and specificity (total of 506 variants) for the 
detection of BRCA1/BRCA2 point mutations with our bioinformatics pipeline using a 
targeted enrichment approach when compared to the gold standard Sanger 
sequencing. Although the majority of the variants were SNVs, 11 indels were present 
in the samples analyzed, which are known to be particularly sensitive to false 
negatives by NGS (Paulo et al., submitted) [30,31]. Other studies have reported the 
validation of NGS for the detection of BRCA1/BRCA2 mutations using different 
workflows and platforms. All achieved a sensitivity of 100% with false positives ranging 
from 1-1.8% in Illumina platforms [32,33] to 7.5-8.8% on the Ion Torrent [31,34]. In a 
diagnostic setting, low coverage regions require Sanger sequencing to ensure that a 
putative mutation is not missed because there were not enough reads covering that 
nucleotide. In our series, only 0.41 (33/80) or 0.13 (10/80) sequencing reactions per 
sample would be required if the minimum coverage threshold used was 30 or 20, 
respectively. Currently, molecular diagnosis of BRCA1/BRCA2 needs to be completed 
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by other methodologies, such as MLPA, for the detection of LGRs, but it is expected 
that in the future these will also be reliably detected by NGS with the validation of 
specific algorithms for detection of copy number variations, such as CONTRA, CNV-
seq or ExomeCNV [35-37]. 
A frequency of 33% pathogenic BRCA1/BRCA2 mutations was observed in our 
94 patients, which is slightly higher than the frequency of 28.9% that we previously 
observed in a larger series of HBOC patients [7], a difference that may be explained 
by the more stringent criteria used for cohort selection in the current study. The 
BRCA2 c.156_157insAlu rearrangement remains the most frequent BRCA1/BRCA2 
mutation in our population (45%) and this Alu insertion is not detectable using regular 
NGS bioinformatic algorithms designed for the detection of SNVs and indels [32] or 
by standard Sanger sequencing. Although its high frequency in our population 
warrants initial screening of this mutation before BRCA1/BRCA2 full screening, in 
other populations patients with Portuguese ancestry should be offered specific testing 
for this mutation somewhere in the genetic testing algorithm [38]. Of all the other 
deleterious mutations identified in this study, the BRCA2 c.2T>G deserves some 
attention, as it had been previously identified by our group and classified as a VUS 
due to nonsegregation in an affected relative in the initial family [39]. However, recent 
evidence suggests that mutations disrupting BRCA2 initiation codon induce exon 2 
skipping, with translation being initiated mostly at an out-of-frame ATG, leading to loss 
of protein function [40].   
The other objective of this work was to characterize the spectrum of mutations 
in other genes predisposing to breast/ovarian cancer in high-risk families. We found 
deleterious mutations in eight families (10% of the families analyzed by NGS and 8.5% 
of all families), corresponding to 20.5% of all deleterious mutations identified (8/39) 
(Fig. 4). In families negative for BRCA1/BRCA2 mutations, the frequency of 
deleterious mutations was 11.1% (7/63), which highlights the genetic heterogeneity 
underlying inherited predisposition to breast/ovarian cancer. Mutations were observed 
in PALB2 (4), ATM (2), CHEK2 (1) and TP53 (1). PALB2 mutations have been 
consistently described in familial and early-onset breast cancer and the cumulative 
risk until age 70y for developing breast cancer in a large cohort of PALB2 mutation 
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carriers has been reported to range from 33% without family history taken into account 
to 58% in those with a strong family history (being 44% and 67%, respectively, at age 
80y), which is similar to the risks described for BRCA2 [12]. In our study, mutations in 
this gene were found in 5% of the families analyzed by NGS. In one of the families, a 
BRCA1 pathogenic mutation was also identified, but they could have arisen from 
different branches of the family as both have relatives affected with breast cancer, 
with segregation studies required to confirm this possibility (Fig. 1a). Truncating 
variants in ATM also confer an increased risk to breast cancer (relative risk=2.8), 
which seems to be similar to CHEK2 (relative risk=3.0) but lower than PALB2 (relative 
risk=5.3) [20]. Both the probands with ATM and CHEK2 deleterious mutations had a 
family history of breast and/or ovarian cancer, but other tumors, such as colorectal, 
stomach and soft tissue, were also present (Fig. 2, 3a).  We also detected a missense 
mutation in TP53 in a proband diagnosed with colorectal cancer at age 17 years and 
a significant family history of breast and colon cancer (Lynch syndrome had been 
excluded). Interestingly, this family did not fulfill the Chompret (or other) criteria for 
TP53 mutation testing to diagnose Li-Fraumeni syndrome [29], being a good example 
of the potential of NGS to increase the molecular diagnosis yield in situations in which 
different syndromes have overlapping clinical features and in which genetic testing 
criteria do not have a 100% sensitivity. Although the index patient had early-onset 
colorectal cancer, which is not part of the most typical tumor spectrum of either HBOC 
or Li-Fraumeni syndrome, this family had been selected because of very strong family 
history of early-onset breast cancer (especially from the paternal side, Fig. 3b)  and 
indeed recent data shows that TP53 mutations are found in 6% of females with breast 
cancer diagnosed before the age of 31 years in the absence of other features 
indicative of Li-Fraumeni syndrome, especially if their tumors are HER2-positive [41]. 
Some of the other genes included in our study and in many commercial NGS panels 
for HBOC still require further evidence from larger studies to confirm the relative risks 
for developing cancer, which will be helpful in determining their clinical utility. One 
example is BRIP1, which was initially described as conferring an increased risk for 
breast cancer [42], but a recent study in a large cohort of patients found no association 
of truncating variants with breast cancer risk [43]. Having said that, the most recent 
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NCCN guidelines already recommend breast MRI screening for carriers of ATM, 
CHEK2 and PALB2 mutations (in addition to previously known breast cancer high-risk 
genes BRCA1, BRCA2, TP53, CDH1, STK11 and PTEN), and that the possibility of 
risk-reducing mastectomy should be discussed with PALB2 carriers. Carriers of 
BRIP1, RAD51C and RAD51D mutations, on the other hand, should consider the 
option of performing risk-reducing salpingo-oophorectomy according to the latest 
NCCN guidelines, in line with what was already recommended for BRCA1/BRCA2 and 
Lynch syndrome carriers [4]. 
 
 
Figure 4 – Deleterious mutations identified per gene (%) in the 94 index patients. 
 
With the adoption of NGS there is some concern about the identification of 
incidental findings, disease-causing variants in high-penetrance genes in patients 
without the associated phenotype. Here, we detected a likely pathogenic mutation in 
MSH6 (c.3848_3862del, p.Ile1283_Tyr1287del) in a patient with breast cancer without 
loss of MSH6 expression in the tumor, indicating that her breast carcinoma was not 
related with the MSH6 germline mutation, contrarily to the existent evidence for its 
involvement in the pathogenesis of colorectal cancer in typical Lynch syndrome 
families. Taking into account the family history of the patient, there was no indication 
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to perform genetic testing of mismatch repair (MMR) genes (Online Resources 1), but 
the carriers of this mutation in this family are still at risk of developing Lynch syndrome-
associated neoplasias and adequate surveillance has been offered to the patient and 
her relatives after genetic counselling.   
The use of bioinformatic tools is mandatory in order to compensate for the 
increased risk of finding VUS when one increases the number of genes analyzed by 
NGS, especially in whole-genome and whole-exome studies [21,44,45]. Here, we 
report the use of a panel of 94 genes with analysis restricted to the genes of interest 
taking into account the clinical phenotype together with the use of in silico prediction 
tools for stratification of VUS. Although these tools cannot be used for classification of 
variants per se, they are useful for prioritization of VUS for further segregation and 
functional studies [23,46]. We identified 12 VUS predicted to be deleterious in silico, 
eight of them in families where no clearly deleterious mutations were found, and these 
are the variants that we will prioritize for segregation studies (Table 3). The BRCA1 
c.190T>A (p.Cys64Ser) is located in the highly conserved RING domain of this gene 
and there are already various missense mutations in this domain described as 
pathogenic [47,48]. Other VUS were identified in ATM, BRCA1, BRCA2, BRIP1, 
CHEK2, MLH1 and MSH6, but the data available for these variants is scarce. Most of 
these variants may in the future be reclassified as deleterious or benign, but in the 
meantime they cannot be used to make clinical decisions.  
There are some limitations in our study. Our sample size is relatively small and 
we selected families with high-risk to breast/ovarian cancer, which may increase the 
likelihood of identifying a deleterious mutation in breast/ovarian cancer predisposing 
genes. Nonetheless, the frequency of BRCA1/BRCA2 mutations identified is only 
slightly higher compared to a previous study where less stringent criteria were used 
and it is not certain that mutations in moderate penetrance genes are more likely to 
be found in high-risk families. Furthermore, the gene panel used in our study did not 
include the RECQL gene, recently reported to be associated with the risk of breast 
cancer in populations from Canada and Poland [49]. 
 In conclusion, we have validated the use of NGS for the detection of 
BRCA1/BRCA2 point mutations in a large series of patients, offering a higher 
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throughput and higher molecular diagnostic yield in the study of inherited 
predisposition to breast/ovarian cancer and making possible to address its extensive 
genetic heterogeneity. This strategy allowed the identification of 39 deleterious 
mutations in 40% of the families (38/94). The detection of deleterious mutations in 
some of these genes already has a significant impact in the clinical management of 
carriers, although further studies are necessary to make reliable estimates of cancer 
risk for many of the other genes included in current multigene panel testing to allow 
appropriate genetic counseling of these patients and their relatives.  
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1. Diagnosis of inherited cancer predisposition in archival tissue 
Molecular testing of BRCA1/BRCA2 is usually performed on genomic DNA 
extracted from peripheral blood leucocytes. Nevertheless, families with a strong family 
history of tumors associated with BRCA1 and BRCA2 mutations without an affected 
member available for genetic testing are not uncommon. This occurs because either 
all affected relatives are already deceased or they are living in other cities or countries. 
Genetic testing in unaffected individuals in such families is not ideal and is often 
uninformative. Hence, the possibility of identifying BRCA1/BRCA2 mutations in 
archival tissue of affected relatives is helpful, being also useful for retrospective 
studies of rarer cancers. Furthermore, it may allow the identification of both somatic 
and germline mutations. However, DNA extracted from formalin-fixed, paraffin-
embedded (FFPE) tissue is usually of low quantity and quality, making harder the 
analysis of large genes such as BRCA1 and BRCA2. 
We developed a method that allows the identification of the BRCA2 
c.156_157insAlu and the BRCA1 c.3331_3334del mutations in FFPE tissue 
(applicable both in neoplastic cells or in the surrounding normal tissue) (Paper I). This 
optimized method for FFPE tissue is especially important for the detection of the 
BRCA2 c.156_157insAlu mutation in patients with Portuguese ancestry, as this 
prevalent mutation is not readily detectable by standard or next-generation 
sequencing technologies [De Brakeleer et al, 2013, Peixoto et al, 2015]. The 
preferential amplification of the shorter allele makes detection of the c.156_157insAlu 
mutation unviable with the standard method used for genomic DNA extracted from 
peripheral leucocytes [Peixoto et al, 2015]. Therefore, our method for the detection of 
this mutation in FFPE tissue consists in the amplification of exon 3 followed by a 
nested PCR specific for the Alu rearrangement. For the detection of the BRCA1 
c.3331_3334del mutation, a shorter amplicon was designed with the presence of the 
mutation being determined by fragment analysis. We have also performed screening 
of the entire coding regions of BRCA1 and BRCA2 in a consecutive series of ampullary 
tumors using a commercial kit optimized for FFPE tissue on a MiSeq, showing that it 
is now feasible to perform full analysis of BRCA1/BRCA2 in archival tissue (Paper I). 
With the approval of a PARP inhibitor for the treatment of BRCA-mutated (germline or 
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somatic) high-grade serous ovarian tumors [Ledermann et al, 2014], and with clinical 
trials ongoing on other tumors associated with HBOC syndrome, it is expected that 
the identification of BRCA1/BRCA2 mutations in archival tissue will soon become 
crucial for several cancers associated with this pathogenetic mechanism.  
 
2. Contribution of the founder mutations BRCA2 c.156_157insAlu 
and BRCA1 c.3331_3334del for cancer etiology in unselected 
hospital-based cohorts of patients diagnosed with rarer cancers 
associated with HBOC syndrome 
Germline mutations in the BRCA1 and BRCA2 genes are responsible for the 
HBOC syndrome, which is characterized by an increased risk to breast and ovarian 
cancer, as well as other tumors like those of the prostate, pancreas, male breast, 
peritoneum and fallopian tube. Recently, a large characterization of the mutational 
spectrum of germline BRCA1/BRCA2 mutations in 1050 Portuguese breast/ovarian 
cancer families was reported [Peixoto et al, 2015]. A total of 119 pathogenic mutations 
were detected, 41.2% in BRCA1 and 58.8% in BRCA2. The BRCA2 c.156_157insAlu 
mutation was present in 32% of all Portuguese HBOC families and represented 55% 
of the BRCA2 mutations, whereas the BRCA1 c.3331_3334del mutation was present 
in 11% of all families and 26% of the families with a BRCA1 mutation. Hence, the two 
most common BRCA1/BRCA2 mutations in the Portuguese population account for 
about 43% of the total deleterious mutations in these genes. One of the applications 
of the analysis of frequent and founder BRCA1/BRCA2 mutations is in the study of 
other tumors that are part of the HBOC syndrome spectrum. We have recently 
evaluated the contribution of the two most frequent BRCA1/BRCA2 founder mutations 
for early-onset and/or familial prostate cancer in Portugal [Maia et al, 2016]. 
 In this work we analyzed a consecutive series of patients diagnosed with rarer 
tumors associated with the HBOC syndrome, namely, cancer of the pancreas, male 
breast, peritoneum, and fallopian tube (Paper I). A total of 102 male breast, 68 
pancreatic and 33 peritoneal/fallopian tube carcinoma cases were included in the 
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study. The BRCA2 c.156_157insAlu mutation was observed with a frequency of 7.8% 
in male breast cancers, 3.0% in peritoneal/fallopian tube cancers, and 1.6% in 
pancreatic cancers, with estimated total contributions of germline BRCA2 mutations 
of 14.3%, 5.5%, and 2.8%, respectively. No carriers of the BRCA1 c.3331_3334del 
mutation were identified. The frequencies of BRCA1/BRCA2 mutations we observed 
in the different tumors analyzed are generally in accordance with the literature, 
although a higher frequency has been reported in other studies of peritoneal and 
fallopian tube cancers, usually similar to frequencies observed in consecutive series 
of ovarian cancer (~15%) [Vicus et al, 2010, Walsh et al, 2011, Alsop et al, 2012]. In 
fact, it is currently accepted that most high grade serous ovarian carcinomas arise 
from a precursor lesion in the fallopian tube, which progress to an invasive, high-grade 
tumor eventually involving the ovary itself [Crum et al, 2007, Kindelberger et al, 2007]. 
Therefore, a similar frequency of BRCA1/BRCA2 mutations is expected in ovarian and 
fallopian tube cancers if they have the same origin. The lower frequency we observed 
can be explained by the fact that only founder mutations were analyzed and the 
BRCA1 founder mutation, which is the gene more commonly associated with these 
tumors, only represents 11% of all families and 26% of the families identified with a 
BRCA1 mutation in Portuguese HBOC families. 
The identification of BRCA1/BRCA2 mutation carriers has implications for both 
the individuals and their family members, allowing reliable genetic counseling and 
predictive genetic testing. Female carriers can decide whether they want to participate 
in surveillance protocols and/or perform risk-reducing surgical interventions such as 
RRM and RRBSO, whereas mutation positive males can engage in breast and/or 
prostate cancer screening [NCCN, 2016]. Furthermore, BRCA1/BRCA2 mutation 
carriers can also benefit from targeted therapy agents, such as olaparib [Ledermann 
et al, 2014, Kaufman et al, 2015]. Taking into account the implications of the 
identification of BRCA1/BRCA2 mutations and the results we obtained, we 
recommend that patients with the neoplasias studied (pancreas, male breast, 
peritoneum and fallopian tube) may be offered BRCA1/BRCA2 genetic testing, or at 
least, testing of founder mutations in the Portuguese population (Paper I). 
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3. Germline BRCA2 mutations in patients with ampullary carcinomas 
 In the course of our study, a patient with an ampulla of Vater carcinoma was 
incidentally found to carry the BRCA2 c.156_157insAlu mutation, so we decided to 
test a consecutive series of additional 15 ampullary carcinomas for BRCA1/BRCA2 
mutations using a combination of direct founder mutation testing and full gene analysis 
with NGS. BRCA2 mutations were observed in two patients with ampulla of vater 
carcinoma, representing a frequency of 14.3% in these tumors (Paper I). In one of the 
patients, the mutation was confirmed to be germline in peripheral blood and he had 
been previously diagnosed with prostate cancer and had two close blood relatives 
affected with female breast cancer. The other patient had no family history of tumors 
associated with HBOC (only one sister diagnosed with colorectal cancer), highlighting 
the fact that in some cases BRCA1/BRCA2 mutations can be identified in families 
without familial aggregation of breast and/or ovarian cancer.  Ampullary cancer is 
currently not part of the HBOC syndrome tumor spectrum, although a BRCA2 mutation 
carrier with a carcinoma of the ampulla of Vater has been previously identified during 
predictive genetic testing [Aburjania et al, 2014]. Our study is the first to perform full 
analysis of the BRCA1/BRCA2 genes in a consecutive series of ampullary 
carcinomas. Considering the small sample size of our study, larger independent 
studies are warranted to confirm the association of BRCA1/BRCA2 mutations with 
ampullary cancer and its eventual inclusion in the tumor spectrum of HBOC syndrome. 
  
4. Sensitivity and specificity of next-generation sequencing for the 
detection of point mutations in the BRCA1 and BRCA2 genes 
compared with Sanger sequencing 
The identification of BRCA1/BRCA2 mutations has been traditionally 
performed by Sanger sequencing or alternative screening methods that are labor-
intensive and have low throughput and high turnaround time. High-throughput NGS 
technologies, which allow the simultaneous analysis of thousands to millions of DNA 
sequence fragments, have unwrapped a new paradigm in the search for the molecular 
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causes of genetic disorders, such as HBOC. Nonetheless, before the implementation 
of a new methodology in a clinical laboratory, a validation is required to ensure that 
quality standards, such as sensitivity and specificity, are maintained.  
We performed a validation of NGS for the detection of BRCA1/BRCA2 point 
mutations by analyzing a total of 80 samples, negative for the two common 
Portuguese founder mutations, in parallel by Sanger sequencing and NGS (Paper II). 
The analysis by NGS was performed using a commercially available kit (TruSight 
Cancer, Illumina) and a previously validated bioinformatics pipeline (Paulo et al., 
submitted). A total of 506 variants (495 SNVs, 11 indels) were detected by both 
methodologies, giving 100% sensitivity and specificity of NGS for the detection of 
BRCA1/BRCA2 point mutations. A median coverage of 285 was obtained for BRCA1 
and of 367 for BRCA2. Overall, 3840 regions were analyzed in both genes considering 
all samples, with only 33 regions (0.86%) having at least one nucleotide with a 
coverage below 30 and 10 (0.26%) with a coverage below 20 (Paper II). Our 
bioinformatics pipeline consists of three different software programs for alignment and 
variant calling. Although in this study all the mutations were identified by the three 
different software programs, we have previously observed that they do not have the 
same sensitivity for the detection of mutations, especially for the detection of deletions 
or insertions of more than one base pair (Paulo et al., submitted). Hence, a 
combination of different algorithms and its proper validation is recommended before 
the implementation of NGS in a clinical laboratory. The maintenance of sensitivity and 
specificity, the faster turnaround time, the possibility in the near future to replace other 
technologies (such as MLPA, for the detection of LGRs, in the same analysis), and 
the higher throughput (allowing the analysis of other genes besides BRCA1 and 
BRCA2), all without an increase in the cost of the analysis, are reasons to recommend 
the implementation of NGS in diagnostic laboratories.  
 
5. Genetic heterogeneity of hereditary breast and ovarian cancer 
 One of the major advantages of NGS is its higher throughput, allowing the 
expansion of the molecular diagnosis of HBOC to other genes not commonly screened 
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due to methodology limitations. In order to evaluate the genetic heterogeneity of 
HBOC, we analyzed a panel of 17 genes (ATM, BRCA1, BRCA2, BRIP1, CDH1, 
CHEK2, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, 
STK11 and TP53) that have been described as conferring an increased risk to the 
development of breast and/or ovarian cancer in a consecutive series of 94 high-risk 
families (Paper II). The two most common BRCA1/BRCA2 Portuguese founder 
mutations were initially screened in all samples, with the negative samples being 
analyzed by NGS for the 17 genes. A total of 39 deleterious mutations in the 94 index 
patients were detected, namely, 10 in BRCA1 (25.6%), 21 in BRCA2 (53.8%), four in 
PALB2 (10.3%), two in ATM (5.1%), one in CHEK2 (2.6%), and one in TP53 (2.6%), 
with 20.5% of the deleterious mutations being found in genes other than 
BRCA1/BRCA2. The BRCA2 c.156_157insAlu mutation was the most common 
mutation identified, being present in 14 (15%) index patients. BRCA1/BRCA2 
mutations were detected in 33% of the index cases tested, a slightly higher frequency 
than we previously observed in a larger series of HBOC patients (29%) [Peixoto et al, 
2015], probably due to the more stringent criteria used for cohort selection.  
 The use of panel gene testing for the molecular diagnosis of HBOC has 
advantages but also brings some concerns. The diagnostic yield can be improved, as 
exemplified by the fact that 20.5% of the mutations we identified are in genes other 
than BRCA1 or BRCA2. A 11.1% frequency of deleterious mutations was found in 
families negative for BRCA1/BRCA2 mutations, representing an overall increase of 
7% in the detection of families with deleterious mutations (from 33% to 40%; Paper 
II). It also provides the opportunity to identify deleterious mutations when different 
syndromes have overlapping clinical features and in which genetic testing criteria do 
not have a 100% sensitivity, as illustrated by the identification of a pathogenic TP53 
missense mutation in a family with a significant family history of breast and colorectal 
cancer but not fulfilling the Chompret (or other) criteria for TP53 mutation testing to 
diagnose LFS. On the other hand, we have identified one index patient with a 
deleterious BRCA1 mutation that also harbored a PALB2 deleterious mutation, 
showing that mutations in different genes can occur in the same family. During 
predictive genetic testing in a family with a deleterious BRCA1 or BRCA2 mutation, it 
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is common to communicate to family members that have not inherited the mutation 
that their risk of breast and/or ovarian is similar to that of the general population. 
However, this may not apply to this family, as a relative of the index patient may not 
be a carrier of the BRCA1 mutation but still be at increased risk for the development 
of breast cancer if it has inherited the PALB2 mutation.  
The major concerns regarding the use of an extended panel of genes are the 
identification of incidental findings (disease-causing variants in high-penetrance 
genes in patients that do not have the associated phenotype) and VUS (variants with 
an unclear clinical significance). We detected a likely pathogenic mutation in MSH6 in 
a patient with breast cancer without loss of MSH6 expression in the tumor, indicating 
that her breast carcinoma was not related with the MSH6 germline mutation. There 
was no indication to perform genetic testing of the MMR genes considering the 
pedigree of the family but carriers of this mutation in this family are still at risk of 
developing Lynch syndrome-associated neoplasias and genetic counseling should be 
offered in such cases. The identification of VUS increases largely with the increase in 
the number of genes being analyzed. This can only be compensated with the use of 
bioinformatic tools to predict the impact of the mutations in silico combined with 
curated settings for variant filtering. Although these tools cannot be used for 
classification of variants per se, they are useful for prioritization of VUS for further 
segregation and functional studies [Houdayer et al, 2012, Vallee et al, 2016]. We have 
identified a total of 12 VUS predicted to be deleterious by algorithms that combine a 
variety of different in silico prediction tools and the population frequency of these 
variants, as the combination of different prediction tools increases the predictive power 
compared to their use individually (Paper II). Until the development of better in silico 
prediction tools or segregation or functional studies that allow reclassification of VUS 
into either pathogenic or benign mutations, these variants cannot be used to make 
clinical decisions. Other concern regarding the use of multigene panel testing is the 
fact that there are many genes that have been described as predisposing to breast 
and/or ovarian cancer, but the relative and cumulative risks for carriers of mutations 
in those genes have not been reliably estimated, which is important to ascertain their 
clinical utility [Easton et al, 2015]. We have analyzed in our study a total of 17 genes 
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associated with HBOC but many more have been described in the literature and others 
will be identified in the future with the increasing adoption of whole-exome and whole-
genome sequencing studies. The majority of the other genes associated with 
predisposition to breast and/or ovarian cancer are involved in HR or in the Fanconi 
anemia pathway [Ghimenti et al, 2002, Heikkinen et al, 2003, Kiiski et al, 2014, 
Cybulski et al, 2015, Ellingson et al, 2015]. They can and should be used in research 
projects in order to evaluate their contribution to HBOC, but only those in which their 
clinical utility has been reliably estimated should be used to engage patients in 
surveillance and/or prevention protocols. 
The BRCA1 and BRCA2 genes are usually the only genes that are recognized 
as the cause of the HBOC syndrome. This is probably because they are the main 
genes that predispose to breast and/or ovarian cancer, and for the most part of the 
last 20 years they were indeed the only ones that were feasible to test routinely in 
familial breast and/or ovarian cancer. Although mutations in these genes mainly 
predispose to breast and ovarian cancer, other tumors are included in the spectrum 
of the HBOC syndrome (Paper I). With the advances introduced by NGS, other genes 
can now easily be included in genetic testing of families with a significant family history 
of breast and/or ovarian cancer (Paper II). Some of these genes, such as PTEN, TP53, 
CDH1 and STK11, have other distinct features associated with germline mutations 
and predisposition to breast cancer is not the main feature of their respective 
syndromes. Other genes such as ATM, CHEK2 and, especially, PALB2, are more 
similar to BRCA1 and BRCA2 with regard to having breast cancer as the core feature. 
However, it is presently unclear whether germline mutation carriers in these genes 
have clinically significant risks for other cancers (namely, ovarian cancer) or indeed 
what is the name of the cancer predisposition disease they carry and what its 
relationship is with HBOC. 
  
 
 
 
 
 
CONCLUSIONS 
  
  
 
 
  
CONCLUSIONS 
119 
 
The main conclusions of this thesis are: 
 
1. The detection of the germline founder mutations BRCA2 
c.156_157insAlu and the BRCA1 c.3331_3334del, and eventually full 
gene analysis, is possible in archival tissue, making it an alternative 
for molecular diagnosis of inherited predisposition. 
 
2. The BRCA2 c.156_157insAlu mutation was observed with a frequency 
of 7.8% in male breast cancers, 3.0% in peritoneal/fallopian tube 
cancers, and 1.6% in pancreatic cancers, with estimated total 
contributions of germline BRCA2 mutations of 14.3%, 5.5%, and 2.8%, 
respectively. 
 
3. BRCA2 germline mutations were observed recurrently for the first time 
in patients with ampulla of Vater carcinomas, with a frequency of 
14.3%, raising the possibility of ampullary cancer being part of the 
cancer spectrum of the HBOC syndrome. 
 
4. The sensitivity and specificity of NGS are as high as those of the gold-
standard Sanger sequencing for the detection of BRCA1/BRCA2 
germline point mutations, when a validated bioinformatic pipeline is 
used. 
 
5. Hereditary breast and ovarian cancer is genetically heterogeneous, 
with 20.5% of the germline deleterious mutations being found in genes 
other than BRCA1/BRCA2. 
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The following points will be addressed in future studies: 
 
1. A lower than expected frequency of BRCA1/BRCA2 mutations was 
observed in peritoneal/fallopian tube cancers, but only the two most 
common founder mutations in Portugal were tested. We will perform 
screening of the entire coding regions of BRCA1/BRCA2 in all samples 
of our series of peritoneal/fallopian tube cancer to ascertain the 
contribution of both somatic and germline BRCA1/BRCA2 mutations 
for the pathogenesis of these tumors.  
 
2. Considering that the frequency of BRCA2 mutations in ampullary 
carcinomas we observed was obtained in a small series of tumors, we 
will attempt to perform BRCA1/BRCA2 screening in a larger series of 
cases to confirm the association of BRCA1/BRCA2 mutations with this 
rare neoplasia. 
 
3. We aim to perform segregation studies in families where VUS were 
identified, starting with those predicted to be deleterious in silico, to 
evaluate the potential pathogenicity of these variants. 
 
4. We identified deleterious mutations in 40% of high-risk HBOC families, 
using a panel of genes associated with HBOC. In selected families with 
a strong family history of breast and/or ovarian cancer and with 
multiple patients available for study, we will perform whole-exome 
sequencing to identify new genes predisposing to breast and/or 
ovarian cancer.
 
 
 
 
   
  
 
 
 
 
REFERENCES
 
 
 
 
 
 
 
   
REFERENCES 
127 
 
Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, Lynch HT, 
Watson P, Tallqvist G, Juhola M, Sistonen P, Hamilton SR, Kinzler KW, Vogelstein B 
and De la Chapelle A. 1994. Replication errors in benign and malignant tumors from 
hereditary nonpolyposis colorectal cancer patients. Cancer Res. 54(7):1645-8. 
 
Aburjania N, Truskinovsky AM, Overman MJ and Lou E. 2014. Ampulla of vater 
adenocarcinoma in a BRCA2 germline mutation carrier. J Gastrointest Cancer. 
45(1):87-90. doi: 10.1007/s12029-013-9479-5. 
 
Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, Ekbom A and 
Janson PO. 1994. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 
344(8932):1250-4. 
 
Adank MA, Jonker MA, Kluijt I, van Mil SE, Oldenburg RA, Mooi WJ, Hogervorst FB, 
van den Ouweland AM, Gille JJ, Schmidt MK, van der Vaart AW, Meijers-Heijboer H 
and Waisfisz Q. 2011. CHEK2*1100delC homozygosity is associated with a high 
breast cancer risk in women. J Med Genet. 48(12):860-3. doi: 10.1136/jmedgenet-
2011-100380. 
 
Ahmed M and Rahman N. 2006. ATM and breast cancer susceptibility. Oncogene. 
25(43):5906-11. doi: 10.1038/sj.onc.1209873. 
 
Aloraifi F, McCartan D, McDevitt T, Green AJ, Bracken A and Geraghty J. 2015. 
Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a 
meta-analysis of high-risk case-control screening studies. Cancer Genet. 208(9):455-
63. doi: 10.1016/j.cancergen.2015.06.001. 
 
Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, 
Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D and Mitchell G. 2012. 
BRCA mutation frequency and patterns of treatment response in BRCA mutation-
positive women with ovarian cancer: a report from the Australian Ovarian Cancer 
Study Group. J Clin Oncol. 30(21):2654-63. doi: 10.1200/JCO.2011.39.8545. 
 
Anderson DE. 1972. A genetic study of human breast cancer. Journal of the National 
Cancer Institute. 48(4):1029-34. 
 
Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, Risch HA, 
Eyfjord JE, Hopper JL, Southey MC, Olsson H, Johannsson O, Borg A, Pasini B, 
Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, 
Lubinski J, Gronwald J, Gorski B, Tryggvadottir L, Syrjakoski K, Kallioniemi OP, Eerola 
REFERENCES 
 
128 
 
H, Nevanlinna H, Pharoah PD and Easton DF. 2008. The BOADICEA model of genetic 
susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 
98(8):1457-66. doi: 10.1038/sj.bjc.6604305. 
 
Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding 
YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade 
OI, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, 
Zaffaroni D, Barile M, Viel A, Allavena A, Dall'Olio V, Peterlongo P, Szabo CI, Zikan 
M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert G, Lejbkowicz F, 
Glendon G, Ozcelik H, Andrulis IL, Ontario Cancer Genetics N, Thomassen M, Gerdes 
AM, Sunde L, Cruger D, Birk Jensen U, Caligo M, Friedman E, Kaufman B, Laitman 
Y, Milgrom R, Dubrovsky M, Cohen S, Borg A, Jernstrom H, Lindblom A, Rantala J, 
Stenmark-Askmalm M, Melin B, Swe B, Nathanson K, Domchek S, Jakubowska A, 
Lubinski J, Huzarski T, Osorio A, Lasa A, Duran M, Tejada MI, Godino J, Benitez J, 
Hamann U, Kriege M, Hoogerbrugge N, van der Luijt RB, van Asperen CJ, Devilee P, 
Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M, Hebon, Cook M, 
Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook 
J, Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins 
H, Peock S, Embrace, Godwin AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer S, 
Bonadona V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P, Faivre L, Gemo, 
Loustalot C, Noguchi T, Sobol H, Rouleau E, Nogues C, Frenay M, Venat-Bouvet L, 
Gemo, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar 
D, Breast Cancer Family R, Singer CF, Dressler AC, Gschwantler-Kaulich D, Pfeiler 
G, Hansen TV, Jonson L, Agnarsson BA, Kirchhoff T, Offit K, Devlin V, Dutra-Clarke 
A, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank 
SV, Toland AE, Montagna M, Casella C, Imyanitov E, Tihomirova L, Blanco I, Lazaro 
C, Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, 
Engel C, Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, 
Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Kast K, 
Schonbuchner I, Caldes T, de la Hoya M, Aittomaki K, Nevanlinna H, Simard J, 
Spurdle AB, Holland H, Chen X, kConFab, Platte R, Chenevix-Trench G, Easton DF 
and CIMBA. 2010. Common breast cancer susceptibility alleles and the risk of breast 
cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. 
Cancer Res. 70(23):9742-54. doi: 10.1158/0008-5472.CAN-10-1907. 
 
Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, Lee A, 
Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan 
S, Aittomaki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A, 
Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE, 
Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KB, Yannoukakos D, Concannon 
REFERENCES 
129 
 
P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N, 
Peterlongo P, Nevanlinna H, King MC, Couch FJ, Southey MC, Winqvist R, Foulkes 
WD and Tischkowitz M. 2014. Breast-cancer risk in families with mutations in PALB2. 
N Engl J Med. 371(6):497-506. doi: 10.1056/NEJMoa1400382. 
 
Ashworth A. 2008. A synthetic lethal therapeutic approach: poly(ADP) ribose 
polymerase inhibitors for the treatment of cancers deficient in DNA double-strand 
break repair. J Clin Oncol. 26(22):3785-90. doi: 10.1200/JCO.2008.16.0812. 
 
Ban KA and Godellas CV. 2014. Epidemiology of breast cancer. Surg Oncol Clin N 
Am. 23(3):409-22. doi: 10.1016/j.soc.2014.03.011. 
 
Beral V, Million Women Study C, Bull D, Green J and Reeves G. 2007. Ovarian cancer 
and hormone replacement therapy in the Million Women Study. Lancet. 
369(9574):1703-10. doi: 10.1016/S0140-6736(07)60534-0. 
 
Bergfeldt K, Rydh B, Granath F, Gronberg H, Thalib L, Adami HO and Hall P. 2002. 
Risk of ovarian cancer in breast-cancer patients with a family history of breast or 
ovarian cancer: a population-based cohort study. Lancet. 360(9337):891-4. doi: 
10.1016/S0140-6736(02)11023-3. 
 
Blanco A, de la Hoya M, Balmana J, Ramon y Cajal T, Teule A, Miramar MD, Esteban 
E, Infante M, Benitez J, Torres A, Tejada MI, Brunet J, Grana B, Balbin M, Perez-
Segura P, Osorio A, Velasco EA, Chirivella I, Calvo MT, Feliubadalo L, Lasa A, Diez 
O, Carracedo A, Caldes T and Vega A. 2012. Detection of a large rearrangement in 
PALB2 in Spanish breast cancer families with male breast cancer. Breast Cancer Res 
Treat. 132(1):307-15. doi: 10.1007/s10549-011-1842-2. 
 
Blesa JR, Garcia JA and Ochoa E. 2000. Frequency of germ-line BRCA1 mutations 
among Spanish families from a Mediterranean area. Hum Mutat. 15(4):381-2. doi: 
10.1002/(SICI)1098-1004(200004)15:4<381::AID-HUMU14>3.0.CO;2-H. 
 
Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud 
R, Buecher B, Bignon YJ, Caron O, Colas C, Nogues C, Lejeune-Dumoulin S, Olivier-
Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux 
D, Duffour J, Manouvrier S, Frebourg T, Sobol H, Lasset C, Bonaiti-Pellie C and 
French Cancer Genetics Network. 2011. Cancer risks associated with germline 
mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 
305(22):2304-10. doi: 10.1001/jama.2011.743. 
 
REFERENCES 
 
130 
 
Bork P, Blomberg N and Nilges M. 1996. Internal repeats in the BRCA2 protein 
sequence. Nat Genet. 13(1):22-3. doi: 10.1038/ng0596-22. 
 
Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, 
Gauthier-Villars M, Stoppa-Lyonnet D, Consolino E, Brugieres L, Caron O, Benusiglio 
PR, Bressac-de Paillerets B, Bonadona V, Bonaiti-Pellie C, Tinat J, Baert-Desurmont 
S and Frebourg T. 2015. Revisiting Li-Fraumeni syndrome from TP53 mutation 
carriers. J Clin Oncol. 33(21):2345-52. doi: 10.1200/JCO.2014.59.5728. 
 
Brownstein MH, Wolf M and Bikowski JB. 1978. Cowden's disease: a cutaneous 
marker of breast cancer. Cancer. 41(6):2393-8. 
 
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, 
Curtin NJ and Helleday T. 2005. Specific killing of BRCA2-deficient tumours with 
inhibitors of poly(ADP-ribose) polymerase. Nature. 434(7035):913-7. doi: 
10.1038/nature03443. 
 
Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, Edery P, 
Bottani A, Layet V, Caron O, Gilbert-Dussardier B, Delnatte C, Dugast C, Fricker JP, 
Bonneau D, Sevenet N, Longy M, Caux F and French Cowden Disease Network. 
2013. High cumulative risks of cancer in patients with PTEN hamartoma tumour 
syndrome. J Med Genet. 50(4):255-63. doi: 10.1136/jmedgenet-2012-101339. 
 
Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, 
Sgroi DC, Lane WS, Haber DA and Livingston DM. 2001. BACH1, a novel helicase-
like protein, interacts directly with BRCA1 and contributes to its DNA repair function. 
Cell. 105(1):149-60. 
 
Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud 
N, Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R, Ardern-Jones A, Ellis 
S, Frost D, Peock S, Evans DG, Tischkowitz M, Cole T, Davidson R, Eccles D, Brewer 
C, Douglas F, Porteous ME, Donaldson A, Dorkins H, Izatt L, Cook J, Hodgson S, 
Kennedy MJ, Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z and 
Eeles R. 2013. Germline BRCA mutations are associated with higher risk of nodal 
involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin 
Oncol. 31(14):1748-57. doi: 10.1200/JCO.2012.43.1882. 
 
Chek Breast Cancer Case-Control Consortium. 2004. CHEK2*1100delC and 
susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer 
REFERENCES 
131 
 
cases and 9,065 controls from 10 studies. Am J Hum Genet. 74(6):1175-82. doi: 
10.1086/421251. 
 
Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD and Lee WH. 1998. The BRC repeats 
in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate 
treatment. Proc Natl Acad Sci U S A. 95(9):5287-92. 
 
Chodick G, Struewing JP, Ron E, Rutter JL and Iscovich J. 2008. Similar prevalence 
of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men 
with breast cancer: evidence from 261 cases in Israel, 1976-1999. Eur J Med Genet. 
51(2):141-7. doi: 10.1016/j.ejmg.2007.11.001. 
 
Clark SL, Rodriguez AM, Snyder RR, Hankins GD and Boehning D. 2012. Structure-
function of the tumor suppressor BRCA1. Comput Struct Biotechnol J. 1(1). doi: 
10.5936/csbj.201204005. 
 
Collaborative Group on Hormonal Factors in Breast Cancer. 1997. Breast cancer and 
hormone replacement therapy: collaborative reanalysis of data from 51 
epidemiological studies of 52,705 women with breast cancer and 108,411 women 
without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. 
Lancet. 350(9084):1047-59. 
 
Couch FJ, Nathanson KL and Offit K. 2014. Two decades after BRCA: setting 
paradigms in personalized cancer care and prevention. Science. 343(6178):1466-70. 
doi: 10.1126/science.1251827. 
 
Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW and Lee Y. 2007. 
The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin 
Obstet Gynecol. 19(1):3-9. doi: 10.1097/GCO.0b013e328011a21f. 
 
Cully M, You H, Levine AJ and Mak TW. 2006. Beyond PTEN mutations: the PI3K 
pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 
6(3):184-92. doi: 10.1038/nrc1819. 
 
Cybulski C, Gorski B, Huzarski T, Byrski T, Gronwald J, Debniak T, Wokolorczyk D, 
Jakubowska A, Serrano-Fernandez P, Dork T, Narod SA and Lubinski J. 2009. Effect 
of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other 
CHEK2 or BRCA1 mutations. J Med Genet. 46(2):132-5. doi: 
10.1136/jmg.2008.061697. 
 
REFERENCES 
 
132 
 
Cybulski C, Carrot-Zhang J, Kluzniak W, Rivera B, Kashyap A, Wokolorczyk D, Giroux 
S, Nadaf J, Hamel N, Zhang S, Huzarski T, Gronwald J, Byrski T, Szwiec M, 
Jakubowska A, Rudnicka H, Lener M, Masojc B, Tonin PN, Rousseau F, Gorski B, 
Debniak T, Majewski J, Lubinski J, Foulkes WD, Narod SA and Akbari MR. 2015. 
Germline RECQL mutations are associated with breast cancer susceptibility. Nat 
Genet. 47(6):643-6. doi: 10.1038/ng.3284. 
 
De Brakeleer S, De Greve J, Lissens W and Teugels E. 2013. Systematic detection 
of pathogenic alu element insertions in NGS-based diagnostic screens: the 
BRCA1/BRCA2 example. Hum Mutat. 34(5):785-91. doi: 10.1002/humu.22297. 
 
DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO and Jemal A. 2015. 
International variation in female breast cancer incidence and mortality rates. Cancer 
Epidemiol Biomarkers Prev. 24(10):1495-506. doi: 10.1158/1055-9965.EPI-15-0535. 
 
Desmond A, Kurian AW, Gabree M, Mills MA, Anderson MJ, Kobayashi Y, Horick N, 
Yang S, Shannon KM, Tung N, Ford JM, Lincoln SE and Ellisen LW. 2015. Clinical 
actionability of multigene panel testing for hereditary breast and ovarian cancer risk 
assessment. JAMA Oncol. 1(7):943-51. doi: 10.1001/jamaoncol.2015.2690. 
 
Ding YC, Steele L, Kuan CJ, Greilac S and Neuhausen SL. 2011. Mutations in BRCA2 
and PALB2 in male breast cancer cases from the United States. Breast Cancer Res 
Treat. 126(3):771-8. doi: 10.1007/s10549-010-1195-2. 
 
Doufekas K and Olaitan A. 2014. Clinical epidemiology of epithelial ovarian cancer in 
the UK. Int J Womens Health. 6:537-45. doi: 10.2147/IJWH.S40894. 
 
Durocher F, Tonin P, Shattuck-Eidens D, Skolnick M, Narod SA and Simard J. 1996. 
Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, 
ovary, and multiple other sites. J Med Genet. 33(10):814-9. 
 
Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, 
Devilee P, Meindl A, Couch FJ, Southey M, Goldgar DE, Evans DG, Chenevix-Trench 
G, Rahman N, Robson M, Domchek SM and Foulkes WD. 2015. Gene-panel 
sequencing and the prediction of breast-cancer risk. N Engl J Med. 372(23):2243-57. 
doi: 10.1056/NEJMsr1501341. 
 
Easton DF, Lesueur F, Decker B, Michailidou K, Li J, Allen J, Luccarini C, Pooley KA, 
Shah M, Bolla MK, Wang Q, Dennis J, Ahmad J, Thompson ER, Damiola F, Pertesi 
M, Voegele C, Mebirouk N, Robinot N, Durand G, Forey N, Luben RN, Ahmed S, 
REFERENCES 
133 
 
Aittomaki K, Anton-Culver H, Arndt V, Australian Ovarian Cancer Study G, Baynes C, 
Beckman MW, Benitez J, Van Den Berg D, Blot WJ, Bogdanova NV, Bojesen SE, 
Brenner H, Chang-Claude J, Chia KS, Choi JY, Conroy DM, Cox A, Cross SS, Czene 
K, Darabi H, Devilee P, Eriksson M, Fasching PA, Figueroa J, Flyger H, Fostira F, 
Garcia-Closas M, Giles GG, Glendon G, Gonzalez-Neira A, Guenel P, Haiman CA, 
Hall P, Hart SN, Hartman M, Hooning MJ, Hsiung CN, Ito H, Jakubowska A, James 
PA, John EM, Johnson N, Jones M, Kabisch M, Kang D, kConFab I, Kosma VM, 
Kristensen V, Lambrechts D, Li N, Lifepool I, Lindblom A, Long J, Lophatananon A, 
Lubinski J, Mannermaa A, Manoukian S, Margolin S, Matsuo K, Meindl A, Mitchell G, 
Muir K, Investigators N, Nevelsteen I, van den Ouweland A, Peterlongo P, Phuah SY, 
Pylkas K, Rowley SM, Sangrajrang S, Schmutzler RK, Shen CY, Shu XO, Southey 
MC, Surowy H, Swerdlow A, Teo SH, Tollenaar RA, Tomlinson I, Torres D, Truong T, 
Vachon C, Verhoef S, Wong-Brown M, Zheng W, Zheng Y, Nevanlinna H, Scott RJ, 
Andrulis IL, Wu AH, Hopper JL, Couch FJ, Winqvist R, Burwinkel B, Sawyer EJ, 
Schmidt MK, Rudolph A, Dork T, Brauch H, Hamann U, Neuhausen SL, Milne RL, 
Fletcher O, Pharoah PD, Campbell IG, Dunning AM, Le Calvez-Kelm F, Goldgar DE, 
Tavtigian SV and Chenevix-Trench G. 2016. No evidence that protein truncating 
variants in BRIP1 are associated with breast cancer risk: implications for gene panel 
testing. J Med Genet. 53(5):298-309. doi: 10.1136/jmedgenet-2015-103529. 
 
Ellingson MS, Hart SN, Kalari KR, Suman V, Schahl KA, Dockter TJ, Felten SJ, 
Sinnwell JP, Thompson KJ, Tang X, Vedell PT, Barman P, Sicotte H, Eckel-Passow 
JE, Northfelt DW, Gray RJ, McLaughlin SA, Moreno-Aspitia A, Ingle JN, Moyer AM, 
Visscher DW, Jones K, Conners A, McDonough M, Wieben ED, Wang L, 
Weinshilboum R, Boughey JC and Goetz MP. 2015. Exome sequencing reveals 
frequent deleterious germline variants in cancer susceptibility genes in women with 
invasive breast cancer undergoing neoadjuvant chemotherapy. Breast Cancer Res 
Treat. 153(2):435-43. doi: 10.1007/s10549-015-3545-6. 
 
Erkko H, Dowty JG, Nikkila J, Syrjakoski K, Mannermaa A, Pylkas K, Southey MC, 
Holli K, Kallioniemi A, Jukkola-Vuorinen A, Kataja V, Kosma VM, Xia B, Livingston 
DM, Winqvist R and Hopper JL. 2008. Penetrance analysis of the PALB2 c.1592delT 
founder mutation. Clin Cancer Res. 14(14):4667-71. doi: 10.1158/1078-0432.CCR-
08-0210. 
 
Evans DG, Birch JM, Ramsden RT, Sharif S and Baser ME. 2006. Malignant 
transformation and new primary tumours after therapeutic radiation for benign 
disease: substantial risks in certain tumour prone syndromes. J Med Genet. 
43(4):289-94. doi: 10.1136/jmg.2005.036319. 
 
REFERENCES 
 
134 
 
Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dorum A, Steel M, 
Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ and Moller P. 2009. 
Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J 
Med Genet. 46(9):593-7. doi: 10.1136/jmg.2008.058248. 
 
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, 
Forman D and Bray F. 2013. Cancer incidence and mortality patterns in Europe: 
estimates for 40 countries in 2012. Eur J Cancer. 49(6):1374-403. doi: 
10.1016/j.ejca.2012.12.027. 
 
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, 
Forman D and Bray F. 2015. Cancer incidence and mortality worldwide: sources, 
methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136(5):E359-86. doi: 
10.1002/ijc.29210. 
 
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, 
Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L and 
Wolmark N. 1998. Tamoxifen for prevention of breast cancer: report of the National 
Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer 
Institute. 90(18):1371-88. 
 
Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, Darnel A, 
Royer R, Poll A, Fafard E, Robidoux A, Martin G, Bismar TA, Tischkowitz M, Rousseau 
F and Narod SA. 2007. Identification of a novel truncating PALB2 mutation and 
analysis of its contribution to early-onset breast cancer in French-Canadian women. 
Breast Cancer Res. 9(6):R83. doi: 10.1186/bcr1828. 
 
Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE and King MC. 
1994. Confirmation of BRCA1 by analysis of germline mutations linked to breast and 
ovarian cancer in ten families. Nat Genet. 8(4):399-404. doi: 10.1038/ng1294-399. 
 
Ghimenti C, Sensi E, Presciuttini S, Brunetti IM, Conte P, Bevilacqua G and Caligo 
MA. 2002. Germline mutations of the BRCA1-associated ring domain (BARD1) gene 
in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations. 
Genes Chromosomes Cancer. 33(3):235-42. 
 
Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, Terry MB, Daly 
MJ, Buys SM, Southey MC, Andrulis I, John EM, Bcfr, kConFab, Khanna KK, Hopper 
JL, Oefner PJ, Lakhani S and Chenevix-Trench G. 2011. Rare variants in the ATM 
gene and risk of breast cancer. Breast Cancer Res. 13(4):R73. doi: 10.1186/bcr2919. 
REFERENCES 
135 
 
 
Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, 
Lowstuter K, Longmate J, Sommer SS and Weitzel JN. 2009. Beyond Li Fraumeni 
Syndrome: clinical characteristics of families with p53 germline mutations. J Clin 
Oncol. 27(8):1250-6. doi: 10.1200/JCO.2008.16.6959. 
 
Graziano F, Humar B and Guilford P. 2003. The role of the E-cadherin gene (CDH1) 
in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann 
Oncol. 14(12):1705-13. 
 
Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson 
H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, 
Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA and Hereditary Breast Cancer 
Clinical Study Group. 2006. Tamoxifen and contralateral breast cancer in BRCA1 and 
BRCA2 carriers: an update. Int J Cancer. 118(9):2281-4. doi: 10.1002/ijc.21536. 
 
Guidugli L, Pankratz VS, Singh N, Thompson J, Erding CA, Engel C, Schmutzler R, 
Domchek S, Nathanson K, Radice P, Singer C, Tonin PN, Lindor NM, Goldgar DE and 
Couch FJ. 2013. A classification model for BRCA2 DNA binding domain missense 
variants based on homology-directed repair activity. Cancer Res. 73(1):265-75. doi: 
10.1158/0008-5472.CAN-12-2081. 
 
Guidugli L, Carreira A, Caputo SM, Ehlen A, Galli A, Monteiro AN, Neuhausen SL, 
Hansen TV, Couch FJ, Vreeswijk MP and Enigma Consortium. 2014. Functional 
assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat. 
35(2):151-64. doi: 10.1002/humu.22478. 
 
Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, 
Ziegler A, Raeburn JA, Campra D, Grutzmann R, Rehder H, Rothmund M, Schmiegel 
W, Neoptolemos JP and Bartsch DK. 2003. BRCA2 germline mutations in familial 
pancreatic carcinoma. Journal of the National Cancer Institute. 95(3):214-21. 
 
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B and King MC. 1990. 
Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 
250(4988):1684-9. 
 
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, 
Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I and de 
la Chapelle A. 2005. Screening for the Lynch syndrome (hereditary nonpolyposis 
colorectal cancer). N Engl J Med. 352(18):1851-60. doi: 10.1056/NEJMoa043146. 
REFERENCES 
 
136 
 
 
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, 
Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, 
Comeras I and de la Chapelle A. 2008. Feasibility of screening for Lynch syndrome 
among patients with colorectal cancer. J Clin Oncol. 26(35):5783-8. doi: 
10.1200/JCO.2008.17.5950. 
 
Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, 
Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, Deffenbaugh A, 
Couch FJ and Jenkins RB. 2001. Efficacy of bilateral prophylactic mastectomy in 
BRCA1 and BRCA2 gene mutation carriers. Journal of the National Cancer Institute. 
93(21):1633-7. 
 
Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ, Keller JJ, 
Westerman AM, Scott RJ, Lim W, Trimbath JD, Giardiello FM, Gruber SB, Offerhaus 
GJ, de Rooij FW, Wilson JH, Hansmann A, Moslein G, Royer-Pokora B, Vogel T, 
Phillips RK, Spigelman AD and Houlston RS. 2006. Frequency and spectrum of 
cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 12(10):3209-15. doi: 
10.1158/1078-0432.CCR-06-0083. 
 
Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collee JM, van 
Doorn HC, Gomez Garcia EB, Kets CM, van Leeuwen FE, Meijers-Heijboer HE, 
Mourits MJ, van Os TA, Vasen HF, Verhoef S, Rookus MA, Hooning MJ, Hereditary 
B and Netherlands Ovarian Cancer Research Group. 2015. Breast cancer risk after 
salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence 
for risk reduction. Journal of the National Cancer Institute. 107(5). doi: 
10.1093/jnci/djv033. 
 
Heikkinen K, Karppinen SM, Soini Y, Makinen M and Winqvist R. 2003. Mutation 
screening of Mre11 complex genes: indication of RAD50 involvement in breast and 
ovarian cancer susceptibility. J Med Genet. 40(12):e131. 
 
Helder-Woolderink JM, Blok EA, Vasen HF, Hollema H, Mourits MJ and De Bock GH. 
2016. Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer. 55:65-
73. doi: 10.1016/j.ejca.2015.12.005. 
 
Helgason H, Rafnar T, Olafsdottir HS, Jonasson JG, Sigurdsson A, Stacey SN, 
Jonasdottir A, Tryggvadottir L, Alexiusdottir K, Haraldsson A, le Roux L, 
Gudmundsson J, Johannsdottir H, Oddsson A, Gylfason A, Magnusson OT, Masson 
G, Jonsson T, Skuladottir H, Gudbjartsson DF, Thorsteinsdottir U, Sulem P and 
REFERENCES 
137 
 
Stefansson K. 2015. Loss-of-function variants in ATM confer risk of gastric cancer. 
Nat Genet. 47(8):906-10. doi: 10.1038/ng.3342. 
 
Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, 
Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, 
Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle 
A and Aaltonen LA. 1998. A serine/threonine kinase gene defective in Peutz-Jeghers 
syndrome. Nature. 391(6663):184-7. doi: 10.1038/34432. 
 
Hobert JA and Eng C. 2009. PTEN hamartoma tumor syndrome: an overview. Genet 
Med. 11(10):687-94. doi: 10.1097/GIM.0b013e3181ac9aea. 
 
Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, Dhani N, Narod S, 
Akbari M, Moore M and Gallinger S. 2015. Germline BRCA Mutations in a large clinic-
based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 33(28):3124-
9. doi: 10.1200/JCO.2014.59.7401. 
 
Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, Bourdon V, Bronner 
M, Buisson M, Coulet F, Gaildrat P, Lefol C, Leone M, Mazoyer S, Muller D, 
Remenieras A, Revillion F, Rouleau E, Sokolowska J, Vert JP, Lidereau R, Soubrier 
F, Sobol H, Sevenet N, Bressac-de Paillerets B, Hardouin A, Tosi M, Sinilnikova OM 
and Stoppa-Lyonnet D. 2012. Guidelines for splicing analysis in molecular diagnosis 
derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 
variants. Hum Mutat. 33(8):1228-38. doi: 10.1002/humu.22101. 
 
Hsieh CC, Trichopoulos D, Katsouyanni K and Yuasa S. 1990. Age at menarche, age 
at menopause, height and obesity as risk factors for breast cancer: associations and 
interactions in an international case-control study. Int J Cancer. 46(5):796-800. 
 
Huen MS, Sy SM and Chen J. 2010. BRCA1 and its toolbox for the maintenance of 
genome integrity. Nat Rev Mol Cell Biol. 11(2):138-48. doi: 10.1038/nrm2831. 
 
Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, Stampfer 
MJ and Willett WC. 2010. Oral contraceptive use and breast cancer: a prospective 
study of young women. Cancer Epidemiol Biomarkers Prev. 19(10):2496-502. doi: 
10.1158/1055-9965.EPI-10-0747. 
 
Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, Bernard L, 
Maisonneuve P and Gandini S. 2010. Oral contraceptive use and breast or ovarian 
REFERENCES 
 
138 
 
cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer. 46(12):2275-84. doi: 
10.1016/j.ejca.2010.04.018. 
 
Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Muller O, Back W and 
Zimmer M. 1998. Peutz-Jeghers syndrome is caused by mutations in a novel serine 
threonine kinase. Nat Genet. 18(1):38-43. doi: 10.1038/ng0198-38. 
 
Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, 
Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, 
Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M and 
Klein AP. 2009. Exomic sequencing identifies PALB2 as a pancreatic cancer 
susceptibility gene. Science. 324(5924):217. doi: 10.1126/science.1171202. 
 
Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, 
Balmana J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, 
Loman N, Bowen K, Fielding A and Domchek SM. 2015. Olaparib monotherapy in 
patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 
33(3):244-50. doi: 10.1200/JCO.2014.56.2728. 
 
Key TJ and Verkasalo PK. 1999. Endogenous hormones and the aetiology of breast 
cancer. Breast Cancer Res. 1(1):18-21. 
 
Key TJ, Verkasalo PK and Banks E. 2001. Epidemiology of breast cancer. Lancet 
Oncol. 2(3):133-40. doi: 10.1016/S1470-2045(00)00254-0. 
 
Kiiski JI, Pelttari LM, Khan S, Freysteinsdottir ES, Reynisdottir I, Hart SN, Shimelis H, 
Vilske S, Kallioniemi A, Schleutker J, Leminen A, Butzow R, Blomqvist C, Barkardottir 
RB, Couch FJ, Aittomaki K and Nevanlinna H. 2014. Exome sequencing identifies 
FANCM as a susceptibility gene for triple-negative breast cancer. Proc Natl Acad Sci 
U S A. 111(42):15172-7. doi: 10.1073/pnas.1407909111. 
 
Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, 
Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG and Crum CP. 2007. 
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a 
causal relationship. Am J Surg Pathol. 31(2):161-9. doi: 
10.1097/01.pas.0000213335.40358.47. 
 
King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, 
Costantino J, Wickerham L, Wolmark N, Fisher B, National Surgical Adjuvant B and 
Bowel P. 2001. Tamoxifen and breast cancer incidence among women with inherited 
REFERENCES 
139 
 
mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel 
Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 286(18):2251-6. 
 
Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, 
Guy M, Edwards S, O'Brien L, Sawyer E, Hall A, Wilkinson R, Dadaev T, Goh C, 
Easton D, Collaborators U, Goldgar D and Eeles R. 2011. BRCA2 is a moderate 
penetrance gene contributing to young-onset prostate cancer: implications for genetic 
testing in prostate cancer patients. Br J Cancer. 105(8):1230-4. doi: 
10.1038/bjc.2011.383. 
 
Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, 
Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk 
JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG and Magnetic 
Resonance Imaging Screening Study Group. 2004. Efficacy of MRI and 
mammography for breast-cancer screening in women with a familial or genetic 
predisposition. N Engl J Med. 351(5):427-37. doi: 10.1056/NEJMoa031759. 
 
Krutilkova V, Trkova M, Fleitz J, Gregor V, Novotna K, Krepelova A, Sumerauer D, 
Kodet R, Siruckova S, Plevova P, Bendova S, Hedvicakova P, Foreman NK and 
Sedlacek Z. 2005. Identification of five new families strengthens the link between 
childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer. 
41(11):1597-603. doi: 10.1016/j.ejca.2005.01.026. 
 
Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, 
McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee 
S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, 
Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jonson L, 
Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, 
Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, 
Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, 
Garber J, Frost D, Perkins J, Platte R, Ellis S, Embrace, Godwin AK, Schmutzler RK, 
Meindl A, Engel C, Sutter C, Sinilnikova OM, Collaborators GS, Damiola F, Mazoyer 
S, Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M, 
O'Malley DM, de la Hoya M, Caldes T, Aittomaki K, Nevanlinna H, Collee JM, Rookus 
MA, Oosterwijk JC, Breast Cancer Family R, Tihomirova L, Tung N, Hamann U, Isaccs 
C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB, Hebon, 
Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald 
J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna 
M, Tognazzo S, Teixeira MR, Investigators KC, Pankratz VS, Wang X, Lindor N, 
Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea MK, 
REFERENCES 
 
140 
 
Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, 
Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, 
Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmalm 
M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, 
Karlan BY, Walsh C, Lester J, Australian Cancer S, Australian Ovarian Cancer Study 
G, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van 
Nieuwenhuysen E, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, 
Rossing MA, Rudolph A, Chang-Claude J, Wang-Gohrke S, Eilber U, Moysich KB, 
Odunsi K, Sucheston L, Lele S, Wilkens LR, Goodman MT, Thompson PJ, Shvetsov 
YB, Runnebaum IB, Durst M, Hillemanns P, Dork T, Antonenkova N, Bogdanova N, 
Leminen A, Pelttari LM, Butzow R, Modugno F, Kelley JL, Edwards RP, Ness RB, du 
Bois A, Heitz F, Schwaab I, Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kjaer 
SK, Hogdall E, Hasmad HN, Azmi MA, Teo SH, Woo YL, Fridley BL, Goode EL, 
Cunningham JM, Vierkant RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MA, Wu 
X, Levine DA, Bisogna M, Berchuck A, Iversen ES, Schildkraut JM, Concannon P, 
Weber RP, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, 
Olson SH, Krakstad C, Salvesen HB, Tangen IL, Bjorge L, van Altena AM, Aben KK, 
Kiemeney LA, Massuger LF, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le 
ND, Cybulski C, Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall 
L, Nedergaard L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, 
Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Ji BT, Zheng W, Shu 
XO, Gao YT, Rosen B, Risch HA, McLaughlin JR, Narod SA, Monteiro AN, Chen A, 
Lin HY, Permuth-Wey J, Sellers TA, Tsai YY, Chen Z, Ziogas A, Anton-Culver H, 
Gentry-Maharaj A, Menon U, Harrington P, Lee AW, Wu AH, Pearce CL, Coetzee G, 
Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J, 
Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP, 
Antoniou AC, Chenevix-Trench G and CIMBA. 2015. Identification of six new 
susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 47(2):164-71. doi: 
10.1038/ng.3185. 
 
Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L and 
Easton DF. 2002. The pathology of familial breast cancer: predictive value of 
immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and 
p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 20(9):2310-8. 
 
Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, McGuffog 
L, Steele D, Devilee P, Klijn JG, Meijers-Heijboer H, Radice P, Pilotti S, Nevanlinna 
H, Butzow R, Sobol H, Jacquemier J, Lyonet DS, Neuhausen SL, Weber B, Wagner 
T, Winqvist R, Bignon YJ, Monti F, Schmitt F, Lenoir G, Seitz S, Hamman U, Pharoah 
REFERENCES 
141 
 
P, Lane G, Ponder B, Bishop DT and Easton DF. 2004. Pathology of ovarian cancers 
in BRCA1 and BRCA2 carriers. Clin Cancer Res. 10(7):2473-81. 
 
Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, 
Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, 
Devilee P, Beckmann MW, Nestle-Kramling C, Daly PA, Haites N, Varley J, Lalloo F, 
Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, 
Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, 
McGuffog L, Easton DF and Consortium Breast Cancer Linkage. 2005. Prediction of 
BRCA1 status in patients with breast cancer using estrogen receptor and basal 
phenotype. Clin Cancer Res. 11(14):5175-80. doi: 10.1158/1078-0432.CCR-04-2424. 
 
Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA, Redston M and Gallinger 
S. 2000. Inherited predisposition to pancreatic adenocarcinoma: role of family history 
and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res. 60(2):409-16. 
 
Lalloo F, Varley J, Moran A, Ellis D, O'Dair L, Pharoah P, Antoniou A, Hartley R, 
Shenton A, Seal S, Bulman B, Howell A and Evans DG. 2006. BRCA1, BRCA2 and 
TP53 mutations in very early-onset breast cancer with associated risks to relatives. 
Eur J Cancer. 42(8):1143-50. doi: 10.1016/j.ejca.2005.11.032. 
 
Lalloo F and Evans DG. 2012. Familial breast cancer. Clin Genet. 82(2):105-14. doi: 
10.1111/j.1399-0004.2012.01859.x. 
 
Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M and Adami HO. 1994. 
Transient increase in the risk of breast cancer after giving birth. N Engl J Med. 
331(1):5-9. doi: 10.1056/NEJM199407073310102. 
 
Lane DP. 1992. Cancer. p53, guardian of the genome. Nature. 358(6381):15-6. doi: 
10.1038/358015a0. 
 
Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, 
Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, 
Pointon LJ, Thompson D, Warren RM and MARIBS Study Group. 2005. Screening 
with magnetic resonance imaging and mammography of a UK population at high 
familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). 
Lancet. 365(9473):1769-78. doi: 10.1016/S0140-6736(05)66481-1. 
 
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier 
W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, 
REFERENCES 
 
142 
 
Hodgson D, Barrett JC and Matulonis U. 2014. Olaparib maintenance therapy in 
patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned 
retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. 
Lancet Oncol. 15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. 
 
Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, 
Goh C, Govindasami K, Guy M, O'Brien L, Sawyer E, Hall A, Wilkinson R, Easton D, 
Collaborators U, Goldgar D, Eeles R and Kote-Jarai Z. 2012. Germline BRCA1 
mutations increase prostate cancer risk. Br J Cancer. 106(10):1697-701. doi: 
10.1038/bjc.2012.146. 
 
Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88(3):323-
31. 
 
Li FP, Fraumeni JF, Jr., Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA and Miller 
RW. 1988. A cancer family syndrome in twenty-four kindreds. Cancer Res. 
48(18):5358-62. 
 
Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, 
Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, Berg J, Brady AF, 
Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, 
Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison 
PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Breast Cancer 
Susceptibility C, Eccles D, Evans DG, Renwick A, Seal S, Lord CJ, Ashworth A, Reis-
Filho JS, Antoniou AC and Rahman N. 2011. Germline mutations in RAD51D confer 
susceptibility to ovarian cancer. Nat Genet. 43(9):879-82. doi: 10.1038/ng.893. 
 
Loveday C, Turnbull C, Ruark E, Xicola RM, Ramsay E, Hughes D, Warren-Perry M, 
Snape K, Breast Cancer Susceptibility C, Eccles D, Evans DG, Gore M, Renwick A, 
Seal S, Antoniou AC and Rahman N. 2012. Germline RAD51C mutations confer 
susceptibility to ovarian cancer. Nat Genet. 44(5):475-6; author reply 6. doi: 
10.1038/ng.2224. 
 
Lu KH and Daniels M. 2013. Endometrial and ovarian cancer in women with Lynch 
syndrome: update in screening and prevention. Fam Cancer. 12(2):273-7. doi: 
10.1007/s10689-013-9664-5. 
 
Lustbader ED, Williams WR, Bondy ML, Strom S and Strong LC. 1992. Segregation 
analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum 
Genet. 51(2):344-56. 
REFERENCES 
143 
 
 
Lynch HT, Krush AJ, Lemon HM, Kaplan AR, Condit PT and Bottomley RH. 1972. 
Tumor variation in families with breast cancer. JAMA. 222(13):1631-5. 
 
Machado PM, Brandao RD, Cavaco BM, Eugenio J, Bento S, Nave M, Rodrigues P, 
Fernandes A and Vaz F. 2007. Screening for a BRCA2 rearrangement in high-risk 
breast/ovarian cancer families: evidence for a founder effect and analysis of the 
associated phenotypes. J Clin Oncol. 25(15):2027-34. doi: 
10.1200/JCO.2006.06.9443. 
 
Maia S, Cardoso M, Paulo P, Pinheiro M, Pinto P, Santos C, Pinto C, Peixoto A, 
Henrique R and Teixeira MR. 2016. The role of germline mutations in the BRCA1/2 
and mismatch repair genes in men ascertained for early-onset and/or familial prostate 
cancer. Fam Cancer. 15(1):111-21. doi: 10.1007/s10689-015-9832-x. 
 
Malkin D, Li FP, Strong LC, Fraumeni JF, Jr., Nelson CE, Kim DH, Kassel J, Gryka 
MA, Bischoff FZ, Tainsky MA and Friend SH. 1990. Germ line p53 mutations in a 
familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 
250(4985):1233-8. 
 
Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro 
HC, Troussard A, Miron P, Tung N, Oliveira C, Collins L, Schnitt S, Garber JE and 
Huntsman D. 2007. Germline E-cadherin mutations in familial lobular breast cancer. 
J Med Genet. 44(11):726-31. doi: 10.1136/jmg.2007.051268. 
 
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava 
Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman 
A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones 
R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, 
Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, 
Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, 
Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E and de Bono 
JS. 2015. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J 
Med. 373(18):1697-708. doi: 10.1056/NEJMoa1506859. 
 
Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, 
Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, 
McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley 
F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, 
Stavropoulou A, Benitez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, 
REFERENCES 
 
144 
 
Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, 
Kriege M, van der Luijt RB, Hebon, Peock S, Frost D, Evans DG, Brewer C, Walker 
L, Rogers MT, Side LE, Houghton C, Embrace, Weaver J, Godwin AK, Schmutzler 
RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler 
H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schonbuchner I, Gevensleben 
H, Stoppa-Lyonnet D, Belotti M, Barjhoux L, Collaborators GS, Isaacs C, Peshkin BN, 
Caldes T, de la Hoya M, Canadas C, Heikkinen T, Heikkila P, Aittomaki K, Blanco I, 
Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, 
Montagna M, Agata S, D'Andrea E, Yan M, Fox S, kConFab I, Rebbeck TR, 
Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, 
Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, 
Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen 
M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson 
K, Collaborators S-B, Steele L, Neuhausen SL, Nussbaum R, Beattie M, Odunsi K, 
Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-
Trench G, Easton DF, Antoniou AC and CIMBA. 2012. Pathology of breast and 
ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the 
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol 
Biomarkers Prev. 21(1):134-47. doi: 10.1158/1055-9965.EPI-11-0775. 
 
Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles 
RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, 
Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, 
Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, 
Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF and EMBRACE. 
2013. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective 
analysis of EMBRACE. Journal of the National Cancer Institute. 105(11):812-22. doi: 
10.1093/jnci/djt095. 
 
Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, Wang Q, 
Dennis J, Dunning AM, Shah M, Luben R, Brown J, Bojesen SE, Nordestgaard BG, 
Nielsen SF, Flyger H, Czene K, Darabi H, Eriksson M, Peto J, Dos-Santos-Silva I, 
Dudbridge F, Johnson N, Schmidt MK, Broeks A, Verhoef S, Rutgers EJ, Swerdlow 
A, Ashworth A, Orr N, Schoemaker MJ, Figueroa J, Chanock SJ, Brinton L, Lissowska 
J, Couch FJ, Olson JE, Vachon C, Pankratz VS, Lambrechts D, Wildiers H, Van 
Ongeval C, van Limbergen E, Kristensen V, Grenaker Alnaes G, Nord S, Borresen-
Dale AL, Nevanlinna H, Muranen TA, Aittomaki K, Blomqvist C, Chang-Claude J, 
Rudolph A, Seibold P, Flesch-Janys D, Fasching PA, Haeberle L, Ekici AB, Beckmann 
MW, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Trentham-Dietz A, Newcomb 
P, Titus L, Egan KM, Hunter DJ, Lindstrom S, Tamimi RM, Kraft P, Rahman N, 
REFERENCES 
145 
 
Turnbull C, Renwick A, Seal S, Li J, Liu J, Humphreys K, Benitez J, Pilar Zamora M, 
Arias Perez JI, Menendez P, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda 
K, Bogdanova NV, Antonenkova NN, Dork T, Anton-Culver H, Neuhausen SL, Ziogas 
A, Bernstein L, Devilee P, Tollenaar RA, Seynaeve C, van Asperen CJ, Cox A, Cross 
SS, Reed MW, Khusnutdinova E, Bermisheva M, Prokofyeva D, Takhirova Z, Meindl 
A, Schmutzler RK, Sutter C, Yang R, Schurmann P, Bremer M, Christiansen H, Park-
Simon TW, Hillemanns P, Guenel P, Truong T, Menegaux F, Sanchez M, Radice P, 
Peterlongo P, Manoukian S, Pensotti V, Hopper JL, Tsimiklis H, Apicella C, Southey 
MC, Brauch H, Bruning T, Ko YD, Sigurdson AJ, Doody MM, Hamann U, Torres D, 
Ulmer HU, Forsti A, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Andrulis IL, Knight 
JA, Glendon G, Marie Mulligan A, Chenevix-Trench G, Balleine R, Giles GG, Milne 
RL, McLean C, Lindblom A, Margolin S, Haiman CA, Henderson BE, Schumacher F, 
Le Marchand L, Eilber U, Wang-Gohrke S, Hooning MJ, Hollestelle A, van den 
Ouweland AM, Koppert LB, Carpenter J, Clarke C, Scott R, Mannermaa A, Kataja V, 
Kosma VM, Hartikainen JM, Brenner H, Arndt V, Stegmaier C, Karina Dieffenbach A, 
Winqvist R, Pylkas K, Jukkola-Vuorinen A, Grip M, Offit K, Vijai J, Robson M, Rau-
Murthy R, Dwek M, Swann R, Annie Perkins K, Goldberg MS, Labreche F, Dumont 
M, Eccles DM, Tapper WJ, Rafiq S, John EM, Whittemore AS, Slager S, Yannoukakos 
D, Toland AE, Yao S, Zheng W, Halverson SL, Gonzalez-Neira A, Pita G, Rosario 
Alonso M, Alvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Luccarini C, Baynes 
C, Ahmed S, Maranian M, Healey CS, Simard J, Hall P, Easton DF and Garcia-Closas 
M. 2015. Prediction of breast cancer risk based on profiling with common genetic 
variants. Journal of the National Cancer Institute. 107(5). doi: 10.1093/jnci/djv036. 
 
Mazoyer S. 2005. Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum 
Mutat. 25(5):415-22. doi: 10.1002/humu.20169. 
 
McCuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod SA and Malkin 
D. 2012. Routine TP53 testing for breast cancer under age 30: ready for prime time? 
Fam Cancer. 11(4):607-13. doi: 10.1007/s10689-012-9557-z. 
 
Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, 
Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt 
F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, 
Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans 
DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo 
C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton 
MR and CHEK2-Breast Cancer Consortium. 2002. Low-penetrance susceptibility to 
breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 
mutations. Nat Genet. 31(1):55-9. doi: 10.1038/ng879. 
REFERENCES 
 
146 
 
 
Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund 
M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann 
HE, Kast K, Deissler H, Engel C, Muller-Myhsok B, Neveling K, Kiechle M, Mathew 
CG, Schindler D, Schmutzler RK and Hanenberg H. 2010. Germline mutations in 
breast and ovarian cancer pedigrees establish RAD51C as a human cancer 
susceptibility gene. Nat Genet. 42(5):410-4. doi: 10.1038/ng.569. 
 
Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, 
Litton JK, Olopade OI, Hortobagyi GN, Strong LC and Arun BK. 2012. Early onset 
HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 
118(4):908-13. doi: 10.1002/cncr.26377. 
 
Mellemkjaer L, Dahl C, Olsen JH, Bertelsen L, Guldberg P, Christensen J, Borresen-
Dale AL, Stovall M, Langholz B, Bernstein L, Lynch CF, Malone KE, Haile RW, 
Andersson M, Thomas DC, Concannon P, Capanu M, Boice JD, Jr., Group WSC and 
Bernstein JL. 2008. Risk for contralateral breast cancer among carriers of the 
CHEK2*1100delC mutation in the WECARE Study. Br J Cancer. 98(4):728-33. doi: 
10.1038/sj.bjc.6604228. 
 
Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK and 
Litton JK. 2015. Cancers associated with BRCA1 and BRCA2 mutations other than 
breast and ovarian. Cancer. 121(2):269-75. doi: 10.1002/cncr.29041. 
 
Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, Maranian MJ, 
Bolla MK, Wang Q, Shah M, Perkins BJ, Czene K, Eriksson M, Darabi H, Brand JS, 
Bojesen SE, Nordestgaard BG, Flyger H, Nielsen SF, Rahman N, Turnbull C, Bocs, 
Fletcher O, Peto J, Gibson L, dos-Santos-Silva I, Chang-Claude J, Flesch-Janys D, 
Rudolph A, Eilber U, Behrens S, Nevanlinna H, Muranen TA, Aittomaki K, Blomqvist 
C, Khan S, Aaltonen K, Ahsan H, Kibriya MG, Whittemore AS, John EM, Malone KE, 
Gammon MD, Santella RM, Ursin G, Makalic E, Schmidt DF, Casey G, Hunter DJ, 
Gapstur SM, Gaudet MM, Diver WR, Haiman CA, Schumacher F, Henderson BE, Le 
Marchand L, Berg CD, Chanock SJ, Figueroa J, Hoover RN, Lambrechts D, Neven P, 
Wildiers H, van Limbergen E, Schmidt MK, Broeks A, Verhoef S, Cornelissen S, 
Couch FJ, Olson JE, Hallberg E, Vachon C, Waisfisz Q, Meijers-Heijboer H, Adank 
MA, van der Luijt RB, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Yoo KY, 
Matsuo K, Ito H, Iwata H, Tajima K, Guenel P, Truong T, Mulot C, Sanchez M, 
Burwinkel B, Marme F, Surowy H, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram 
DO, Gonzalez-Neira A, Benitez J, Zamora MP, Perez JI, Shu XO, Lu W, Gao YT, Cai 
H, Cox A, Cross SS, Reed MW, Andrulis IL, Knight JA, Glendon G, Mulligan AM, 
REFERENCES 
147 
 
Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, kConFab I, Group A, Lindblom A, Margolin 
S, Teo SH, Yip CH, Taib NA, Tan GH, Hooning MJ, Hollestelle A, Martens JW, Collee 
JM, Blot W, Signorello LB, Cai Q, Hopper JL, Southey MC, Tsimiklis H, Apicella C, 
Shen CY, Hsiung CN, Wu PE, Hou MF, Kristensen VN, Nord S, Alnaes GI, Nbcs, Giles 
GG, Milne RL, McLean C, Canzian F, Trichopoulos D, Peeters P, Lund E, Sund M, 
Khaw KT, Gunter MJ, Palli D, Mortensen LM, Dossus L, Huerta JM, Meindl A, 
Schmutzler RK, Sutter C, Yang R, Muir K, Lophatananon A, Stewart-Brown S, 
Siriwanarangsan P, Hartman M, Miao H, Chia KS, Chan CW, Fasching PA, Hein A, 
Beckmann MW, Haeberle L, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, 
Ashworth A, Orr N, Schoemaker MJ, Swerdlow AJ, Brinton L, Garcia-Closas M, Zheng 
W, Halverson SL, Shrubsole M, Long J, Goldberg MS, Labreche F, Dumont M, 
Winqvist R, Pylkas K, Jukkola-Vuorinen A, Grip M, Brauch H, Hamann U, Bruning T, 
Network G, Radice P, Peterlongo P, Manoukian S, Bernard L, Bogdanova NV, Dork 
T, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RA, 
Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska K, Huzarski T, 
Sangrajrang S, Gaborieau V, Brennan P, McKay J, Slager S, Toland AE, Ambrosone 
CB, Yannoukakos D, Kabisch M, Torres D, Neuhausen SL, Anton-Culver H, Luccarini 
C, Baynes C, Ahmed S, Healey CS, Tessier DC, Vincent D, Bacot F, Pita G, Alonso 
MR, Alvarez N, Herrero D, Simard J, Pharoah PP, Kraft P, Dunning AM, Chenevix-
Trench G, Hall P and Easton DF. 2015. Genome-wide association analysis of more 
than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat 
Genet. 47(4):373-80. doi: 10.1038/ng.3242. 
 
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, 
Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, 
Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, 
Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, 
Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett 
JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A and 
Skolnick MH. 1994. A strong candidate for the breast and ovarian cancer susceptibility 
gene BRCA1. Science. 266(5182):66-71. 
 
Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG and Goodman MT. 2004. 
Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in 
women with and without endometriosis. Am J Obstet Gynecol. 191(3):733-40. doi: 
10.1016/j.ajog.2004.03.035. 
 
Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo 
Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD and Myers ER. 2013. 
Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk 
REFERENCES 
 
148 
 
women: a systematic review and meta-analysis. J Clin Oncol. 31(33):4188-98. doi: 
10.1200/JCO.2013.48.9021. 
 
Moran A, O'Hara C, Khan S, Shack L, Woodward E, Maher ER, Lalloo F and Evans 
DG. 2012. Risk of cancer other than breast or ovarian in individuals with BRCA1 and 
BRCA2 mutations. Fam Cancer. 11(2):235-42. doi: 10.1007/s10689-011-9506-2. 
 
Moreira MA, Bobrovnitchaia IG, Lima MA, Santos AC, Ramos JP, Souza KR, Peixoto 
A, Teixeira MR and Vargas FR. 2012. Portuguese c.156_157insAlu BRCA2 founder 
mutation: gastrointestinal and tongue neoplasias may be part of the phenotype. Fam 
Cancer. 11(4):657-60. doi: 10.1007/s10689-012-9551-5. 
 
Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Giles GG, Hopper JL 
and Southey MC. 2010. Population-based estimate of the contribution of TP53 
mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family 
Study. Cancer Res. 70(12):4795-800. doi: 10.1158/0008-5472.CAN-09-0851. 
 
Moynahan ME, Chiu JW, Koller BH and Jasin M. 1999. Brca1 controls homology-
directed DNA repair. Mol Cell. 4(4):511-8. 
 
Moynahan ME, Pierce AJ and Jasin M. 2001. BRCA2 is required for homology-
directed repair of chromosomal breaks. Mol Cell. 7(2):263-72. 
 
Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban 
RH and Kern SE. 2002. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, 
and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. 
Cancer Res. 62(13):3789-93. 
 
Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J and Lenoir GM. 
1991. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet. 
338(8759):82-3. 
 
Narod SA and Foulkes WD. 2004. BRCA1 and BRCA2: 1994 and beyond. Nat Rev 
Cancer. 4(9):665-76. doi: 10.1038/nrc1431. 
 
National Comprehensive Cancer Network (NCCN). Genetic/familial high-risk 
assessment: breast and ovarian (Version 2.2016) 2016. Available from: 
http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. 
 
REFERENCES 
149 
 
Newman B, Austin MA, Lee M and King MC. 1988. Inheritance of human breast 
cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl 
Acad Sci U S A. 85(9):3044-8. 
 
NICE guidelines [CG164]. 2015. Familial breast cancer: classification, care and 
managing breast cancer and related risks in people with a family history of breast 
cancer. 
 
Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, 
Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, 
Lankes HA, Ramirez NC, King MC, Swisher EM and Birrer MJ. 2016. Inherited 
mutations in women with ovarian carcinoma. JAMA Oncol. 2(4):482-90. doi: 
10.1001/jamaoncol.2015.5495. 
 
Oliver AW, Swift S, Lord CJ, Ashworth A and Pearl LH. 2009. Structural basis for 
recruitment of BRCA2 by PALB2. EMBO Rep. 10(9):990-6. doi: 
10.1038/embor.2009.126. 
 
Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Gulino A, 
Giannini G, Bianchi S, Sera F and Palli D. 2009. BRCA1/BRCA2 mutation status and 
clinical-pathologic features of 108 male breast cancer cases from Tuscany: a 
population-based study in central Italy. Breast Cancer Res Treat. 116(3):577-86. doi: 
10.1007/s10549-008-0194-z. 
 
Parmigiani G, Berry D and Aguilar O. 1998. Determining carrier probabilities for breast 
cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 62(1):145-58. 
 
Peixoto A, Santos C, Rocha P, Pinheiro M, Principe S, Pereira D, Rodrigues H, Castro 
F, Abreu J, Gusmao L, Amorim A and Teixeira MR. 2009. The c.156_157insAlu 
BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA 
mutations in northern/central Portugal. Breast Cancer Res Treat. 114(1):31-8. doi: 
10.1007/s10549-008-9978-4. 
 
Peixoto A, Santos C, Pinheiro M, Pinto P, Soares MJ, Rocha P, Gusmao L, Amorim 
A, van der Hout A, Gerdes AM, Thomassen M, Kruse TA, Cruger D, Sunde L, Bignon 
YJ, Uhrhammer N, Cornil L, Rouleau E, Lidereau R, Yannoukakos D, Pertesi M, Narod 
S, Royer R, Costa MM, Lazaro C, Feliubadalo L, Grana B, Blanco I, de la Hoya M, 
Caldes T, Maillet P, Benais-Pont G, Pardo B, Laitman Y, Friedman E, Velasco EA, 
Duran M, Miramar MD, Valle AR, Calvo MT, Vega A, Blanco A, Diez O, Gutierrez-
Enriquez S, Balmana J, Ramon y Cajal T, Alonso C, Baiget M, Foulkes W, Tischkowitz 
REFERENCES 
 
150 
 
M, Kyle R, Sabbaghian N, Ashton-Prolla P, Ewald IP, Rajkumar T, Mota-Vieira L, 
Giannini G, Gulino A, Achatz MI, Carraro DM, de Paillerets BB, Remenieras A, Benson 
C, Casadei S, King MC, Teugels E and Teixeira MR. 2011. International distribution 
and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. 
Breast Cancer Res Treat. 127(3):671-9. doi: 10.1007/s10549-010-1036-3. 
 
Peixoto A, Santos C, Pinto P, Pinheiro M, Rocha P, Pinto C, Bizarro S, Veiga I, 
Principe AS, Maia S, Castro F, Couto R, Gouveia A and Teixeira MR. 2015. The role 
of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer 
families of Portuguese ancestry. Clin Genet. 88(1):41-8. doi: 10.1111/cge.12441. 
 
Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist 
C, Aittomaki K, Butzow R and Nevanlinna H. 2011. RAD51C is a susceptibility gene 
for ovarian cancer. Hum Mol Genet. 20(16):3278-88. doi: 10.1093/hmg/ddr229. 
 
Pelttari LM, Kiiski J, Nurminen R, Kallioniemi A, Schleutker J, Gylfe A, Aaltonen LA, 
Leminen A, Heikkila P, Blomqvist C, Butzow R, Aittomaki K and Nevanlinna H. 2012. 
A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and 
colorectal cancer. J Med Genet. 49(7):429-32. doi: 10.1136/jmedgenet-2012-100852. 
 
Pharoah PD, Day NE, Duffy S, Easton DF and Ponder BA. 1997. Family history and 
the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 
71(5):800-9. 
 
Pharoah PD, Guilford P, Caldas C and International Gastric Cancer Linkage 
Consortium. 2001. Incidence of gastric cancer and breast cancer in CDH1 (E-
cadherin) mutation carriers from hereditary diffuse gastric cancer families. 
Gastroenterology. 121(6):1348-53. 
 
Pilarski R. 2009. Cowden syndrome: a critical review of the clinical literature. J Genet 
Couns. 18(1):13-27. doi: 10.1007/s10897-008-9187-7. 
 
Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM and Swisher E. 2013. Cowden 
syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised 
diagnostic criteria. Journal of the National Cancer Institute. 105(21):1607-16. doi: 
10.1093/jnci/djt277. 
 
Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, 
Besenbacher S, Lundin P, Stacey SN, Gudmundsson J, Magnusson OT, le Roux L, 
Orlygsdottir G, Helgadottir HT, Johannsdottir H, Gylfason A, Tryggvadottir L, 
REFERENCES 
151 
 
Jonasson JG, de Juan A, Ortega E, Ramon-Cajal JM, Garcia-Prats MD, Mayordomo 
C, Panadero A, Rivera F, Aben KK, van Altena AM, Massuger LF, Aavikko M, Kujala 
PM, Staff S, Aaltonen LA, Olafsdottir K, Bjornsson J, Kong A, Salvarsdottir A, 
Saemundsson H, Olafsson K, Benediktsdottir KR, Gulcher J, Masson G, Kiemeney 
LA, Mayordomo JI, Thorsteinsdottir U and Stefansson K. 2011. Mutations in BRIP1 
confer high risk of ovarian cancer. Nat Genet. 43(11):1104-7. doi: 10.1038/ng.955. 
 
Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, 
Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Breast 
Cancer Susceptibility C, Easton DF and Stratton MR. 2007. PALB2, which encodes a 
BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 
39(2):165-7. doi: 10.1038/ng1959. 
 
Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, Fraser L, 
Gentry-Maharaj A, Hayward J, Philpott S, Anderson C, Edlund CK, Conti D, Harrington 
P, Barrowdale D, Bowtell DD, Alsop K, Mitchell G, Group AS, Cicek MS, Cunningham 
JM, Fridley BL, Alsop J, Jimenez-Linan M, Poblete S, Lele S, Sucheston-Campbell L, 
Moysich KB, Sieh W, McGuire V, Lester J, Bogdanova N, Durst M, Hillemanns P, 
Ovarian Cancer Association C, Odunsi K, Whittemore AS, Karlan BY, Dork T, Goode 
EL, Menon U, Jacobs IJ, Antoniou AC, Pharoah PD and Gayther SA. 2015. Germline 
mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian 
cancer. Journal of the National Cancer Institute. 107(11). doi: 10.1093/jnci/djv214. 
 
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans 
GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI and Weber BL. 2004. 
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 
mutation carriers: the PROSE Study Group. J Clin Oncol. 22(6):1055-62. doi: 
10.1200/JCO.2004.04.188. 
 
Rebbeck TR, Kauff ND and Domchek SM. 2009. Meta-analysis of risk reduction 
estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 
mutation carriers. Journal of the National Cancer Institute. 101(2):80-7. doi: 
10.1093/jnci/djn442. 
 
Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, 
Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, Consortium C, Laitman 
Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, 
Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, 
Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, 
Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, 
REFERENCES 
 
152 
 
Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung 
WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van 
Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlertsen B, Gerdes AM, Hansen T, 
Ramon y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, 
Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, 
Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice 
P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, 
Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, 
Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, 
Walker L, Porteous ME, Kennedy MJ, Izatt L, Adlard J, Donaldson A, Ellis S, Sharma 
P, Schmutzler RK, Wappenschmidt B, Becker A, Rhiem K, Hahnen E, Engel C, Meindl 
A, Engert S, Ditsch N, Arnold N, Plendl HJ, Mundhenke C, Niederacher D, Fleisch M, 
Sutter C, Bartram CR, Dikow N, Wang-Gohrke S, Gadzicki D, Steinemann D, Kast K, 
Beer M, Varon-Mateeva R, Gehrig A, Weber BH, Stoppa-Lyonnet D, Sinilnikova OM, 
Mazoyer S, Houdayer C, Belotti M, Gauthier-Villars M, Damiola F, Boutry-Kryza N, 
Lasset C, Sobol H, Peyrat JP, Muller D, Fricker JP, Collonge-Rame MA, 
Mortemousque I, Nogues C, Rouleau E, Isaacs C, De Paepe A, Poppe B, Claes K, 
De Leeneer K, Piedmonte M, Rodriguez G, Wakely K, Boggess J, Blank SV, Basil J, 
Azodi M, Phillips KA, Caldes T, de la Hoya M, Romero A, Nevanlinna H, Aittomaki K, 
van der Hout AH, Hogervorst FB, Verhoef S, Collee JM, Seynaeve C, Oosterwijk JC, 
Gille JJ, Wijnen JT, Gomez Garcia EB, Kets CM, Ausems MG, Aalfs CM, Devilee P, 
Mensenkamp AR, Kwong A, Olah E, Papp J, Diez O, Lazaro C, Darder E, Blanco I, 
Salinas M, Jakubowska A, Lubinski J, Gronwald J, Jaworska-Bieniek K, Durda K, 
Sukiennicki G, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Zlowocka-
Perlowska E, Menkiszak J, Arason A, Barkardottir RB, Simard J, Laframboise R, 
Montagna M, Agata S, Alducci E, Peixoto A, Teixeira MR, Spurdle AB, Lee MH, Park 
SK, Kim SW, Friebel TM, Couch FJ, Lindor NM, Pankratz VS, Guidugli L, Wang X, 
Tischkowitz M, Foretova L, Vijai J, Offit K, Robson M, Rau-Murthy R, Kauff N, Fink-
Retter A, Singer CF, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Berger 
A, Greene MH, Mai PL, Imyanitov EN, Toland AE, Senter L, Bojesen A, Pedersen IS, 
Skytte AB, Sunde L, Thomassen M, Moeller ST, Kruse TA, Jensen UB, Caligo MA, 
Aretini P, Teo SH, Selkirk CG, Hulick PJ and Andrulis I. 2015. Association of type and 
location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. 
JAMA. 313(13):1347-61. doi: 10.1001/jama.2014.5985. 
 
Reid S, Renwick A, Seal S, Baskcomb L, Barfoot R, Jayatilake H, Pritchard-Jones K, 
Stratton MR, Ridolfi-Luthy A, Rahman N, Breast Cancer Susceptibility Collaboration 
and Familial Wilms Tumour Collaboration. 2005. Biallelic BRCA2 mutations are 
associated with multiple malignancies in childhood including familial Wilms tumour. J 
Med Genet. 42(2):147-51. doi: 10.1136/jmg.2004.022673. 
REFERENCES 
153 
 
 
Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, 
Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, 
Tischkowitz M, Mathew CG, Auerbach AD and Rahman N. 2007. Biallelic mutations 
in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. 
Nat Genet. 39(2):162-4. doi: 10.1038/ng1947. 
 
Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake 
H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D, Breast Cancer 
Susceptibility C, Easton DF, Stratton MR and Rahman N. 2006. ATM mutations that 
cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 
38(8):873-5. doi: 10.1038/ng1837. 
 
Riegert-Johnson DL, Gleeson FC, Roberts M, Tholen K, Youngborg L, Bullock M and 
Boardman LA. 2010. Cancer and Lhermitte-Duclos disease are common in Cowden 
syndrome patients. Hered Cancer Clin Pract. 8(1):6. doi: 10.1186/1897-4287-8-6. 
 
Roy R, Chun J and Powell SN. 2012. BRCA1 and BRCA2: different roles in a common 
pathway of genome protection. Nat Rev Cancer. 12(1):68-78. doi: 10.1038/nrc3181. 
 
Schlacher K, Christ N, Siaud N, Egashira A, Wu H and Jasin M. 2011. Double-strand 
break repair-independent role for BRCA2 in blocking stalled replication fork 
degradation by MRE11. Cell. 145(4):529-42. doi: 10.1016/j.cell.2011.03.041. 
 
Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake 
H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Breast Cancer 
Susceptibility C, Easton DF, Stratton MR and Rahman N. 2006. Truncating mutations 
in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility 
alleles. Nat Genet. 38(11):1239-41. doi: 10.1038/ng1902. 
 
Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, 
Prestigiacomo L, Vogelstein B and Davidson N. 1992. Inherited p53 gene mutations 
in breast cancer. Cancer Res. 52(10):2984-6. 
 
Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, 
James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, 
Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, 
Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis 
IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-
Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova 
REFERENCES 
 
154 
 
E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma 
P, Kim SW, kConFab I, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, 
Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, 
Balmana J, Diez O, Ivady G, Papp J, Olah E, Kwong A, Hereditary B, Ovarian Cancer 
Research Group N, Nevanlinna H, Aittomaki K, Perez Segura P, Caldes T, Van 
Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, 
Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, 
Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, 
Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S, Embrace, 
Hamann U, Garber J, Fostira F, Fountzilas G, Pasini B, Giannini G, Rizzolo P, Russo 
A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian 
S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, 
Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes AM, Ejlertsen B, 
Hansen TV, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly 
MB, Bane A, Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, 
Antoniou AC and Ottini L. 2016. Male breast cancer in BRCA1 and BRCA2 mutation 
carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. 
Breast Cancer Res. 18(1):15. doi: 10.1186/s13058-016-0671-y. 
 
Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoptolemos JP, 
Greenhalf W and Bartsch DK. 2010. PALB2 mutations in European familial pancreatic 
cancer families. Clin Genet. 78(5):490-4. doi: 10.1111/j.1399-0004.2010.01425.x. 
 
Sluiter MD and van Rensburg EJ. 2011. Large genomic rearrangements of the BRCA1 
and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. 
Breast Cancer Res Treat. 125(2):325-49. doi: 10.1007/s10549-010-0817-z. 
 
Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, Edlund CK, Conti 
D, Harrington P, Fraser L, Philpott S, Anderson C, Rosenthal A, Gentry-Maharaj A, 
Bowtell DD, Alsop K, Cicek MS, Cunningham JM, Fridley BL, Alsop J, Jimenez-Linan 
M, Hogdall E, Hogdall CK, Jensen A, Kjaer SK, Lubinski J, Huzarski T, Jakubowska 
A, Gronwald J, Poblete S, Lele S, Sucheston-Campbell L, Moysich KB, Odunsi K, 
Goode EL, Menon U, Jacobs IJ, Gayther SA and Pharoah PD. 2015. Contribution of 
germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer 
in the population. J Clin Oncol. 33(26):2901-7. doi: 10.1200/JCO.2015.61.2408. 
 
Spain BH, Larson CJ, Shihabuddin LS, Gage FH and Verma IM. 1999. Truncated 
BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc Natl Acad Sci U 
S A. 96(24):13920-5. 
 
REFERENCES 
155 
 
Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, 
Kauff ND, Kurtz RC, Kelsen DP, Offit K and Robson ME. 2012. Prevalence of BRCA1 
and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic 
cancer. Cancer. 118(2):493-9. doi: 10.1002/cncr.26191. 
 
Starink TM, van der Veen JP, Arwert F, de Waal LP, de Lange GG, Gille JJ and 
Eriksson AW. 1986. The Cowden syndrome: a clinical and genetic study in 21 patients. 
Clin Genet. 29(3):222-33. 
 
Stracker TH, Usui T and Petrini JH. 2009. Taking the time to make important 
decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage 
response. DNA Repair (Amst). 8(9):1047-54. doi: 10.1016/j.dnarep.2009.04.012. 
 
Swift M, Sholman L, Perry M and Chase C. 1976. Malignant neoplasms in the families 
of patients with ataxia-telangiectasia. Cancer Res. 36(1):209-15. 
 
Sy SM, Huen MS and Chen J. 2009. PALB2 is an integral component of the BRCA 
complex required for homologous recombination repair. Proc Natl Acad Sci U S A. 
106(17):7155-60. doi: 10.1073/pnas.0811159106. 
 
Tai YC, Domchek S, Parmigiani G and Chen S. 2007. Breast cancer risk among male 
BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute. 
99(23):1811-4. doi: 10.1093/jnci/djm203. 
 
Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS and Eng C. 2012. Lifetime cancer 
risks in individuals with germline PTEN mutations. Clin Cancer Res. 18(2):400-7. doi: 
10.1158/1078-0432.CCR-11-2283. 
 
ten Broeke SW, Brohet RM, Tops CM, van der Klift HM, Velthuizen ME, Bernstein I, 
Capella Munar G, Gomez Garcia E, Hoogerbrugge N, Letteboer TG, Menko FH, 
Lindblom A, Mensenkamp AR, Moller P, van Os TA, Rahner N, Redeker BJ, Sijmons 
RH, Spruijt L, Suerink M, Vos YJ, Wagner A, Hes FJ, Vasen HF, Nielsen M and Wijnen 
JT. 2015. Lynch syndrome caused by germline PMS2 mutations: delineating the 
cancer risk. J Clin Oncol. 33(4):319-25. doi: 10.1200/JCO.2014.57.8088. 
 
Teugels E, De Brakeleer S, Goelen G, Lissens W, Sermijn E and De Greve J. 2005. 
De novo Alu element insertions targeted to a sequence common to the BRCA1 and 
BRCA2 genes. Hum Mutat. 26(3):284. doi: 10.1002/humu.9366. 
 
REFERENCES 
 
156 
 
Thompson D, Easton DF and Breast Cancer Linkage Consortium. 2002. Cancer 
incidence in BRCA1 mutation carriers. Journal of the National Cancer Institute. 
94(18):1358-65. 
 
Tilanus-Linthorst M, Verhoog L, Obdeijn IM, Bartels K, Menke-Pluymers M, 
Eggermont A, Klijn J, Meijers-Heijboer H, van der Kwast T and Brekelmans C. 2002. 
A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor 
independently contribute to a frequent false-negative mammography. Int J Cancer. 
102(1):91-5. doi: 10.1002/ijc.10666. 
 
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. 2015. Global 
cancer statistics, 2012. CA Cancer J Clin. 65(2):87-108. doi: 10.3322/caac.21262. 
 
Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, Tawil M, Torregrosa 
L, Briceno I and Hamann U. 2007. High proportion of BRCA1/2 founder mutations in 
Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat. 
103(2):225-32. doi: 10.1007/s10549-006-9370-1. 
 
Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, Lund E, Fournier A, 
Overvad K, Hansen L, Tjonneland A, Fedirko V, Rinaldi S, Romieu I, Clavel-Chapelon 
F, Engel P, Kaaks R, Schutze M, Steffen A, Bamia C, Trichopoulou A, Zylis D, Masala 
G, Pala V, Galasso R, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van 
Duijnhoven FJ, Braem MG, Onland-Moret NC, Gram IT, Rodriguez L, Travier N, 
Sanchez MJ, Huerta JM, Ardanaz E, Larranaga N, Jirstrom K, Manjer J, Idahl A, 
Ohlson N, Khaw KT, Wareham N, Mouw T, Norat T and Riboli E. 2011. Oral 
contraceptive use and reproductive factors and risk of ovarian cancer in the European 
Prospective Investigation into Cancer and Nutrition. Br J Cancer. 105(9):1436-42. doi: 
10.1038/bjc.2011.371. 
 
Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, Hartman AR, Winer EP and 
Garber JE. 2016. Frequency of germline mutations in 25 cancer susceptibility genes 
in a sequential series of patients with breast cancer. J Clin Oncol. 34(13):1460-8. doi: 
10.1200/JCO.2015.65.0747. 
 
Turnbull C and Rahman N. 2008. Genetic predisposition to breast cancer: past, 
present, and future. Annu Rev Genomics Hum Genet. 9:321-45. doi: 
10.1146/annurev.genom.9.081307.164339. 
 
Vallee MP, Sera TL, Nix DA, Paquette AM, Parsons MT, Bell R, Hoffman A, 
Hogervorst FB, Goldgar DE, Spurdle AB and Tavtigian SV. 2016. Adding in silico 
REFERENCES 
157 
 
assessment of potential splice aberration to the integrated evaluation of BRCA gene 
unclassified variants. Hum Mutat. doi: 10.1002/humu.22973. 
 
van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen 
HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, van 
Houwelingen JC, van't Veer LJ, Rookus MA, van Leeuwen FE and Netherlands 
Collaborative Group on Hereditary Breast Cancer. 2005. Cancer risks in BRCA2 
families: estimates for sites other than breast and ovary. J Med Genet. 42(9):711-9. 
doi: 10.1136/jmg.2004.028829. 
 
Varley JM, Evans DG and Birch JM. 1997. Li-Fraumeni syndrome--a molecular and 
clinical review. Br J Cancer. 76(1):1-14. 
 
Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, Nagengast 
FM, Meijers-Heijboer EH, Bertario L, Varesco L, Bisgaard ML, Mohr J, Fodde R and 
Khan PM. 1996. Cancer risk in families with hereditary nonpolyposis colorectal cancer 
diagnosed by mutation analysis. Gastroenterology. 110(4):1020-7. 
 
Venkitaraman AR. 2009. Linking the cellular functions of BRCA genes to cancer 
pathogenesis and treatment. Annu Rev Pathol. 4:461-87. doi: 
10.1146/annurev.pathol.3.121806.151422. 
 
Venkitaraman AR. 2014. Cancer suppression by the chromosome custodians, BRCA1 
and BRCA2. Science. 343(6178):1470-5. doi: 10.1126/science.1252230. 
 
Venn A, Watson L, Lumley J, Giles G, King C and Healy D. 1995. Breast and ovarian 
cancer incidence after infertility and in vitro fertilisation. Lancet. 346(8981):995-1000. 
 
Vicus D, Finch A, Cass I, Rosen B, Murphy J, Fan I, Royer R, McLaughlin J, Karlan B 
and Narod SA. 2010. Prevalence of BRCA1 and BRCA2 germ line mutations among 
women with carcinoma of the fallopian tube. Gynecol Oncol. 118(3):299-302. doi: 
10.1016/j.ygyno.2010.05.011. 
 
Wacholder S, Han SS and Weinberg CR. 2011. Inference from a multiplicative model 
of joint genetic effects for [corrected] ovarian cancer risk. Journal of the National 
Cancer Institute. 103(2):82-3. doi: 10.1093/jnci/djq510. 
 
Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, 
Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC and 
Swisher EM. 2011. Mutations in 12 genes for inherited ovarian, fallopian tube, and 
REFERENCES 
 
158 
 
peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci 
U S A. 108(44):18032-7. doi: 10.1073/pnas.1115052108. 
 
Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, Gygi SP and Elledge SJ. 
2007. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA 
damage response. Science. 316(5828):1194-8. doi: 10.1126/science.1139476. 
 
Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer 
G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA and Narod SA. 2004. Surveillance 
of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, 
ultrasound, mammography, and clinical breast examination. JAMA. 292(11):1317-25. 
doi: 10.1001/jama.292.11.1317. 
 
Whittemore AS, Harris R and Itnyre J. 1992. Characteristics relating to ovarian cancer 
risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of 
epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol. 
136(10):1212-20. 
 
Wilson JR, Bateman AC, Hanson H, An Q, Evans G, Rahman N, Jones JL and Eccles 
DM. 2010. A novel HER2-positive breast cancer phenotype arising from germline 
TP53 mutations. J Med Genet. 47(11):771-4. doi: 10.1136/jmg.2010.078113. 
 
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, 
Gumbs C and Micklem G. 1995. Identification of the breast cancer susceptibility gene 
BRCA2. Nature. 378(6559):789-92. doi: 10.1038/378789a0. 
 
Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, 
Bowcock AM and Baer R. 1996. Identification of a RING protein that can interact in 
vivo with the BRCA1 gene product. Nat Genet. 14(4):430-40. doi: 10.1038/ng1296-
430. 
 
Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ and 
Livingston DM. 2006. Control of BRCA2 cellular and clinical functions by a nuclear 
partner, PALB2. Mol Cell. 22(6):719-29. doi: 10.1016/j.molcel.2006.05.022. 
 
Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami 
A, Gluckman E, Llera J, Wang W, Livingston DM, Joenje H and de Winter JP. 2007. 
Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 
39(2):159-61. doi: 10.1038/ng1942. 
 
REFERENCES 
159 
 
Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, Thoma NH, Zheng N, Chen PL, Lee 
WH and Pavletich NP. 2002. BRCA2 function in DNA binding and recombination from 
a BRCA2-DSS1-ssDNA structure. Science. 297(5588):1837-48. doi: 
10.1126/science.297.5588.1837. 
 
 
